10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to

Commission File Number 000-52985

SANUWAVE Health, Inc.

(Exact name of registrant as specified in its charter)

Nevada	20-1176000
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3360 Martin Farm Road, Suite 100
Suwanee, GA	30024
(Address of principal executive offices)	(Zip Code)

(770) 419-7525

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes   ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  ☒ Yes   ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes   ☒ No

Securities registered pursuant to Section 12(b) of the Exchange Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	SNWV	OTCQB

As of June 23, 2021, there were issued and outstanding 481,619,621 shares of the registrant’s common stock, $0.001 par value.

EXPLANATORY NOTE

This Amendment No. 1 to the Form 10-Q (this “Amendment”) amends the Quarterly Report on Form 10-Q of SANUWAVE Health, Inc. (the “Company”) for the quarterly period ended September 30, 2020 (the “Form 10-Q”), filed on November 23, 2020 with the Securities and Exchange Commission (the “SEC”). This Amendment restates the Company’s financial statements in order to correct an accounting error resulting in the underreporting the amount of warrant derivative liability. The error relates to the determination of the number of shares of common stock subject to a warrant issued by the Company in June 2020 as previously reported by the Company, which warrant contains certain anti-dilution adjustment provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrant, warrant liability associated with the company not having enough authorized shares at the time those anti-dilution provision were triggered  A summary of the accounting impact of these adjustments to the Company’s condensed consolidated unaudited financial statements as of and for the three and nine months ended September 30, 2020 is provided at “Note 20. Restatement of Financial Statements.” We have also added Note 22 which describes a non-compliance notification from a supplier, as well as reclassification of warrant liabilities to current.

Except as described in Notes 8, 11, 14, 20, 22, and the corresponding changes in Net Income and other changes as described above, no other changes have been made to the Company’s Interim Report on Form 10-Q for the three months ended September 30, 2020 (the “Original 10-Q”) except to update the latest number of outstanding shares on the cover page of this Form 10-Q/A. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing or modify or update any disclosures that may have been affected by subsequent events.

In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is also including with this Amendment certifications of the Company’s Chief Executive Officer and Chief Financial Officer (attached as Exhibits 31.1, 31.2, 32.1, and 32.2) dated as the date of the Amendment.

SANUWAVE Health, Inc.

Table of Contents

	PART I – FINANCIAL INFORMATION	Page
Item 1.	Financial Statements (Unaudited)	2
	Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019 (Restated)	3
	Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019 (Restated)	4
	Condensed Consolidated Statements of Stockholders’ Deficit for the three and nine months ended September 30, 2020 and 2019 (Restated)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (Restated)	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38
Item 4.	Controls and Procedures	38
	PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 3.	Defaults Upon Senior Securities	41
Item 4.	Mine Safety Disclosures	41
Item 5.	Other Information	41
Item 6.	Exhibits	42
SIGNATURES		43

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q of SANUWAVE Health, Inc. and its subsidiaries (“SANUWAVE” or the “Company”) contains forward-looking statements. All statements in this Quarterly Report on Form 10-Q, including those made by the management of the Company, other than statements of historical fact, are forward-looking statements. Examples of forward-looking statements include statements regarding: any expected benefits of the Celularity Inc. asset acquisition and its impact on the Company; the potential impact of the COVID-19 pandemic on our business, results of operations, liquidity, and operations, including the effect of governmental lockdowns, restrictions and new regulations on our operations and processes, including the execution of clinical trials; the Company’s future financial results, operating results, and projected costs; market acceptance of and demand for dermaPACE and our product candidates; success of future business development and acquisition activities; management’s plans and objectives for future operations; industry trends; regulatory actions that could adversely affect the price of or demand for our approved products; the successful filing with the Secretary of State of Nevada of amendments to our Articles of Incorporation to effect the changes approved by our stockholders at our 2020 Annual Meeting; our intellectual property portfolio; our business, marketing and manufacturing capacity and strategy; estimates regarding our capital requirements, the anticipated timing of the need for additional funds, and our expectations regarding future capital-raising transactions, including through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing agreements, or raising capital through the conversion of outstanding warrants or issuances of securities; product liability claims; economic conditions that could affect the level of demand for our products; timing of clinical studies and eventual FDA approval of our products; financial markets; the competitive environment; and our plans to remediate our material weaknesses in our disclosure controls and procedures and our internal control over financial reporting. These forward-looking statements are based on management’s estimates, projections and assumptions as of the date hereof and include the assumptions that underlie such statements. Forward-looking statements may contain words such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and “continue,” the negative of these terms, or other comparable terminology. Any expectations based on these forward-looking statements are subject to risks and uncertainties and other important factors, including those discussed in the reports we file with the Securities and Exchange Commission (the “SEC”), specifically the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed on March 30, 2020 and in the Company’s Quarterly Reports on Form 10-Q. Other risks and uncertainties are and will be disclosed in the Company’s prior and future SEC filings. These and many other factors could affect the Company’s future financial condition and operating results and could cause actual results to differ materially from expectations based on forward-looking statements made in this document or elsewhere by the Company or on its behalf. The Company undertakes no obligation to revise or update any forward-looking statements. The following information should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed on March 30, 2020.

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” are to the consolidated business of the Company.

PART I — FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

2

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2020			December 31, 2019
	(As Restated)
ASSETS	(Unaudited)
CURRENT ASSETS
Cash and cash equivalents	$	5,391,591		$	1,760,455
Accounts receivable, net of allowance for doubtful accounts of $32,558 in 2020 and $72,376 in 2019		1,395,815			75,543
Inventory		2,539,475			542,955
Prepaid expenses and other current assets		627,751			125,405
TOTAL CURRENT ASSETS		9,954,632			2,504,358
PROPERTY AND EQUIPMENT, net		979,673			512,042
RIGHT OF USE ASSETS, net		442,197			323,661
OTHER INTANGIBLE ASSETS, net		7,259,795			-
GOODWILL		14,198,799			-
OTHER ASSETS		31,010			41,931
TOTAL ASSETS	$	32,866,106		$	3,381,992
LIABILITIES
CURRENT LIABILITIES
Accounts payable	$	2,322,192		$	1,439,413
Accrued expenses		1,603,543			1,111,109
Accrued employee compensation		2,544,768			1,452,910
Warrant Liability		17,546,260			-
Convertible promissory notes payable		4,000,000			-
Convertible promissory notes, related parties		1,596,254			-
SBA loans		321,821			-
Accrued interest		354,062			-
Operating lease liability		251,372			173,270
Finance lease liability		187,416			121,634
Contract liabilities		65,037			66,577
Accrued interest, related parties		28,864			1,859,977
Notes payable, related parties, net		-			5,372,743
Short term notes payable		-			587,233
Line of credit, related parties		-			212,388
Advances from related parties		-			18,098
TOTAL CURRENT LIABILITIES		30,821,589			12,415,352
NON-CURRENT LIABILITIES
Promissory note payable		10,448,039			-
SBA loans		142,514			-
Finance lease liability		284,588			271,240
Operating lease liability		222,815			185,777
Contract liabilities		45,519			573,224
TOTAL NON-CURRENT LIABILITIES		11,143,475			1,030,241
TOTAL LIABILITIES		41,965,064			13,445,593
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, par value $0.001, 5,000,000 shares authorized; 6,175 and 293 shares designated Series A and Series B, respectively		-			-
COMMON STOCK, par value $0.001, 600,000,000 (Note 18) shares authorized; 466,094,621 and 293,780,400 issued and outstanding in 2020 and 2019, respectively		466,095			293,781
ADDITIONAL PAID-IN CAPITAL		135,521,907			115,457,808
ACCUMULATED DEFICIT		(145,025,761	)		(125,752,956	)
ACCUMULATED OTHER COMPREHENSIVE LOSS		(61,199	)		(62,234	)
TOTAL STOCKHOLDERS' DEFICIT		(9,098,958	)		(10,063,601	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	32,866,106		$	3,381,992

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

3

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	Three Months Ended September 30, 2020			Three Months Ended September 30, 2019			Nine Months Ended September 30, 2020			Nine Months Ended September 30, 2019
	(As Restated)						(As Restated)
REVENUES
Product	$	1,321,248		$	158,855		$	1,465,147		$	444,087
License fees		29,447			16,250			39,447			189,307
Other revenue		616,201			22,535			694,194			59,185
TOTAL REVENUES		1,966,896			197,640			2,198,788			692,579
COST OF REVENUES
Product		533,629			91,179			637,369			334,749
Other		14,777			31,744			26,261			67,908
TOTAL COST OF REVENUES		548,406			122,923			663,630			402,657
GROSS MARGIN		1,418,490			74,717			1,535,158			289,922
OPERATING EXPENSES
Research and development		432,155			299,903			983,816			867,825
Selling and marketing		1,373,476			335,472			2,414,477			901,031
General and administrative		5,054,508			1,802,659			9,529,218			4,746,519
Amortization		244,626			-			244,626			-
Depreciation		82,493			22,338			200,282			40,150
TOTAL OPERATING EXPENSES		7,187,258			2,460,372			13,372,419			6,555,525
OPERATING LOSS		(5,768,768	)		(2,385,655	)		(11,837,261	)		(6,265,603	)
OTHER INCOME (EXPENSE)
Gain or (Loss) on warrant liability		(5,590,806	)		-			(5,590,806	)		227,669
Loss on extinguishment of debt		(503,234	)		-			(503,234	)		-
Interest expense		(690,659	)		(182,001	)		(878,331	)		(1,120,440	)
Interest expense, related party		(61,334	)		(175,522	)		(431,070	)		(508,193	)
Loss on foreign currency exchange		(23,836	)		(4,840	)		(32,103	)		(13,199	)
TOTAL OTHER INCOME (EXPENSE), NET		(6,869,869	)		(362,363	)		(7,435,544	)		(1,414,163	)
NET LOSS		(12,638,637	)		(2,748,018	)		(19,272,805	)		(7,679,766	)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments		2,792			(14,061	)		869			13,152
TOTAL COMPREHENSIVE LOSS	$	(12,635,845	)	$	(2,762,079	)	$	(19,271,936	)	$	(7,666,614	)
LOSS PER SHARE:
Net loss - basic and diluted	$	(0.03	)	$	(0.01	)	$	(0.06	)	$	(0.04	)
Weighted average shares outstanding - basic and diluted		384,502,450			211,423,362			326,405,397			181,088,995

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

4

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

(UNAUDITED)

	Preferred Stock				Common Stock
	Number of Shares Issued and Outstanding		Par Value		Number of Shares Issued and Outstanding		Par Value		Additional Paid- in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total
Balances as of Janaury 1, 2019		-	$	-		155,665,138	$	155,665	$	101,153,882		$	(116,602,778	)	$	(62,868	)	$	(15,356,099	)
Net loss		-		-		-		-		-			(2,197,317	)		-			(2,197,317	)
Cashless warrant exercises		-		-		704,108		704		(704	)		-			-			-
Proceeds from warrant exercise		-		-		620,000		620		52,580			-			-			53,200
Conversion of short term notes and convertible notes payable		-		-		3,333,334		3,334		263,333			-			-			266,667
Reclassification of warrant liability to equity due to adoption of ASU 2017-11		-		-		-		-		262,339			1,279,661			-			1,542,000
Foreign currency translation adjustment		-		-		-		-		-			-			(2,398	)		(2,398	)
Balances as of March 31, 2019		-	$	-		160,322,580	$	160,323	$	101,731,430		$	(117,520,434	)	$	(65,266	)	$	(15,693,947	)
Net loss		-		-		-		-		-			(2,734,431	)		-			(2,734,431	)
Cashless warrant exercises		-		-		2,997,375		2,997		13,003			-			-			16,000
Proceeds from warrant exercise		-		-		17,051,769		17,052		1,333,005			-			-			1,350,057
Other warrant exercise		-		-		5,804,167		5,804		451,697									457,501
Conversion of short term notes and convertible notes payable		-		-		2,475,000		2,475		177,525			-			-			180,000
Stock-based compensation		-		-		-		-		31,758			-			-			31,758
Warrants issued for consulting services		-		-		-		-		36,067			-			-			36,067
Foreign currency translation adjustment		-		-		-		-		-			-			1,489			1,489
Balances as of June 30, 2019		-	$	-		188,650,891	$	188,651	$	103,774,485		$	(120,254,865	)	$	(63,777	)	$	(16,355,506	)
Net loss		-		-		-		-		-			(2,748,018	)		-			(2,748,018	)
Cashless warrant exercises		-		-		1,710,674		1,711		18,289			-			-			20,000
Proceeds from warrant exercise		-		-		10,506,593		10,506		961,528			-			-			972,034
Other warrant exercise		-		-		40,355,006		40,355		4,014,500			-			-			4,054,855
Conversion of line of credit, related parties to equity		-		-		4,545,455		4,545		495,455			-			-			500,000
Stock-based compensation		-		-		-		-		224,400			-			-			224,400
Foreign currency translation adjustment		-		-		-		-		-			-			14,061			14,061
Balances as of September 30, 2019		-	$	-		245,768,619	$	245,768	$	109,488,657		$	(123,002,883	)	$	(49,716	)	$	(13,318,174	)
																		As Restated
Balances as of Janaury 1, 2020		-	$	-		293,780,400	$	293,781	$	115,457,808		$	(125,752,956	)	$	(62,234	)	$	(10,063,601	)
Net loss		-		-		-		-		-			(3,001,148	)		-			(3,001,148	)
Proceeds from warrant exercise		-		-		1,000,000		1,000		9,000			-			-			10,000
Shares issued for services		-		-		1,000,000		1,000		199,000			-			-			200,000
Stock-based compensation		-		-		-		-		21,900			-			-			21,900
Conversion of short term notes		-		-		1,820,461		1,820		262,164			-			-			263,984
Conversion of advances from related parties		-		-		62,811		63		2,035			-			-			2,098
Foreign currency translation adjustment		-		-		-		-		-			-			4,826			4,826
Balances as of March 31, 2020		-	$	-		297,663,672	$	297,664	$	115,951,907		$	(128,754,104	)	$	(57,408	)	$	(12,561,941	)
Net loss		-		-		-		-		-			(3,633,020	)		-			(3,633,020	)
Proceeds from PIPE		-		-		1,071,428		1,071		148,929			-			-			150,000
Proceeds from stock option exercise		-		-		225,000		225		44,025			-			-			44,250
Beneficial conversion feature on convertible debt		-		-		-		-		560,682			-			-			560,682
Shares issued for services		-		-		2,200,000		2,200		515,300			-			-			517,500
Conversion of short term notes and settlements		-		-		759,328		759		89,986			-			-			90,745
Conversion of advances from related parties		-		-		200,000		200		15,800			-			-			16,000
Foreign currency translation adjustment		-		-		-		-		-			-			(6,749	)		(6,749	)
Balances as of June 30, 2020		-	$	-		302,119,428	$	302,119	$	117,326,629		$	(132,387,124	)	$	(64,157	)	$	(14,822,533	)
Net loss    (As Restated)		-		-		-		-		-			(12,638,637	)		-			(12,638,637	)
Proceeds from PIPE (As Restated)		-		-		123,550,000		123,550		12,408,966			-			-			12,532,516
LGH Warrant Liability (As Restated)										(249,049	)								(249,049	)
Series C Preferred Conversion		-		-		16,071,390		16,072		2,233,928			-			-			2,250,000
Series D Preferred Conversion		-		-		1,428,568		1,429		198,571			-			-			200,000
Shares issued for services		-		-		5,000,000		5,000		1,075,000			-			-			1,080,000
Inducement shares issued						200,000		200		44,540									44,740
Conversion of short term notes and settlements		-		-		2,250,000		2,250		207,750			-			-			210,000
Conversion of notes payable, related parties to equity		-		-		15,475,235		15,475		2,275,572			-			-			2,291,047
Foreign currency translation adjustment		-		-		-		-		-			-			2,958			2,958
Balances as of September 30, 2020     (As Restated)		-	$	-		466,094,621	$	466,095	$	135,521,907		$	(145,025,761	)	$	(61,199	)	$	(9,098,958	)

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

5

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended September 30, 2020 (As Restated)			Nine Months Ended September 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(19,272,805	)	$	(7,679,766	)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of intangibles		244,626			-
Depreciation		200,282			40,150
Bad Debt Expense		(39,818	)		(18,835	)
Share-based payment		21,900			256,158
Shares issued for services		1,797,500			-
Shares issued for inducement shares		44,740			-
Loss on extinguishment of debt		503,234			-
Warrants issued for consulting services		-			36,067
Gain or (Loss) on warrant liability		5,590,806			(227,669	)
Amortization of debt issuance costs		214,431			-
Accrued interest		191,031			1,139,904
Interest payable, related parties		696,208			508,193
Amortization of operating leases		(3,396	)		(14,634	)
Waived proceeds from warrant exercise		-			36,000
Changes in operating assets and liabilities
Accounts receivable - trade		(1,280,454	)		197,301
Inventory		(136,555	)		66,884
Prepaid expenses		(502,346	)		(83,007	)
Due from related parties		-			1,228
Other assets		10,921			(13,567	)
Operating leases		-			9,513
Financing leases		1,980
Accounts payable		882,779			118,908
Accrued expenses		492,434			127,586
Accrued employee compensation		1,091,858			863,400
Contract liabilties		(529,245	)		(48,425	)
NET CASH USED BY OPERATING ACTIVITIES		(9,779,889	)		(4,684,611	)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of UltraMIST (Note 4)		(20,000,000	)		-
Purchases of property and equipment		(39,142	)		(28,990	)
NET CASH USED BY INVESTING ACTIVITIES		(20,039,142	)		(28,990	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of convertible preferred stock		2,450,000			-
Proceeds from convertible promissory note		1,100,000			-
Proceeds from SBA loan		614,335			-
Proceeds from PIPE offering		21,456,468			-
Proceeds from senior promissory notes		13,346,547
Proceeds from stock option exercise		44,250			90,000
Proceeds from short term note		-			1,215,000
Proceeds from warrant exercise		10,000			1,378,142
Advances from related parties		-			2,055,414
Payments of debt		(5,457,663	)
Payments of principal on finance leases		(114,806	)		-
NET CASH PROVIDED BY FINANCING ACTIVITIES		33,449,131			4,738,556
EFFECT OF EXCHANGE RATES ON CASH		1,036			13,152
NET INCREASE IN CASH AND CASH EQUIVALENTS		3,631,136			38,107
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		1,760,455			364,549
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	5,391,591		$	402,656
NONCASH INVESTING AND FINANCING ACTIVITIES
Acquisition of UltraMIST partially financed with convertible promissory note	$	4,000,000			-
Conversion of short term notes payable to equity	$	564,729		$	2,860,769
Other warrant exercise		-		$	924,649
Conversion of line of credit, related parties to equity		-		$	680,000
Conversion of advances from related party to equity	$	18,098			-
Additions to right of use assets from new finance lease liabilities	$	127,611			-
Beneficial conversion feature on convertible debt	$	560,682			-
Reclassification of warrant liability to equity		-		$	1,542,000
Accounts payable and Accrued employee compensation converted to equity		-		$	36,500
Conversion of convertible promissory notes to equity		-		$	1,918,254

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

6

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

1. Nature of the Business

SANUWAVE Health, Inc. and Subsidiaries (the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Through its recent acquisition of Celularity’s UltraMIST® assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market.

The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. Food and Drug Administration (FDA) granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo process. As a result of this decision, the Company was able to immediately market the product for the treatment of Diabetic Foot Ulcers (DFU) as described in the De Novo request, subject to the general control provisions of the FD&C Act and the special controls identified in this order.

On August 6, 2020 the Company entered into an Asset Purchase Agreement with Celularity Inc. (“Celularity”) pursuant to which the Company acquired Celularity’s UltraMIST assets, as more fully described in Note 4. The UltraMIST® System is a proprietary technology cleared by the FDA for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.

In connection with the Asset Purchase Agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl® (the “License Agreement”). The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the “Field” and “Territory” (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term.

The Company’s portfolio of regenerative medicine products and product candidates activate tissue regeneration biological signaling and angiogenic responses, producing new vascularization and microcirculatory improvement combined with tissue growth which helps restore the body’s normal healing processes. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions. The Company is marketing its dermaPACE System for treatment usage in the United States and is able to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities.

In March 2020, the World Health Organization characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. Since then, the COVID-19 pandemic has rapidly spread across the globe and has already resulted in significant volatility, uncertainty and economic disruption. The primary impact of the COVID-19 pandemic has been seen in our dermaPACE System placements in the United States as our treatment is not widely recognized as an “essential” service. In addition, stay-at-home policies deployed to combat the spread of COVID-19 has greatly constrained visits to wound care centers, doctor’s offices and hospitals since late March 2020 and continuing as of this filing and have therefore delayed placements of new devices that were included in our revenue forecast. The future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. It is difficult at this time to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in future periods due to numerous uncertainties. The Company is closely monitoring the impact of the pandemic on all aspects of its business and operations including its recent acquired assets.

7

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

1. Nature of the Business (continued)

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The financial information as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2020.

The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2020 (the “2019 Annual Report”).

2. Going Concern

The Company does not currently generate significant recurring revenue and may require additional capital during 2020. As of September 30, 2020, the Company had cash and cash equivalents of $5,391,591. For the nine months ended September 30, 2020, the net cash used by operating activities was $9,779,889. The Company incurred a restated net loss of $19,272,805 for the nine months ended September 30, 2020. Such factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this report.

The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

3 Summary of Significant Accounting Policies

The significant accounting policies followed by the Company are summarized below and should be read in conjunction with the 2019 Annual Report:

Principles of consolidation - The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

8

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

3 Summary of Significant Accounting Policies (continued)

Estimates – These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of condensed consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These condensed consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimate of the net realizable value of inventory, the determination of the valuation allowances for deferred taxes the estimated fair value of stock-based compensation, debt discounts and warrants, and valuation of acquired assets related to the acquisition of UltraMIST (Note 4).

Fair value of financial instruments - The carrying values of accounts payable, and other short-term obligations approximate their fair values, principally because of the short-term maturities of these instruments.

The Company has adopted ASC 820-10, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value and requires disclosures about fair value measurements. The framework that is set forth in this standard is applicable to the fair value measurements where it is permitted or required under other accounting pronouncements.

The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions.

The Company recognizes all derivatives on the balance sheet at fair value. The fair value of the warrant liability is determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate, and therefore is classified within level 3 of the fair value hierarchy. (See Note 14).

The Company’s notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace.

Inventory - Inventory consists of finished medical equipment and parts and is stated at the lower of cost, which is valued using the first in, first out (“FIFO”) method, or net realizable value less allowance for selling and distribution expenses. The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete. As of September 30, 2020, inventory consists of goods of $2,273,436 and parts of $266,039 for a total inventory of $2,539,475. As of December 31, 2019, inventory consisted of goods of $357,264 and parts of $185,691 for a total inventory of $542,955.

Preferred stock – The Company evaluates Preferred Stock issuances for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and determines appropriate equity or liability accounting treatment. Additionally, the Company determines, if classified as equity, whether it would be recorded as permanent or temporary equity.

9

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

3 Summary of Significant Accounting Policies (continued)

Sequencing policy – The Company has granted certain options and warrants which, upon settlement, may exceed the limit on the authorized number of shares of common stock. The Company follows a sequencing policy for which in the event partial reclassifications of contracts subject to ASC 815-40-25 is necessary, due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of earliest issuance date of potentially dilutive instruments with the earliest grants receiving first allocation of shares. On August 6, 2020, the Company issued shares of common stock, convertible debt and warrants exercisable into shares of common stock in connection with a private placement funding and Senior Notes. In the event that all outstanding convertible securities were converted into shares of common stock of the Company, the Company would exceed the total number of shares authorized for issuance in the Company’s Articles of Incorporation. The Company has applied its sequencing policy to and determined that all convertible securities are convertible into shares of common stock other than warrants to purchase 64,119,742 shares of common stock issued on August 6, 2020.  These warrants were valued at $8,656,165 at August 6, 2020 and recorded as a liability in the condensed consolidated balance sheet.

Convertible instruments and liabilities related to warrants issued –  The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with FASB ASC 815 “Derivatives and Hedging” (“ASC 815”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the consolidated statements of operations over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.  A binomial model was used to estimate the fair value of the ECOs of warrants that are classified as derivative liabilities on the consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments.

Recent Accounting Pronouncements

In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

10

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

4. Asset Purchase Agreement

On August 6, 2020, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Celularity pursuant to which the Company acquired (the “Transaction”) Celularity’s UltraMIST assets (“UltraMIST”, or the “Assets”). The acquisition provides the Company with a robust product offering in the advanced wound care market and gives the Company an end-to-end advanced wound care product portfolio that addresses the entire care pathway. The aggregate consideration paid for the Assets was $24,000,000, which consisted of (i) a cash payment of $18,890,000, (ii) the issuance of a convertible promissory note to Celularity in the principal amount of $4,000,000 (the “Seller Note”), and (iii) a credit of $1,110,000 for the previous payment made by the Company to Celularity pursuant to that certain letter of intent between the Company and Celularity dated June 7, 2020.

In connection with the Asset Purchase Agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl® (the “License Agreement”). The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the “Field” and “Territory” (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term.

The Company evaluated whether the Transaction should be accounted for as an asset acquisition or a business combination and determined that the Transaction met the definition of a business per Accounting Standard Update (ASU) 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The Company has treated the transaction as a business combination and applied the related accounting guidance as required, using the acquisition method and a fair value model.

The tables below present the fair value of the consideration exchanged and the preliminary estimates of the fair value of assets acquired of UltraMIST.  Due to the limited amount of time since the UltraMIST acquisition, the valuation of the acquired assets is preliminary and subject to change.  The Company is still evaluating the income tax effects of the transaction.

Purchase consideration
	August 6, 2020
Cash paid at closing	$	18,890,000
Seller convertible note		4,000,000
Previous cash deposit pursuant to letter of intent		1,110,000
Total	$	24,000,000

Net assets acquired	Fair Value at August 6, 2020
Inventory	$	1,859,965
Property, plant and equipment		436,815
Intangible assets (a)		14,443,425
Goodwill (b)		7,259,795
Total	$	24,000,000

11

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

4. Asset Purchase Agreement (continued)

^(a) Intangible assets, as provided in the table below, are recorded at estimated fair value.  The estimated fair value of the acquired customer relationships is based on a variation of the income valuation approach and is determined using the multi-period excess earnings method. The estimated fair value of the acquired patent and trade names is based on a variation of the income valuation approach known as the relief from royalty method. The estimated useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows.

	Estimated Fair Value		Estimated Weighted Average Life (Years)
Customer relationships - UltraMIST	$	3,820,000		7
Customer relationships - Biologics		7,618,100		7
Patent		2,311,825		19
Trade names		693,500		19
	$	14,443,425

^(b) Goodwill represents the excess of the total purchase consideration over fair value of the assets recognized and represents the future economic benefits that we believe will result from combining the operations of Sanuwave and UltraMIST, including expected future synergies and operating efficiencies. Goodwill resulting from the Transaction has been assigned to the Company’s lone operating segment. None of the goodwill recognized is expected to be deductible for income tax purposes.

Acquisition and related costs

During the three and nine months ended September 30, 2020, acquisition costs of $995,353 and $1,084,994, respectively, were expensed as incurred and included in general and administrative expenses in the Condensed Consolidated Statement of Comprehensive Loss. Such costs include professional fees of advisors and integration and synergy costs related to the combination of UltraMIST and Sanuwave. Additionally, $1,653,453 of debt issuance costs related to the NWPSA Senior Debt described in Note 7 were capitalized as a reduction in the principal amount of a promissory note on the Condensed Consolidated Balance Sheet. These debt issuance costs are amortized to interest expense over the life of the NWPSA Senior Debt.

Unaudited actual and pro forma information

The following unaudited pro forma information has been prepared by combining the historical results of Sanuwave and historical results of UltraMIST. The unaudited pro forma combined financial data for all periods presented were adjusted to give effect to pro forma events that are directly attributable to the aforementioned transaction and are factually supportable. The adjustments are based on information available to the Company at this time. Accordingly, the adjustments are subject to change and the impact of such changes may be material. The unaudited pro forma results do not include any incremental cost savings that may result from the integration.

The unaudited combined pro forma information is for informational purposes only and is not necessarily indicative of what the combined company's results actually would have been had the acquisition been completed as of the beginning of the periods as indicated. In addition, the unaudited pro forma information does not purport to project the future results of the combined company.

12

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

4. Asset Purchase Agreement (continued)

The acquired Assets were consolidated into our financial statements starting on the acquisition date. The total revenues and net loss of UltraMIST consolidated into our financial statements since the date of acquisition through September 30, 2020 were $1,206,847 and $1,509,943, respectively. The following financial information presents our results as if the Transaction had occurred on January 1, 2019:

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
	(restated)						(restated)
Total revenue	$	2,770,646		$	2,325,640		$	5,973,538		$	6,810,404
Net loss	$	(12,549,181	)	$	(4,863,590	)	$	(23,869,495	)	$	(14,855,293	)

Significant adjustments to the pro forma information above include recognition of non-recurring direct incremental acquisition costs in the nine months ended September 30, 2019 and exclusion of those costs from all other periods presented; recognition of the Biovance® license fee pursuant to the License Agreement; increase in interest expense related to the NWPSA Senior Debt Notes described in Note 7, the Seller Note described in Note 8, the HealthTronics Note described in Note 8, and the Stolarski Note described in Note 10; increase in depreciation expense related to the fair value adjustment of acquired property and equipment; and amortization associated with an estimate of the acquired intangible assets.

5. Accrued expenses

Accrued expenses consist of the following:

	September 30, 2020		December 31, 2019
Accrued outside services	$	615,547	$	108,033
Accrued legal and professional fees		370,985		134,970
Accrued board of director’s fees		260,000		400,000
Accrued executive severance		167,500		154,000
Accrued travel		120,000		120,000
Accrued inventory		50,275		167,050
Accrued clinical study expenses		13,650		13,650
Accrued other		5,586		13,406
	$	1,603,543	$	1,111,109

13

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

6. Contract liabilities

As of September 30, 2020, the Company has contract assets and liabilities from contracts with customers (see Note 16).

Contract liabilities consist of the following:

	September 30, 2020			December 31, 2019
Service agreement	$	77,538		$	133,510
License fees		-			500,000
Devices		22,500			-
Other		10,518			6,291
Total Contract liabilities		110,556			639,801
Non-Current		(45,519	)		(573,224	)
Total Current	$	65,037		$	66,577

The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate contract liability balances as of September 30, 2020, the Company expects to satisfy its remaining performance obligations associated with $65,037 and $45,519 of contract liability balances within the next twelve months and following thirty-two months, respectively. Of the aggregate contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 and $573,224 of contract liability balances within the next twelve months and following thirty-eight months, respectively.

14

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

7. Senior promissory notes

On August 6, 2020, the Company entered into a Note and Warrant Purchase and Security Agreement (the “NWPSA”), with the noteholder party thereto and NH Expansion Credit Fund Holdings LP, as agent. As a result, the Company issued a $15,000,000 Secured Promissory Note (the “Senior Notes”) and Warrant exercisable into shares of the Company’s common stock (the “Warrant”) in exchange for cash to support operations, repay outstanding debt and close on the acquisition of the UltraMIST assets from Celularity, among other transactions. The Company received net proceeds from issuing the Notes and NH Warrant of $13,346,547. The NWPSA provides for (i) the sale and purchase of secured notes in an aggregate original principal amount of $15 million and (ii) the issuance of 13,091,160 warrants equal to 2.0% of the fully-diluted common stock of the Company as of the issue date. The warrant has an exercise price of $0.01 per share and a 10 year term (Note 11). The warrant agreement contains a put option. Upon payment in full of the Note, the holder has the ability to require the Company to purchase the warrants from the holder for cash. Accordingly, the warrant has been classified as a derivative liability. The holder has the option to exercise the put any time between the payment of the Note and the expiration of the warrants. The Note has a maturity date of September 30, 2025 and accrues interest at a rate that is the sum of: (a) the greater of the quarter end prime rate or 3% plus (b) 9%, due in quarterly arrears.  The Senior Notes are secured by substantially all assets of the Company including in the event of default placing bank accounts under a control agreement, copyrights, trademarks, patents, applications, registered and unregistered, licenses, designs, held or acquired after August 6, 2020 by the Company. The NWPSA contains several default conditions, including non-monetary default events including misrepresentations and material adverse changes. In the case of default, the agent has the right to declare the Senior Notes immediately due, not extend further credit, take actions to protect security (title changes), demand and take possession of the books, and is appointed an Attorney in Fact in certain conditions. Covenants include restrictions on dispositions, mergers or acquisitions, incurring indebtedness and minimum liquidity provisions. As of September 30, 2020, the Company was in compliance with all financial covenants under the NWPSA.

The Company recorded a current warrant liability of $3,050,240 for the fair value of the warrant. The outstanding balance of the Note at September 30, 2020 was $10,448,039 and accrued interest of $280,729. Further, as of September 30, 2020, the Company had unamortized debt issuance costs of $1,600,115.

8. Convertible promissory notes (Restated)

On August 6, 2020, the Company entered into an asset purchase agreement with Celularity Inc., described in Note 4 pursuant to which the Company acquired Celularity’s UltraMIST assets. A portion of the aggregate consideration of $24,000,000 paid for the assets included the issuance of a promissory note to Celularity in the principal amount of $4,000,000. The Seller Note has a maturity date of August 6, 2021 and accrues interest at a rate equal to 12.0% per annum. In the event that the Seller Note has not been repaid prior to January 1, 2021, Celularity may elect to convert the outstanding principal amount plus any accrued but unpaid interest thereon into shares of the Company’s common stock, at a conversion price of $0.10 per share. As this conversion option is contingent on a future event, the conversion option has not been bifurcated from the host instrument as of September 30, 2020. The Seller Note is expressly subordinate to the NWPSA “Senior Debt” described in Note 7. The Company may prepay the outstanding principal balance, together with any accrued but unpaid interest without premium or penalty. As of September 30, 2020, $4,000,000 remained outstanding and had accrued interest of $73,333.

15

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

8. Convertible promissory notes (Restated) (continued)

On June 5, 2020, the Company entered into a Securities Purchase Agreement with investor LGH Investments LLC (the “Investor”) for (i) a Promissory Note (the “Convertible Promissory Note”) in the original principal amount of $1,210,000, convertible into shares of common stock, (ii) warrants entitling the Investor to acquire 1,075,000 shares of common stock (the “Warrants”) and (iii) 200,000 restricted common shares in the Company as an inducement grant (the “Inducement Shares”). Such note contained certain default provisions, as defined, resulting in net proceeds of $1,100,000. As part of the Securities Purchase Agreement, the Company established a reserve of shares of its authorized but unissued and unreserved common stock in the amount of 11,000,000 shares for purposes of exercise of the Warrant or conversion of the Convertible Promissory Note. The Convertible Promissory Note matures on February 5, 2021 and includes a one-time interest charge of 8% to be applied on the issuance date to the original principal amount. The Investor can convert the Convertible Promissory Note and interest at any time prior to maturity to the number of shares of common stock, equal to the amount obtained by dividing (i) the amount of the unpaid principal and interest on the note by (ii) $0.25. The Warrants have an exercise price of $0.35 per share and have a term of five years and recorded as a derivative liability (see Footnote 12). With respect to the Inducement Shares, in the event the Company’s share price has declined on the date on which the Investor seeks to have the restricted legend removed on such shares, the Company agrees to issue the Investor additional shares such that the aggregate value of the Inducement Shares equals the aggregate value of the Inducement Shares as of June 5, 2020. The Inducement Shares were issued on September 11, 2020 and included in common stock and additional paid in capital.

On August 6, 2020, the Company repaid all amounts owing to LGH Investments, LLC in the original principal amount of $1,210,000. As a result, all obligations of the Company under the convertible promissory note have been terminated. The Company recorded a loss on extinguishment of debt of approximately $503,234 during the three and nine months ended September 30, 2020. The Warrants issued to LGH Investments, as more fully described in Note 11, contain certain ratchet provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrants. As a result of certain dilutive issuances of securities by the Company during the third quarter of 2020, the exercise price of the Warrants decreased to $0.01 per share and the number of shares subject to the Warrants increased to 35,000,000 shares as of September 30, 2020.  A Derivative Liability – Warrant was recorded for this decrease in exercise price with the offset to  loss on warrant liability.

9. SBA Loans

On May 28, 2020, the Company received proceeds from a loan in the approximate amount of $460,000 (the “PPP Loan”) from Truist Bank, as lender, pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (15 U.S.C. 636(a)(36)) (the “CARES Act”). The PPP Loan matures on May 28, 2022 and bears interest at a rate of 1% per annum. Commencing December 12, 2020, the Company is required to pay the lender equal monthly payments of principal and interest. The PPP Loan is evidenced by a promissory note dated May 28, 2020 (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties and covenants. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

16

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

9. SBA Loans (continued)

All or a portion of the PPP Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application by the Company beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements.The ultimate forgiveness of the PPP Loan is also predicated upon regulatory authorities concurring with management’s good faith assessment that the current economic uncertainty made the loan request necessary to support ongoing operations. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for the PPP Loan, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive the PPP Loan, the Company may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. Under the terms of the PPP Loan, the Company may be eligible for full or partial loan forgiveness in the third quarter of 2020. The Company plans to complete the application for loan forgiveness in the fourth quarter of 2020, however, no assurance is provided that the Company will apply for, or obtain forgiveness for, any portion of the PPP Loan. As of September 30, 2020, $321,821 is classified as current and $142,514 is classified as non-current.

On June 10, 2020, the Company secured a loan offered by the U.S. Small Business Administration (SBA) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of COVID-19 pandemic on the Company’s business. The principal amount of this loan was $150,000 and interest accrued at the rate of 3.75% per annum. This loan was paid off in full on August 5, 2020 with proceeds from the NWPSA Senior Notes as part of the conditions of that agreement.

10. Convertible notes payable, related parties and Notes payable, related parties

The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal was due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because it is a shareholder in the Company and has a security agreement with the Company to provide a first security interest in the assets of the Company. An Event of Default under the notes payable, related parties occurred on December 31, 2016 (“Default”). As a result of the Default, the notes payable, related parties accrued interest at the rate of 10% per annum since January 2, 2017 through August 5, 2020.

On August 6, 2020, the Company entered into a letter agreement (the “HealthTronics Agreement”) with HealthTronics, Inc. (“HealthTronics”), pursuant to which the Company paid off all outstanding debt due and owed to HealthTronics. Pursuant to the HealthTronics Agreement, as consideration for the extinguishment of the debt due and owed to HealthTronics, (i) the Company paid to HealthTronics an amount in cash equal to $4,000,000, (ii) HealthTronics exercised all of its outstanding Class K Warrants to purchase 7,200,000 shares of common stock, (iii) the Company issued to HealthTronics a convertible promissory note in the principal amount of $1,372,743, and (iv) the Company and HealthTronics entered into a Securities Purchase Agreement dated August 6, 2020 pursuant to which the Company issued to HealthTronics an aggregate of 8,275,235 shares of common stock and an accompanying Class E warrant to purchase up to an additional 8,275,235 shares of common stock. The warrant has an exercise price of $0.25 per share and a three year term.

17

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

10. Convertible notes payable, related parties and Notes payable, related parties (continued)

The convertible promissory note, with principal amount of $1,372,743, matures on August 6, 2021 and accrues interest at a rate equal to 12.0% per annum.  In the event that the Seller Note has not been repaid prior to January 1, 2021, Healthronics may elect to convert the outstanding principal amount plus any accrued but unpaid interest thereon into shares of the Company’s common stock, at a conversion price of $0.10 per share. As this conversion option is contingent, the conversion option has not been bifurcated from the host instrument as of September 30, 2020. The convertible promissory note is expressly subordinate to the NWPSA “Senior Notes” described in Note 8. The Company may prepay the outstanding principal balance, together with any accrued but unpaid interest without premium or penalty. As of September 30, 2020, $1,372,743 remained outstanding and had accrued interest of $24,822.

The notes payable, related parties were fully paid off as of September 30, 2020 due to the letter agreement described above and had an aggregate outstanding principal balance of $5,372,743 at December 31, 2019. The related accrued interest, related parties currently payable totaled $1,859,977 at December 31, 2019. Interest expense on notes payable, related parties totaled $61,334 and $175,522 for the three months ended September 30, 2020 and 2019, respectively and $431,070 and $508,193 for the nine months ended September 30, 2020 and 2019, respectively.

On August 6, 2020, the Company terminated that certain line of credit agreement with A. Michael Stolarski, a member of the Company’s board of directors, dated December 29, 2017 and as amended November 12, 2018, in the amount of $1,000,000 (the “Stolarski Line of Credit”). As consideration for the termination of the Stolarski Line of Credit, the Company issued to A. Michael Stolarski a convertible promissory note in the principal amount of $223,511 (the “Stolarski Note”). The Stolarski Note has a maturity date of August 6, 2021 and accrues interest at a rate equal to 12.0% per annum. In the event that the Stolarski Note has not been repaid prior to January 1, 2021, the holder may elect to convert the outstanding principal amount plus any accrued by unpaid interest thereon into shares of common stock at a conversion price of $0.10 per share.

11. Warrant Liabilities (Restated)

On August 6, 2020, the Company, issued 132,816,250 warrants to investors and the placement agent in connection with a private placement offering (Note 14). Additionally, on that date, the Company issued 13,091,160 warrants to the holder of the Senior Notes (Note 7) and 8,275,235 warrants to settle certain outstanding debt (Note 10).

At the time of issuance of the warrants, if all outstanding convertible securities were converted into shares of common stock, the Company would have exceeded its available authorized shares of common stock of 600,000,000 shares. If all outstanding convertible securities were converted into shares of common stock, the Company would have 713,439,897 shares issued and outstanding.  As a result of the limits on the Company’s authorized shares, a portion of the Company’s obligations under the warrants have been determined to be a liability.

The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480 “Distinguishing Liabilities from Equity”. In accordance with the accounting guidance, 111,210,902 of the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations.

18

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

11. Warrant Liabilities (continued)

The fair value of the warrant liabilities was measured using the binomial model. Significant inputs into the model at the inception and reporting period measurement dates are as follows:

Private Placement Warrants

Binomial Assumptions		Issuance date (1) August 6, 2020				Period ended September 30, 2020
Exercise Price(1)		$	0.25			$	0.25
Warrant Expiration Date (1)	August 6, 2023				August 6, 2023
Stock Price (2)		$	0.24			$	0.22
Interest Rate (annual) (3)			0.13	%			0.16	%
Volatility (annual) (4)			91.49	%			88.96	%
Time to Maturity (Years)			3				3
Calculated fair value per share		$	0.135			$	0.119

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company. dated August 6, 2020.}

_{(2) Based on the trading value of common stock of the Company. as of August 6, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of  the Company as of August 6, 2020 and each presented period ending date.}

NH Expansion Warrants:

Binomial Assumptions		Issuance date (1) August 6, 2020				Period ended September 30, 2020
Exercise Price(1)		$	0.01			$	0.01
Warrant Expiration Date (1)	August 6, 2030				August 6, 2030
Stock Price (2)		$	0.24			$	0.22
Interest Rate (annual) (3)			0.21	%			0.69	%
Volatility (annual) (4)			102.09	%			184.77	%
Time to Maturity (Years)			10				10
Calculated fair value per share		$	0.233			$	0.22

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.}

_{(2) Based on the trading value of common stock of the Company as of August 6, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of the Company as of August 6, 2020 and each presented period ending date.}

On August 6, 2020, the Company consummated a series of transactions, involving the issuance of common stock and various equity-linked instruments, each of which constitutes a dilutive issuance in the LGH Warrant Agreement (see Note 8) which triggered the ratchet provision, with the effect of decreasing the warrant’s exercise price to $0.01. With the reduction of the warrant exercise price from the initial $0.35 to $0.01 per share, in order to maintain the $350,000 aggregate exercise amount in effect prior to the adjustment (1,000,000 warrant shares with an exercise price of $0.35), as required by the ratchet provision, the Company was required to increase the number of warrant shares to 35,000,000, thereby entitling LGH to purchase 35,000,000 shares of the Company’s common stock at $0.01 per share.

The Company determined that these warrants meet the definition of a derivative liability.  Pursuant to this conclusion, the warrant was recorded as derivative liability at inception, initially measured at its fair value, and subsequently remeasured at fair value at each reporting date, with changes in the fair value reported in earnings.

19

The derivative liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility as inputs.  The fair value of the derivative warrant liability was measured using the Black Scholes Merton (“BSM") option pricing model.  Given the plain vanilla nature of the Warrant terms, including the absence of any exercise contingencies, the BSM sufficiently captures the terms of the Warrant as inputs to the valuation and produces a value that is not materially different from a binomial/lattice model using the following assumptions:

LGH
Binomial Assumptions	Issuance date (1) 5-Jun-20			Period ended 30-Jun-20			Ratchet Date (5) 6-Aug-20			Period ended 30-Sep-20
Exercise Price(1)	$	0.35		$	0.35		$	0.01		$	0.01
Warrant Expiration Date (1)	5-Jun-25			5-Jun-25			5-Jun-25			5-Jun-25
Stock Price (2)	$	0.27		$	0.2625		$	0.2437		$	0.22
Interest Rate (annual) (3)		0.29	%		0.29	%		0.20	%		0.26	%
Volatility (annual) (4)		107	%		107	%		103	%		101	%
Time to Maturity (Years)		5			4.93			4.83			4.68
Calculated fair value per share	$	0.25		$	0.25		$	0.24		$	0.21

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated June 5, 2020.}

_{(2) Based on the trading value of common stock of the Company as of June 5, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of June 5, 2020, and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of the Company as of June 6, 2020, and each presented period ending date.}

_{(5) Based on the terms provided in the warrant agreement to purchase common stock at date of the ratchet trigger August 6, 2020.}

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

Warrant Liability	Warrants Outstanding		Fair Value per Share		Fair Value
Fair Value at remeasurement date of June 30, 2020		1,000,000		0.249	$	249,049
Additional Warrants classified as Liabilities August 6, 2020		111,210,902		0.206		22,888,017
Fair Value at date of August 6, 2020		112,210,902		0.206	$	23,137,066
Gain or (Loss) on warrant liability						(5,590,806	)
Fair Value as of period ended September 30, 2020		112,210,902		0.156		17,546,260

During the three and nine months ending September 30, 2020, the Company recorded a loss on changes in fair value of warrant liability of $ 5,590,806, respectively. During the three and nine months ending September 30, 2019, there were no warrant liabilities or corresponding changes in valuation.

20

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

12. Preferred Stock

On February 6, 2020, the Company entered into a Series C Preferred Stock Purchase Agreement (the “Series C Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of 90 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series C Preferred Stock”), for an aggregate total purchase price of $2,250,000.

On January 31, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series C Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate 90 shares of our preferred stock as Series C Convertible Preferred Stock. On May 14, 2020, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of eight shares of the Company’s Series D Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series D Preferred Stock”), for an aggregate total purchase price of $200,000. On May 14, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series D Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate eight shares of our preferred stock as Series D Convertible Preferred Stock.

Subject to the terms of the Certificates of Designation, each share of Series C Preferred Stock and Series D Preferred Stock is convertible into shares of common stock of the Company at a rate equal to the stated value of such share of Series C Preferred Stock and Series D Preferred Stock of $25,000, divided by the conversion price of $0.14 per share (subject to adjustment from time to time upon the occurrence of certain events as described in the Certificate of Designation). The Certificates of Designation became effective upon filing with the Secretary of State of the State of Nevada. If all outstanding shares of Series C Preferred Stock and Series D Preferred Stock were converted into common stock at the original conversion rate, such shares would convert into an aggregate of 17,500,000 shares of common stock.

On July 23, 2020, in connection with the Company’s 2020 Annual Meeting of Stockholders, the Company’s stockholders approved, among other matters, an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 355,000,000 to 600,000,000.  On September 20, 2020, Series C and D holders converted their preferred shares into 17,499,958 shares of common stock.

13. Equity transactions

Approval of reverse split of common stock

On July 23, 2020, in connection with the Company’s 2020 Annual Meeting of Stockholders, the Company’s stockholders approved the Company to amend the Company’s Articles of Incorporation to effect a reverse split of the Company’s outstanding common stock at a ratio of between 1-for-10 and 1-for-50, with the exact ratio to be determined by the board of directors of the Company in its sole discretion. As of the filing of this 10-Q report, the Company has not effected a reverse split of its stock.

21

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

13. Equity transactions (continued)

Warrant Exercises

During the nine months ended September 30, 2020, the Company issued 1,000,000 shares of common stock upon the exercise of 1,000,000 Class P Warrants to purchase shares of stock and an exercise price of $0.01 per share under the terms of the respective warrant agreement.

During the nine months ended September 30, 2020, the Company issued 7,200,000 shares of common stock to a related party upon the exercise of Class K Warrants upon the conversion of accrued interest related to a note payable, related party totaling $636,000, as described in Note 10.

Conversion of liabilities

During the nine months ended September 30, 2020, the Company issued 2,579,789 shares of common stock upon the conversion of short term notes payable in the principal and accrued interest amount of $354,729 with the receipt of notices of Class L warrant exercises, all pursuant to the terms of the short term notes payable.

During the nine months ended September 30, 2020, the Company issued 2,250,000 shares of common stock upon the conversion of short term notes payable in the principal and accrued interest amount of $210,000 pursuant to the terms of the short term notes payable.

During the nine months ended September 30, 2020, the Company issued 15,475,235 shares of common stock to a related party upon the conversion of accrued interest related to a note payable, related party totaling $2,291,047, as described in Note 10.

Conversion of advances from related parties

During the nine months ended September 30, 2020, the Company issued 262,811 shares of common stock upon the conversion of advances from related parties in the amount of $18,098 with the receipt of notice of Series A Warrant exercise to purchase shares of stock under the terms of the respective warrant agreement.

Consulting Agreement

In January 2020, the Company entered into a nine month consulting agreement for which the fee for the services was to be paid with common stock. The number of shares to be paid with common stock was 1,000,000 earned upon signing and an additional 1,000,000 upon agreement by both consultant and the Company no later than May 1, 2020. The Company issued 1,000,000 shares in March 2020 and 1,000,000 shares in April 2020. The fair value of the shares of $380,000 was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

The consulting agreement was extended to November 30, 2020 with an additional 2,000,000 common stock shares issued for services in August and September 2020. The fair value of the shares of $450,000 was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

The Company entered into a separate agreement for investor relations services for which the fee was paid with common stock. The Company issued 3,000,000 common stock shares with a fair value of $630,000 which was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

22

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

13. Equity transactions (continued)

PIPE Offering (Restated)

On December 11, 2019, the Company entered into a common stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stock at a purchase price of $0.14 per share. During the nine months ended September 30, 2020, the Company issued 1,071,428 shares of common stock in conjunction with this offering and received $150,000 in cash proceeds.

On August 6, 2020, the Company entered into a Securities Purchase Agreement in connection with the acquisition of UltraMIST, as discussed in Note 4, and issued 123,550,000 shares of common stock and accompanying Class E Warrants to purchase up to an additional 123,550,000 shares of common stock to certain investors for an aggregate purchase price of $0.20 per share of common stock and accompanying Warrant. It also issued Class E Warrants to a third-party placement agent to purchase up to 9,266,250 shares of common stock on the same terms as the Warrants. The Warrants have an exercise price of $0.25 per share and a three year term.  The private placement generated net proceeds of $21,456,468. The shares of common stock issued in the private placement have a par value of $0.001, resulting in an increase to common stock of $123,550. Since at the date of issuance the Company did not have a sufficient number of authorized shares to satisfy the Warrants in the event that they were exercised (and all other outstanding convertible securities were converted into shares of common stock) which could cause the net cash settlement of the Warrants, the Company recorded a liability of $ 8,656,165 for the fair value of the Warrants that were in excess of the available authorized shares. The Company recorded the residual amount of $ 12,408,966 from the net proceeds to stockholders’ equity.

Inducement Shares

During the nine months ended September 30, 2020, the Company issued 200,000 shares of common stock related to the June 5, 2020, Securities Purchase Agreement with LGH Investments, LLC, as described in Note 10.

Stock Option Exercise

During the nine months ended September 30, 2020, the Company issued 225,000 shares of common stock upon the exercise of stock options resulting in net proceeds of $44,250.

Litigation Settlement

During the nine months ended September 30, 2020, the Company issued 200,000 shares of restricted common stock upon the settlement of outstanding litigation. The fair value of the shares of $50,000 was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

23

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

14. Warrants (Restated)

A summary of the warrant activity during the nine months ended September 30, 2020 is presented as follows:

Warrant class	Outstanding as of December 31, 2019		Issued		Exercised			Expired			Outstanding as of September 30, 2020
Class E Warrants		-		141,091,485		-			-			141,091,485
Class K Warrants		7,200,000		-		(7,200,000	)		-			-
Class O Warrants		909,091		-		-			-			909,091
Class P Warrants		1,365,000		-		(1,000,000	)		(100,000	)		265,000
LGH Warrant		-		35,000,000		-			-			35,000,000
NH Warrant		-		13,091,160		-			-			13,091,160
		9,474,091		189,182,645		(8,200,000	)		(100,000	)		190,356,736

A summary of the warrant exercise price per share and expiration date is presented as follows:

	Exercise price/share		Expiration date
Class E Warrants	$	0.25	August 2023
Class K Warrants	$	0.08	June 2025
Class K Warrants	$	0.11	August 2027
Class O Warrants	$	0.11	January 2022
Class P Warrants	$	0.20	June 2024
LGH Warrant	$	0.01	June 2025
NH Warrant	$	0.01	August 2030

The fair value of the common stock purchase warrants is estimated on the date of grant using the Black-Scholes option pricing model which approximates the binomial model using the following weighted average assumptions for the three and nine months ended September 30, 2020:

Weighted average contractual terms in years	1.3
Weighted average risk free interest rate	0.15	%
Weighted average volatility	92.76	%

15. Commitments and contingencies

Operating Leases

The Company is a party to certain operating leases. The Company has entered into a lease agreement, as amended, for office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis.

24

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

15. Commitments and contingencies (continued)

For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as separate lease components. Non-leasing components are not included in the ROU asset.

Right of use assets and Lease liability – right of use consist of the following:

	September 30, 2020
Right of use assets	$	442,197

	September 30, 2020
Lease liability - right of use
Current portion	$	251,372
Long term portion		222,815
	$	474,187

As of September 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following:

Year ending December 31,	Amount
2020 (remainder)	$	71,918
2021		290,552
2022		96,195
2023		68,017
2024		8,028
2025		3,345
Total lease payments		538,055
Less: Present value adjustment		(63,868	)
Lease liability - right of use	$	474,187

25

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

15. Commitments and contingencies (continued)

As of September 30, 2020, the Company’s operating lease had a weighted average remaining lease term of 2.5 years and a weighted average discount rate of 12%.

Rent expense for the three months ended September 30, 2020 and 2019 was $84,115 and $49,217, respectively, and for the nine months ended September 30, 2020 and 2019 was $201,991 and $148,172, respectively.

Financing Lease

For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease is included in Property and equipment, net on our Condensed Consolidated Balance Sheets. Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense.

Right of use assets and Lease liability – right of use consist of the following:

	September 30, 2020
Right of use assets	$	462,405

	September 30, 2020
Lease liability - right of use
Current portion	$	187,416
Long term portion		284,588
	$	472,004

As of September 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following:

Year ending December 31,	Amount
2020 (remainder)	$	58,648
2021		234,593
2022		199,793
2023		18,388
Total	$	511,422

As of September 30, 2020, the Company’s financing leases had a weighted average remaining lease term of 2.7 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 12.6%.

As of September 30, 2020, the Company did not have additional operating or financing leases that have yet commenced.

26

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

15. Commitments and contingencies (continued)

Litigation

From time to time, the Company is subject to various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The Company believes that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

16. Revenue

The Company accounts for revenue in accordance with ASC 606.

Disaggregation of Revenue

The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and nine months ended September 30, 2020 and 2019:

	Three Months Ended September 30, 2020						Three Months Ended September 30, 2019
	United States		International		Total		United States		International		Total
Product	$	1,301,942	$	19,306	$	1,321,248	$	9,832	$	149,023	$	158,855
License fees		-		29,447		29,447		6,250		10,000		16,250
Other Revenue		7,811		608,390		616,201		25		22,510		22,535
	$	1,309,753	$	657,143	$	1,966,896	$	16,107	$	181,533	$	197,640

	Nine Months Ended September 30, 2020						Nine Months Ended September 30, 2019
	United States		International		Total		United States		International		Total
Product	$	1,398,672	$	66,475	$	1,465,147	$	147,999	$	296,088	$	444,087
License fees		-		39,447		39,447		18,750		170,557		189,307
Other Revenue		7,486		686,708		694,194		25		59,160		59,185
	$	1,406,158	$	792,630	$	2,198,788	$	166,774	$	525,805	$	692,579

The Company’s partner in the joint venture agreement in Brazil, the IDIC Group, will have the right to receive prioritized dividends until the full reimbursement of the $600,000 partnership fee and expenses incurred in the formation of the joint venture company.

Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited.

17. Related party transactions

During the three and nine months ended September 30, 2020 and 2019, the Company recorded $10,105 and $10,682, respectively, and $36,315 and $148,849 respectively, in revenue from an entity owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. Contract liabilities includes a balance at September 30, 2020 and 2019 of $80,838 from this related party.

27

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

18. Stock-based compensation

During the nine months ended September 30, 2020, 60,000 stock options to purchase the Company’s common stock were forfeited due to termination and 1,500,000 stock options to purchase the Company’s common stock expired without exercise.

The range of exercise prices for options was $0.04 to $2.00 for options outstanding at September 30, 2020 and December 31, 2019, respectively. The aggregate intrinsic value for all vested and exercisable options was $1,994,741 and $2,085,866 at September 30, 2020 and December 31, 2019, respectively.

The weighted average remaining contractual term for outstanding exercisable stock options was 6.14 and 6.6 years as of September 30, 2020 and December 31, 2019, respectively.

19. Earnings (loss) per share

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following:

	September 30, 2020		September 30, 2019
Stock options		32,618,385		33,683,385
Warrants		190,356,736		12,854,091
Convertible promissory notes		56,988,540		9,204,160
Shares issuable		-		14,617,225
Anti-dilutive equity securities		279,963,661		70,358,861

20. Restatement of financial statements

On February 12, 2021, the Company determined an error in the accounting for certain of the Company’s warrants previously issued. Such warrants should have been reflected as liabilities on the condensed consolidated balance sheets included in the Original 10-Q, rather than as a component of equity.

Specifically, the Company’s financial statements as of and for the three and nine months ended September 30, 2020, contained the following errors: (i) understatement of derivative warrant liability of $8,225,956 (ii) understatement of weighted average shares outstanding of 82,383,022 for the three months ended September 30, 2020 and 2,674,538 for the nine months ended September 30, 2020 and (iii) understatement of the Net Loss on the Statement of Operations of $6,626,907.

28

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

20. Restatement of financial statements (continued)

The effects of the adjustments on the Company’s previously issued financial statements as of and for the three and nine months ended September 30, 2020 are summarized as follows:

As of September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
LIABILITIES
CURRENT LIABILITIES
Warrant Liability		6,440,249			11,106,011			17,546,260
TOTAL CURRENT LIABILITIES		19,715,578			11,106,011			30,821,589
NON - CURRENT LIABILITIES
Warrant Liability		2,880,055			(2,880,055	)		-
TOTAL NON-CURRENT LIABILITIES		14,023,530			(2,880,055	)		11,143,475
TOTAL LIABILITIES		33,739,108			8,225,956			41,965,064
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
ADDITIONAL PAID-IN CAPITAL		137,120,956			(1,599,049	)		135,521,907
ACCUMULATED DEFICIT		(138,398,688	)		(6,626,907	)		(145,025,761	)
TOTAL STOCKHOLDERS' DEFICIT		(873,002	)		(8,225,956	)		(9,098,958	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	32,866,106		$	(0	)	$	32,866,106

Three Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
OTHER INCOME (EXPENSES)
Gain or (Loss) on warrant derivative liability		1,036,101			(6,626,907	)		(5,590,806	)
TOTAL OTHER INCOME (EXPENSES)		(242,962	)		(6,626,907	)		(6,869,869	)
NET LOSS		(6,011,730	)		(6,626,907	)		(12,638,637	)
TOTAL COMPREHENSIVE LOSS	$	(6,008,938	)	$	(6,626,907	)	$	(12,635,845	)
LOSS PER SHARE
Net loss - basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.03	)
Weighed average shares outstanding - basic and diluted		302,119,428			82,383,022			384,502,450

Nine Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
OTHER INCOME (EXPENSES)
Loss on warrant liability		1,036,101			(6,626,907	)		(5,590,806	)
TOTAL OTHER INCOME (EXPENSES)		(808,637	)		(6,626,907	)		(7,435,544	)
NET LOSS		(12,645,898	)		(6,626,907	)		(19,272,805	)
TOTAL COMPREHENSIVE LOSS	$	(12,645,029	)	$	(6,626,907	)	$	(19,271,936	)
LOSS PER SHARE
Net loss - basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.06	)
Weighed average shares outstanding - basic and diluted		323,730,859			2,674,538			326,405,397

Nine Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(12,645,898	)		(6,626,907	)		(19,272,805	)
Gain or (Loss) on warrant liability		(1,036,101	)		6,626,907			5,590,806
NET CASH USED BY OPERATING ACTVITIES		(9,779,889	)		-			(9,779,889	)

29

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2020

21. Subsequent events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.

Option Exercise

Subsequent to September 30, 2020, the Company issued 100,000 shares of common stock upon the exercise of 100,000 stock options to purchase shares of stock under the terms of the respective option agreement.

Shares issued for services

Subsequent to September 30, 2020, the Company issued 1,000,000 shares of common stock for consulting services previously rendered.

22. Supplier Dispute

In May 2021, the Company received notification that it is not in compliance with the License Agreement discussed in Note 6.  The Company is in the process of reviewing the notification and preparing a response.  It is too early to determine the outcome of this matter.  Any potential impact to the Company cannot be fully determined at this time.

30

Item 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this report, and together with our audited consolidated financial statements, related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as of and for the year ended December 31, 2019 included in our Annual Report on Form 10-K, filed with the SEC on March 30, 2020 (the “2019 Annual Report”).

Overview

We are a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. Our initial focus is regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures.

Our lead regenerative product in the United States is the dermaPACE^® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. FDA granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo process. As a result of this decision, the Company was able to immediately market the product for the treatment of Diabetic Foot Ulcers (DFU) as described in the De Novo request, subject to the general control provisions of the FD&C Act and the special controls identified in this order.

On August 6, 2020 the Company entered into an Asset Purchase Agreement with Celularity pursuant to which the Company acquired Celularity’s UltraMIST assets.  The UltraMIST® System provides through a fluid mist a low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The ultrasound acoustic waves promote healing by reducing inflammation and bacteria in the wound bed, while also increasing the growth of new blood vessels to the area.  The UltraMIST® System treatment must be administered by a healthcare professional.  This proprietary technology has been cleared by the U.S. Food and Drug Administration (FDA) for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.

In connection with the Asset Purchase Agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl®. The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the Field and Territory (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term.

Our portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. We intend to apply our Pulsed Acoustic Cellular Expression (PACE^®) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions. The Company is marketing its dermaPACE System for treatment usage in the United States and will continue to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities.

31

Our lead product candidate for the global wound care market, dermaPACE, has received FDA clearance for commercial use to treat diabetic foot ulcers in the United States and the CE Mark allowing for commercial use on acute and chronic defects of the skin and subcutaneous soft tissue. We believe we have demonstrated that our patented technology is safe and effective in stimulating healing in chronic conditions of the foot and the elbow through our United States FDA Class III Premarket Approvals (“PMAs”) approved OssaTron® device, and in the stimulation of bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of our OssaTron, Evotron®, and orthoPACE® devices in Europe and Asia.

We are focused on developing our Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in:

● wound conditions, including diabetic foot ulcers, venous and arterial ulcers, pressure sores, burns and other skin eruption conditions;

● orthopedic applications, such as eliminating chronic pain in joints from trauma, arthritis or tendons/ligaments inflammation, speeding the healing of fractures (including nonunion or delayed-union conditions), improving bone density in osteoporosis, fusing bones in the extremities and spine, and other potential sports injury applications;

● plastic/cosmetic applications such as cellulite smoothing, graft and transplant acceptance, skin tightening, scarring and other potential aesthetic uses; and

● cardiac applications for removing plaque due to atherosclerosis improving heart muscle performance.

In addition to healthcare uses, our high-energy, acoustic pressure shock waves, due to their powerful pressure gradients and localized cavitational effects, may have applications in secondary and tertiary oil exploitation, for cleaning industrial waters and food liquids and finally for maintenance of industrial installations by disrupting biofilms formation. Our business approach will be through licensing and/or partnership opportunities.

In March 2020, the World Health Organization characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. Since then, the COVID-19 pandemic has rapidly spread across the globe and has already resulted in significant volatility, uncertainty and economic disruption. While the COVID-19 pandemic has not had a material adverse financial impact on the Company’s operations to date, the pandemic has resulted in the decreased demand for a broad variety of products, including from our customers, and will also disrupt supply channels and marketing activities for an unknown period of time until the disease is contained. Future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. It is difficult at this time to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in future periods due to numerous uncertainties. The Company is closely monitoring the impact of the pandemic on all aspects of its business and operations. We have received funds for disaster relief loans through the SBA to help minimize the impact on our business.

We were formed as a Nevada corporation in 2004. We maintain a public internet site at www.sanuwave.com. The information on our websites is not part of this Form 10-Q.

Recent Clinical Highlights and Updates

A dosage study has been developed for launch in Poland to optimize dermaPACE system treatment dosage for producing a more rapid reduction in size of a diabetic foot ulcer (“DFU”). The focus will be on increasing the number of shock waves delivered per treatment, as a function of DFUs area. To determine the dosage necessary, three new distinctive regimens will be assessed during the study. This study started in April 2019 and is expected to be finalized in the fourth quarter of 2020, depending on availability of patients due to the COVID-19 pandemic.

A post-market pilot study to evaluate the effects of high energy acoustic shock wave therapy on local skin perfusion and healing of DFUs will be conducted at two sites: one in New Jersey and one in California. The intent of this trial is to quantify the level of increased perfusion and oxygenation during and after treatment with the dermaPACE system. This study started in April 2019 and is expected to be finalized in the fourth quarter of 2020, depending on availability of patients due to the COVID-19 pandemic.

32

Financial Overview (Restated)

Since our inception, our operations have primarily been funded from the sale of capital stock, notes payable, and convertible debt securities. We expect to devote substantial resources for the commercialization of the dermaPACE System and UltraMIST product line and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources. We incurred a net loss of $12,638,637 and $2,748,018 for the three months ended September 30, 2020 and September 30, 2019, respectively, and $19,272,805 and $7,679,766 for the nine months ended September 30, 2020 and the September 30, 2019, respectively.

These factors create substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the financial statement issuance date. Although no assurances can be given, we believe that potential additional issuances of equity, debt or other potential financing will provide the necessary funding for us to continue as a going concern for the next year. See “Liquidity and Capital Resources” for further information regarding our financial condition.

We cannot reasonably estimate the nature, timing and costs of the efforts necessary to complete the development and approval of, or the period in which material net cash flows are expected to be generated from, any of our products, due to the numerous risks and uncertainties associated with developing and marketing products, including the uncertainty of:

● the scope, rate of progress and cost of our clinical trials;

● future clinical trial results;

● the cost and timing of regulatory approvals;

● the establishment of successful marketing, sales and distribution channels and partnerships, including our efforts to expand our marketing, sales and distribution reach through joint ventures and other contractual arrangements;

● the cost and timing associated with establishing reimbursement for our products;

● the effects of competing technologies and market developments; and

● the industry demand and patient wellness behavior.

Any failure to complete the development of our product candidates in a timely manner, or any failure to successfully market and commercialize our product candidates, would have a material adverse effect on our operations, financial position and liquidity. A discussion of the risks and uncertainties associated with us and our business are set forth under the section entitled “Risk Factors – Risks Related to Our Business” in our 2019 Annual Report.

On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (15 U.S.C. 636(a)(36)) (the “CARES Act”) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain refundable employee retention credits.

On May 29, 2020, the Company received the proceeds from a loan in the amount of approximately $460,000 (the “PPP Loan”) from Truist Bank, as lender, pursuant to the Paycheck Protection Program (“PPP”) of under the CARES Act. The PPP Loan matures on May 28, 2022 and bears interest at a rate of 1% per annum. Commencing December 12, 2020, the Company is required to pay the lender equal monthly payments of principal and interest. The PPP Loan is evidenced by a promissory note dated May 28, 2020, which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties and covenants. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Under the terms of the PPP Loan, the Company may be eligible for full or partial loan forgiveness in the fourth quarter of 2020, however, no assurance is provided that the Company will apply for, or obtain forgiveness for, any portion of the PPP Loan.

33

Critical Accounting Policies and Estimates

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses.

On an ongoing basis, we evaluate our estimates and judgments, including those related to the recording of the allowances for doubtful accounts, estimated reserves for inventory, estimated useful life of property and equipment, the determination of the valuation allowance for deferred taxes, the estimated fair value of the warrant liability, and the estimated fair value of stock-based compensation. We base our estimates on authoritative literature and pronouncements, historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions. The results of our operations for any historical period are not necessarily indicative of the results of our operations for any future period.

Our significant accounting policies are more fully described in Note 2 to our consolidated financial statements filed with our 2019 Annual Report. For a description of recent accounting policies and the impact on our financial statements, refer to Note 3 in the condensed consolidated financial statements in this 10-Q filing.

Restatement of Previously Issued Financial Statements

This quarterly report contains the restated condensed consolidated balance sheet as of September 30, 2020 and the effects of the restated condensed consolidated statements of operations for the three and nine months ended September 30, 2020.  Notes to the accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for further detail.

On February 12, 2021, the Company determined an error in the accounting related to underreporting of the amount of derivative warrant liability.  The Company changed its accounting for certain of the Company’s warrants previously issued in connection with convertible note payable as well as reclassification of warrants issued in the Aug 6, 2020 financing due to a lack of authorized shares.  Such warrants, should have been reflected as liabilities on the consolidated balance sheets included in the Original 10-Q, rather than as a component of equity.

Specifically, the change in treatment of the warrants resulted in a change to the equity, and liability portions of the consolidated balance sheets as of September 30, 2020 and resulted in a loss on the fair value of the derivative liabilities which impacted our results of operations and earnings (loss) per share as reported in our Original 10-Q.

Results of Operations for the Three Months ended September 30, 2020 and 2019 (Restated)

Revenues and Cost of Revenues

Revenues for the three months ended September 30, 2020 were $1,966,896, compared to $197,640 for the same period in 2019, an increase of $1,769,256, or 895%. Revenue resulted primarily from sales of Ultramist, Biovance and Interfyl, recognition of Brazil distribution fee and dermaPACE treatments. The increase in revenue for 2020 is primarily due to acquisition of Celularity assets and licensing fees and international distribution fees, as compared to the prior year.

Cost of revenues for the three months ended September 30, 2020 were $548,406 compared to $122,923 for the same period in 2019. Gross profit as a percentage of revenues was 72% for the three months ended September 30, 2020, compared to 38% for the same period in 2019. The increase in gross profit as a percentage of revenues in 2020 was primarily due to sales of Ultramist, Biovance and Interfyl which have a 60% gross profit and increase in high margin dermaPACE treatment fees.

34

Research and Development Expenses

Research and development expenses for the three months ended September 30, 2020 were $432,155, compared to $299,903 for the same period in 2019, an increase of $132,252, or 44%. The increase in research and development expenses in 2020, as compared to 2019, was due to higher salary and related costs due to increased headcount as a result of the Celularity asset acquisition and Profile repackaging project in 2020.

Selling and Marketing Expenses

Selling and marketing expenses for the three months ended September 30, 2020 were $1,373,475, compared to $335,472 for the same period in 2019, an increase of $1,038,003, or 309%. The increase in selling and marketing expenses in 2020, as compared to 2019, was due to higher salary and related costs due to increased headcount as a result of the Celularity asset acquisition, higher commissions and higher costs for tradeshows.

General and Administrative Expenses

General and administrative expenses for the three months ended September 30, 2020 were $5,054,508, as compared to $1,802,659 for the same period in 2019, an increase of $3,251,849, or 180%. The increase in general and administrative expenses in 2020, as compared to 2019, was due to engagement of specialists for integration of acquisition, implementation of ERP system and accounting for acquisition, increase in legal and consulting fees related to acquisition and increased operating costs such as utilities, rent, and IT services as a result of the acquisition.

Depreciation and amortization

Depreciation and amortization for the three months ended September 30, 2020 was $327,120, compared to $22,338 for the same period in 2019, an increase of $304,782 or 1,364%. The increase was due to goodwill recorded as a part of the acquisition and higher depreciation related to increase in fixed assets as a result of acquisition and leased dermaPACE devices.

Other Income (Expense)

Other income (expense) was a net expense of $6,869,869 for the three months ended September 30, 2020 as compared to a net expense of $362,363 for the same period in 2019, an increase of $6,507,506, or 1796%. The increase was primarily due to a loss on warrant valuation, a loss on extinguishment of debt and increase in interest expense due to entering into new debt.

Net Loss

Net loss for the three months ended September 30, 2020 was $12,638,637, or ($0.03) per basic and diluted share, compared to a net loss of $2,748,018, or ($0.01) per basic and diluted share, for the same period in 2019, an increase in the net loss of $9,890,619, or 358%.

35

Results of Operations for the Nine Months ended September 30, 2020 and 2019 (Restated)

Revenues and Cost of Revenues

Revenues for the nine months ended September 30, 2020 were $2,198,788, compared to $692,579 for the same period in 2019, an increase of $1,506,209, or 217%. Revenue resulted primarily from sales of Ultramist, Biovance and Interfyl, recognition of Brazil distribution fee and dermaPACE treatments. The increase in revenue for 2020 is primarily due to acquisition of Celularity assets and licensing fees and international distribution fees, as compared to the prior year.

Cost of revenues for the nine months ended September 30, 2020 were $663,630, compared to $402,657 for the same period in 2019. Gross profit as a percentage of revenues was 70% for the nine months ended September 30, 2020, compared to 42% for the same period in 2019. The increase in gross profit as a percentage of revenues in 2020 was primarily due to sales of Ultramist, Biovance and Interfyl which have a 60% gross profit and an increase in high margin dermaPACE treatment fees.

Research and Development Expenses

Research and development expenses for the nine months ended September 30, 2020 were $983,816, compared to $867,825 for the same period in 2019, an increase of $115,991, or 13%. The increase in research and development expenses in 2020, as compared to 2019, was due to higher salary and related costs due to increased headcount as a result of the Celularity asset acquisition and Profile repackaging project in 2020.  This is partially offset by decreased study expenses related to our new dosage study in Poland due to COVID-19 pandemic.

Selling and Marketing Expenses

Selling and marketing expenses for the nine months ended September 30, 2020 were $2,414,477, compared to $901,031 for the same period in 2019, an increase of $1513,446, or 168%. The increase in selling and marketing expenses in 2020, as compared to 2019, was due to higher salary and related costs due to increased headcount as a result of the Celularity asset acquisition and higher commissions.  There was a continued slow-down in the commercialization of dermaPACE in the third quarter of 2020 due to the COVID pandemic.

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2020 were $9,529,218, as compared to $4,746,519 for the same period in 2019, an increase of $4,782,699, or 101%. The increase in general and administrative expenses in 2020, as compared to 2019, was due to engagement of specialists for integration of acquisition, implementation of ERP system and accounting for acquisition, increase in legal and consulting fees related to acquisition and increased operating costs such as utilities, rent, and IT services as a result of the acquisition.

Depreciation and amortization

Depreciation and amortization for the nine months ended September 30, 2020 was $444,908, compared to $40,150 for the same period in 2019, an increase of $404,758 or 1,008%. The increase was due to goodwill recorded as a part of the acquisition and higher depreciation related to increase in fixed assets as a result of acquisition and leased dermaPACE devices.

Other Income (Expense)

Other income (expense) was a net expense of $7,435,544 for the nine months ended September 30, 2020 as compared to a net expense of $1,414,163 for the same period in 2019, an increase of $6,011,381, or 426%, in the net expense. The increase was primarily due to loss on warrant valuation, an increase in interest expense and loss on extinguishment of debt.

Net Loss

Net loss for the nine months ended September 30, 2020 was $19,272,805, or ($0.06) per basic and diluted share, compared to a net loss of $7,679,766, or ($0.04) per basic and diluted share, for the same period in 2019, an increase in the net loss of $11,593,039, or 151%.

36

Liquidity and Capital Resources (Restated)

We expect to devote substantial resources for the commercialization of the dermaPACE System and UltraMIST product line and will continue to research and develop the next generation of our technology as well as the non-medical uses of the PACE technology, both of which will require additional capital resources. We incurred a net loss of $19,272,805 and $7,679,766 for the nine months ended September 30, 2020 and September 30, 2019, respectively. Management is currently evaluating the impact on cash flows of the Company’s acquisition of certain assets of Celularity Inc., as more fully described in Note 4 to the Company’s condensed consolidated financial statements in this report. These factors create substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the financial issuance date.

Since inception in 2005, our operations have primarily been funded from the sale of capital stock, notes payable, and convertible debt securities.

The continuation of our business is dependent upon raising additional capital to fund operations through the next quarter and into the first quarter of 2021. Management expects the cash used in operations for the Company will be approximately $100,000 to $205,000 per month for the second half of 2020 as resources are devoted to the commercialization of the dermaPACE product including hiring of new employees, expansion of our international business and continued research and development of next generation of our technology as well as non-medical uses of our technology. Management’s plans are to obtain additional capital in 2020 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or obtain funds through financing transactions with unfavorable terms. The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.

We may also attempt to raise additional capital if there are favorable market conditions or other strategic considerations even if we have sufficient funds for planned operations. To the extent that we raise additional funds by issuance of equity securities, our shareholders will experience dilution and we may be required to use some or all of the net proceeds to repay our indebtedness, and debt financings, if available, may involve restrictive covenants or may otherwise constrain our financial flexibility. To the extent that we raise additional funds through collaborative arrangements, it may be necessary to relinquish some rights to our intellectual property or grant licenses on terms that are not favorable to us. In addition, payments made by potential collaborators or licensors generally will depend upon our achievement of negotiated development and regulatory milestones. Failure to achieve these milestones would harm our future capital position.

For the nine months ended September 30, 2020 and 2019, net cash used by operating activities was $9,779,889 and $4,684,611, respectively, primarily consisting of professional and consulting fees, compensation costs, research and development activities and general corporate operations. The increase in the use of cash for operating activities for the nine months ended September 30, 2020, as compared to the same period for 2019, was primarily due to the increase in net loss due to legal, professional and consulting fees related to integration of the acquisition, an increase in accrued expenses of $492,434 an increase in prepaid expenses of $502,346, an increase in accounts payable of $882,779, an increase of accrued employee compensation  of $1,091,858 and increase in interest payable, related parties of $785,132. Net cash used by investing activities for the nine months ended September 30, 2020 was $20,039,142 as compared to net cash used by investing activities for the same period in 2019 of $28,990. The increase in cash used by investing activities is due to the acquisition of UltraMIST from Celularity, as described in Note 4. Net cash provided by financing activities for the nine months ended September 30, 2020 was $33,449,131, which primarily consisted of $21,456,468 from private placement offerings, $13,346,547 from senior promissory notes, $2,450,000 proceeds from purchase of preferred stock, $1,100,000 from convertible notes, and $614,335 from SBA Loans. These proceeds were partially offset by debt payments of $5,457,663 and principal payments on financing leases of $114,806. Net cash provided by financing activities for the nine months ended September 30, 2019 was $4,738,556, which primarily consisted of $1,215,000 of proceeds from short term note, $2,055,414 of proceeds from exercise of warrants, $1,378,142 of proceeds from advances from related parties and $90,000 net increase in line of credit, related parties. Cash and cash equivalents increased by $3,631,136 for the nine months ended September 30, 2020.

37

Segment and Geographic Information

We have determined that we have one operating segment. Our revenues are generated from sales in United States, Europe, Canada, Asia and Asia/Pacific. All significant expenses are generated in the United States and all significant assets are located in the United States.

Contractual Obligations

Our major outstanding contractual obligations relate to our operating lease for our facility, purchase and supplier obligations for product component materials and equipment, and our notes payable, related parties. We have disclosed these obligations in our 2019 Annual Report.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Effects of Inflation

Due to the fact that our assets are, to an extent, liquid in nature, they are not significantly affected by inflation. However, the rate of inflation affects such expenses as employee compensation, office space leasing costs and research and development charges, which may not be readily recoverable during the period of time that we are bringing the product candidates to market. To the extent inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our condensed consolidated financial condition and results of operations.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required under Regulation S-K for “smaller reporting companies”.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2020. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not operating effectively as of September 30, 2020. Our disclosure controls and procedures were not effective because of the “material weakness” described below under “Management’s Annual Report on Internal Control over Financial Reporting.”

38

On February 12, 2021, the Company determined an error in the accounting related to underreporting of the amount of derivative warrant liabilities. The Company changed its accounting for certain of the Company’s warrants previously issued in connection with convertible note payable as well as reclassification of warrants issued in the August 6, 2020 financing due to a lack of authorized shares. Such warrants, and reservation of additional shares should have been reflected as liabilities on the consolidated balance sheets included in the Original 10-Q, rather than as a component of equity.

Specifically, the change in treatment of the warrants resulted in a change to the equity, and liability portions of the condensed consolidated balance sheets as of September 30, 2020 and resulted in a loss on the fair value of the derivative liabilities which impacted our results of operations and earnings (loss) per share as reported in our Original 10-Q.

Management’s Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the Company. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

Management, with the participation of the Chief Executive Officer (principal executive officer) and the Chief Financial Officer (principal financial and accounting officer), evaluated the effectiveness of the Company’s internal control over financial reporting as of September 30, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework (2013).

We have identified three material weaknesses in our internal control over financial reporting process resulting from a lack of internal expertise and resources to analyze and properly apply generally accepted accounting principles to complex and non-routine transactions such as complex financial instruments and derivatives and complex sales distribution agreements, a lack of internal resources to analyze and properly apply generally accepted accounting principles to accounting for equity components of service agreements with select vendors and cybersecurity breaches from email spoofing. As a result, management concluded that our internal control over reporting was not effective as of September 30, 2020.

39

Management’s Plan to Remediate Material Weaknesses

Beginning in 2019 and continuing in 2020, we engaged external consultants with appropriate experience applying GAAP technical accounting guidance, and we have hired additional accounting personnel. We engaged external consultants to review revenue recognition for new products, lease agreements, internal controls and related procedures and review of documentation of internal controls in addition to new equity and debt financing arrangements. We also contracted with an external financial reporting consultants in 2020, and the company plans on hiring additional account staff to enable further segregation of duties and additional review procedures.

We have also implemented cybersecurity training for all employees and redesign of procedures that cyber security breaches may impact and worked with our third party IT vendor to develop a training plan for all existing and new employees related to cyber and implemented related controls around information technology infrastructure. In addition, an additional employee was hired to assist with the management of IT controls and enhance internal IT resources. Going forward, this employee will monitor our third party IT vendor’s testing and monitoring efforts and where necessary implement new controls as the Company grows. These internal controls have been documented and procedures implemented.

There is no assurance that the measures described above will be sufficient to remediate the previously identified material weaknesses.

Changes in Internal Control over Financial Reporting

There continue to be management review and discussion around internal control over financial reporting. Management is in the process of designing updated changes to its controls as discussed above in “Management’s Plan to Remediate Material Weaknesses.” Further, management is monitoring and reviewing the impact of new processes and need for additional controls due to the acquisition of the UltraMIST business during the quarter.

PART II — OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS.

None.

Item1A. RISK FACTORS.

Sanuwave is supplementing the risk factors previously disclosed in Part I, Item 1A, “Risk Factors” of its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Securities and Exchange on March 30, 2020, to include the following risk factor:

Sanuwave’s growth strategy includes acquisitions that entail significant execution, integration and operational risks.

Sanuwave is pursuing a growth strategy based in part on acquisitions.  In August 2020, the Company entered into an asset purchase agreement with Celularity pursuant to which Sanuwave acquired Celularity’s UltraMIST assets.  The UltraMIST® System is a proprietary technology cleared by the FDA for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.  The aggregate cash and stockconsideration paid for the UltraMIST assets was $24,000,000 paid in the form of a combination of cash and debt.  This growth strategy involves significant risks.  Sanuwave is subject to operational and financial risks in connection with historical and future acquisitions if it is unable to:

• properly value prospective acquisitions, especially those with limited operating histories;

• successfully integrate the operations, as well as the accounting, financial controls, management information, technology, human resources and other administrative systems of acquired businesses with its existing operations and systems;

• successfully identify and realize potential synergies among acquired and existing businesses and retain or hire senior management and other key personnel at acquired businesses; and

• successfully manage acquisition-related strain on its management, operations and financial resources.

40

In connection with the acquisition of the UltraMIST assets, Sanuwave has not timely filed a Form 8-K/A containing audited historical financial statements of the acquired business assets.  The audited financial statements are required under Rule 3-05 of Regulation S-X.  Until such time as we are able to file these financial statements for the periods required, we will not be in a position to have the SEC declare effective any registration statement.  In addition, any failure to timely file our periodic reports with the SEC could harm our reputation and reduce the market price of our common stock.

Furthermore, Sanuwave may not be successful in addressing other challenges encountered in connection with its acquisitions. The anticipated benefits of one or more of its acquisitions may not be realized or the value of goodwill and other intangible assets acquired could be impacted by one or more continuing unfavorable events or trends, which could result in significant impairment charges. The occurrence of any these events could have an adverse effect on our business, financial condition and results of operations.

Acquisitions also involve operational risks and uncertainties, such as unknown or contingent liabilities with no available manner of recourse, exposure to unexpected problems, the retention of key employees and customers, and other issues that could negatively affect our business. Any such liabilities, individually or in the aggregate, could have a material adverse effect on our business.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Item 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

Item 4. MINE SAFETY DISCLOSURES.

Not applicable.

Item 5. OTHER INFORMATION.

Not applicable.

41

Item 6. EXHIBITS

Exhibit No.	Description
31.1*	Rule 13a-14(a)/15d-14(a) Certification of the Principal Executive Officer.
31.2*	Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.
32.1**	Section 1350 Certification of the Principal Executive Officer.
32.2**	Section 1350 Certification of the Chief Financial Officer.
101.INS*†	XBRL Instance.
101.SCH*†	XBRL Taxonomy Extension Schema.
101.CAL*†	XBRL Taxonomy Extension Calculation.
101.DEF*†	XBRL Taxonomy Extension Definition.
101.LAB*†	XBRL Taxonomy Extension Labels.
101.PRE*†	XBRL Taxonomy Extension Presentation.

^Ꚙ Indicates management contract or compensatory plan or arrangement.

* Filed herewith.

** Furnished herewith.

† XBRL-related documents are not deemed filed for purposes of section 11 of the Securities Act of 1933, as amended, section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject the liabilities of these sections, and are not part of any registration statement to which they relate.

42

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SANUWAVE HEALTH, INC.
Date: July 1, 2021	By:	/s/ Kevin A. Richardson, II
		Name: Kevin A. Richardson, II
		Title: Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

Signatures	Capacity	Date
By: /s/ Kevin A. Richardson, II
Name: Kevin A. Richardson, II	Chief Executive Officer and Chairman of the Board of Directors	July 1, 2021
	(principal executive officer)
By: /s/ Lisa E. Sundstrom
Name: Lisa E. Sundstrom	Chief Financial Officer	July 1, 2021
	(principal financial and accounting officer)

43

EX-31.1

EXHIBIT 31.1

Certification of Principal Executive Officer

Pursuant to Rule 13a-14(a) or Rule 15d-14(a)

Under the Securities Exchange Act of 1934, As Amended

I, Kevin A Richardson II, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of SANUWAVE Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  July 1, 2021

/s/ Kevin A. Richardson II

Kevin A. Richardson II

Chief Executive Officer

(principal executive officer)

EX-31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) or Rule 15d-14(a)

Under the Securities Exchange Act of 1934, As Amended

I, Lisa E. Sundstrom, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of SANUWAVE Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 1, 2021

/s/ Lisa E. Sundstrom

Lisa E. Sundstrom

Controller and Chief Financial Officer

(principal financial officer and principal accounting officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION

In connection with the periodic report of SANUWAVE Health, Inc. (the “Company”) on Form 10-Q/A for the period ended September 30, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Kevin A. Richardson II, Chief Executive Officer (and principal executive officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: July 1, 2021

/s/ Kevin A. Richardson II

Kevin A. Richardson II

Chief Executive Officer

(principal executive officer)

EX-32.2

EXHIBIT 32.2

CERTIFICATION

In connection with the periodic report of SANUWAVE Health, Inc. (the “Company”) on Form 10-Q/A for the period ended September 30, 2020 as filed with the Securities and Exchange Commission (the “Report”), I I, Lisa S. Sundstrom, Controller and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date:  July 1, 2021

/s/ Lisa E. Sundstrom

Lisa E. Sundstrom

Controller and Chief Financial Officer

(principal financial officer and principal accounting officer)

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Jun. 23, 2021
Cover page.
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Current Fiscal Year End Date	--12-31
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 to the Form 10-Q (this “Amendment”) amends the Quarterly Report on Form 10-Q of SANUWAVE Health, Inc. (the “Company”) for the quarterly period ended September 30, 2020 (the “Form 10-Q”), filed on November 23, 2020 with the Securities and Exchange Commission (the “SEC”). This Amendment restates the Company’s financial statements in order to correct an accounting error resulting in the underreporting the amount of warrant derivative liability and the reclassification of warrant liabilities as short term liabilities. The error relates to the determination of the number of shares of common stock subject to a warrant issued by the Company in June 2020 as previously reported by the Company, which warrant contains certain anti-dilution adjustment provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrant, warrant liability associated with the company not having enough authorized shares at the time those anti-dilution provision were triggered. A summary of the accounting impact of these adjustments to the Company’s condensed consolidated unaudited financial statements as of and for the three and nine months ended September 30, 2020 is provided at “Note 20. Restatement of Financial Statements.” We have also added Note 22 which describes a non-compliance notification from a supplier, as well as reclassification of warrant liabilities to current. Except as described in Notes 8, 11, 14, 20, 22, and the corresponding changes in Net Income and other changes as described above, no other changes have been made to the Company’s Interim Report on Form 10-Q for the three months ended September 30, 2020 (the “Original 10-Q”) except to update the latest number of outstanding shares on the cover page of this Form 10-Q/A. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing or modify or update any disclosures that may have been affected by subsequent events. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is also including with this Amendment certifications of the Company’s Chief Executive Officer and Chief Financial Officer (attached as Exhibits 31.1, 31.2, 32.1, and 32.2) dated as the date of the Amendment.
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Address, State or Province	NV
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		481,619,621

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 5,391,591	$ 1,760,455
Accounts receivable, net of allowance for doubtful accounts of $32,558 in 2020 and $72,376 in 2019	1,395,815	75,543
Inventory	2,539,475	542,955
Prepaid expenses and other current assets	627,751	125,405
TOTAL CURRENT ASSETS	9,954,632	2,504,358
PROPERTY AND EQUIPMENT, net	979,673	512,042
RIGHT OF USE ASSETS, net	442,197	323,661
OTHER INTANGIBLE ASSETS, net	7,259,795	0
GOODWILL	14,198,799	0
OTHER ASSETS	31,010	41,931
TOTAL ASSETS	32,866,106	3,381,992
CURRENT LIABILITIES [Abstract]
Accounts payable	2,322,192	1,439,413
Accrued expenses	1,603,543	1,111,109
Accrued employee compensation	2,544,768	1,452,910
Warrant Liability	17,546,260	0
Convertible promissory note payable	4,000,000	0
Convertible promissory notes, related parties	1,596,254	0
SBA loans	321,821	0
Accrued interest	354,062	0
Operating lease liability	251,372	173,270
Finance lease liability	187,416	121,634
Contract liabilities	65,037	66,577
Accrued interest, related parties	28,864	1,859,977
Notes payable, related parties, net	0	5,372,743
Short term notes payable	0	587,233
Line of credit, related parties	0	212,388
Advances from related parties	0	18,098
TOTAL CURRENT LIABILITIES	30,821,589	12,415,352
NON-CURRENT LIABILITIES
Promissory note payable	10,448,039	0
SBA loans	142,514	0
Finance lease liability	284,588	271,240
Operating lease liability	222,815	185,777
Contract liabilities	45,519	573,224
TOTAL NON-CURRENT LIABILITIES	11,143,475	1,030,241
TOTAL LIABILITIES	41,965,064	13,445,593
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, par value $0.001, 5,000,000 shares authorized; 6,175 and 293 shares designated Series A and Series B, respectively	0	0
COMMON STOCK, par value $0.001, 600,000,000 (Note 18) shares authorized; 466,094,621 and 293,780,400 issued and outstanding in 2020 and 2019, respectively	466,095	293,781
ADDITIONAL PAID-IN CAPITAL	135,521,907	115,457,808
ACCUMULATED DEFICIT	(145,025,761)	(125,752,956)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(61,199)	(62,234)
TOTAL STOCKHOLDERS' DEFICIT	(9,098,958)	(10,063,601)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 32,866,106	$ 3,381,992

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Accounts receivable, allowance for doubtful accounts	$ 32,558	$ 72,376
STOCKHOLDERS' DEFICIT
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	466,094,621	293,780,400
Common stock, shares outstanding (in shares)	466,094,621	293,780,400
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	6,175	6,175
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	293	293

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
REVENUES [Abstract]
TOTAL REVENUES	$ 1,966,896	$ 197,640	$ 2,198,788	$ 692,579
COST OF REVENUES
TOTAL COST OF REVENUES	548,406	122,923	663,630	402,657
GROSS MARGIN	1,418,490	74,717	1,535,158	289,922
OPERATING EXPENSES
Research and development	432,155	299,903	983,816	867,825
Selling and marketing	1,373,476	335,472	2,414,477	901,031
General and administrative	5,054,508	1,802,659	9,529,218	4,746,519
Amortization	244,626	0	244,626	0
Depreciation	82,493	22,338	200,282	40,150
TOTAL OPERATING EXPENSES	7,187,258	2,460,372	13,372,419	6,555,525
OPERATING LOSS	(5,768,768)	(2,385,655)	(11,837,261)	(6,265,603)
OTHER INCOME (EXPENSE)
Gain or (Loss) on warrant liability	(5,590,806)	0	(5,590,806)	227,669
Loss on extinguishment of debt	(503,234)	0	(503,234)	0
Interest expense	(690,659)	(182,001)	(878,331)	(1,120,440)
Interest expense, related party	(61,334)	(175,522)	(431,070)	(508,193)
Loss on foreign currency exchange	(23,836)	(4,840)	(32,103)	(13,199)
TOTAL OTHER INCOME (EXPENSE), NET	(6,869,869)	(362,363)	(7,435,544)	(1,414,163)
NET LOSS	(12,638,637)	(2,748,018)	(19,272,805)	(7,679,766)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	2,792	(14,061)	869	13,152
TOTAL COMPREHENSIVE LOSS	$ (12,635,845)	$ (2,762,079)	$ (19,271,936)	$ (7,666,614)
LOSS PER SHARE:
Net loss - basic and diluted (in dollars per share)	$ (0.03)	$ (0.01)	$ (0.06)	$ (0.04)
Weighted average shares outstanding - basic and diluted (in shares)	384,502,450	211,423,362	326,405,397	181,088,995
Product [Member]
REVENUES [Abstract]
TOTAL REVENUES	$ 1,321,248	$ 158,855	$ 1,465,147	$ 444,087
COST OF REVENUES
TOTAL COST OF REVENUES	533,629	91,179	637,369	334,749
License Fees [Member]
REVENUES [Abstract]
TOTAL REVENUES	29,447	16,250	39,447	189,307
Other Revenue [Member]
REVENUES [Abstract]
TOTAL REVENUES	616,201	22,535	694,194	59,185
COST OF REVENUES
TOTAL COST OF REVENUES	$ 14,777	$ 31,744	$ 26,261	$ 67,908

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Conversion [Member]	Preferred Stock [Member] Series D Preferred Conversion [Member]	Common Stock [Member]	Common Stock [Member] Series C Preferred Conversion [Member]	Common Stock [Member] Series D Preferred Conversion [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Series C Preferred Conversion [Member]	Additional Paid-in Capital [Member] Series D Preferred Conversion [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Series C Preferred Conversion [Member]	Accumulated Deficit [Member] Series D Preferred Conversion [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Other Comprehensive Loss [Member] Series C Preferred Conversion [Member]	Accumulated Other Comprehensive Loss [Member] Series D Preferred Conversion [Member]	Total	Series C Preferred Conversion [Member]	Series D Preferred Conversion [Member]
Beginning balance at Dec. 31, 2018	$ 0			$ 155,665			$ 101,153,882			$ (116,602,778)			$ (62,868)			$ (15,356,099)
Beginning balance (in shares) at Dec. 31, 2018	0			155,665,138
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0			$ 0			0			(2,197,317)			0			(2,197,317)
Cashless warrant exercises	$ 0			$ 704			(704)			0			0			0
Cashless warrant exercises (in shares)	0			704,108
Proceeds from warrant exercise	$ 0			$ 620			52,580			0			0			53,200
Proceeds from warrant exercise (in shares)	0			620,000
Conversion of short term notes and convertible notes payable	$ 0			$ 3,334			263,333			0			0			266,667
Conversion of short term notes and convertible notes payable (in shares)	0			3,333,334
Reclassification of warrant liability to equity due to adoption of ASU 2017-11	$ 0			$ 0			262,339			1,279,661			0			1,542,000
Foreign currency translation adjustment	0			0			0			0			(2,398)			(2,398)
Ending balance at Mar. 31, 2019	$ 0			$ 160,323			101,731,430			(117,520,434)			(65,266)			(15,693,947)
Ending balance (in shares) at Mar. 31, 2019	0			160,322,580
Beginning balance at Dec. 31, 2018	$ 0			$ 155,665			101,153,882			(116,602,778)			(62,868)			(15,356,099)
Beginning balance (in shares) at Dec. 31, 2018	0			155,665,138
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss																(7,679,766)
Beneficial conversion feature on convertible debt																0
Conversion of advances from related parties																0
Ending balance at Sep. 30, 2019	$ 0			$ 245,768			109,488,657			(123,002,883)			(49,716)			(13,318,174)
Ending balance (in shares) at Sep. 30, 2019	0			245,768,619
Beginning balance at Mar. 31, 2019	$ 0			$ 160,323			101,731,430			(117,520,434)			(65,266)			(15,693,947)
Beginning balance (in shares) at Mar. 31, 2019	0			160,322,580
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0			$ 0			0			(2,734,431)			0			(2,734,431)
Cashless warrant exercises	$ 0			$ 2,997			13,003			0			0			16,000
Cashless warrant exercises (in shares)	0			2,997,375
Proceeds from warrant exercise	$ 0			$ 17,052			1,333,005			0			0			1,350,057
Proceeds from warrant exercise (in shares)	0			17,051,769
Other warrant exercise	$ 0			$ 5,804			451,697			0			0			457,501
Other warrant exercise (in shares)	0			5,804,167
Conversion of short term notes and convertible notes payable	$ 0			$ 2,475			177,525			0			0			180,000
Conversion of short term notes and convertible notes payable (in shares)	0			2,475,000
Stock-based compensation	$ 0			$ 0			31,758			0			0			31,758
Warrants issued for consulting services	0			0			36,067			0			0			36,067
Foreign currency translation adjustment	0			0			0			0			1,489			1,489
Ending balance at Jun. 30, 2019	$ 0			$ 188,651			103,774,485			(120,254,865)			(63,777)			(16,355,506)
Ending balance (in shares) at Jun. 30, 2019	0			188,650,891
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0			$ 0			0			(2,748,018)			0			(2,748,018)
Cashless warrant exercises	$ 0			$ 1,711			18,289			0			0			20,000
Cashless warrant exercises (in shares)	0			1,710,674
Proceeds from warrant exercise	$ 0			$ 10,506			961,528			0			0			972,034
Proceeds from warrant exercise (in shares)	0			10,506,593
Other warrant exercise	$ 0			$ 40,355			4,014,500			0			0			4,054,855
Other warrant exercise (in shares)	0			40,355,006
Conversion of short term notes and convertible notes payable	$ 0			$ 4,545			495,455			0			0			500,000
Conversion of short term notes and convertible notes payable (in shares)	0			4,545,455
Stock-based compensation	$ 0			$ 0			224,400			0			0			224,400
Foreign currency translation adjustment	0			0			0			0			14,061			14,061
Ending balance at Sep. 30, 2019	$ 0			$ 245,768			109,488,657			(123,002,883)			(49,716)			(13,318,174)
Ending balance (in shares) at Sep. 30, 2019	0			245,768,619
Beginning balance at Dec. 31, 2019	$ 0			$ 293,781			115,457,808			(125,752,956)			(62,234)			(10,063,601)
Beginning balance (in shares) at Dec. 31, 2019	0			293,780,400
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0			$ 0			0			(3,001,148)			0			(3,001,148)
Proceeds from warrant exercise	$ 0			$ 1,000			9,000			0			0			10,000
Proceeds from warrant exercise (in shares)	0			1,000,000
Shares issued for services	$ 0			$ 1,000			199,000			0			0			200,000
Shares issued for services (in shares)	0			1,000,000
Conversion of short term notes and settlements	$ 0			$ 1,820			262,164			0			0			263,984
Conversion of short term notes and settlements (in shares)	0			1,820,461
Stock-based compensation	$ 0			$ 0			21,900			0			0			21,900
Conversion of advances from related parties	$ 0			$ 63			2,035			0			0			2,098
Conversion of advances from related parties to equity (in shares)	0			62,811
Foreign currency translation adjustment	$ 0			$ 0			0			0			4,826			4,826
Ending balance at Mar. 31, 2020	$ 0			$ 297,664			115,951,907			(128,754,104)			(57,408)			(12,561,941)
Ending balance (in shares) at Mar. 31, 2020	0			297,663,672
Beginning balance at Dec. 31, 2019	$ 0			$ 293,781			115,457,808			(125,752,956)			(62,234)			(10,063,601)
Beginning balance (in shares) at Dec. 31, 2019	0			293,780,400
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss																$ (19,272,805)
Proceeds from stock option exercise (in shares)																225,000
Beneficial conversion feature on convertible debt																$ 560,682
Conversion of short term notes and settlements (in shares)																2,250,000
Conversion of advances from related parties																$ 18,098
Conversion of notes payable, related parties to equity																$ 2,291,047
Conversion of notes payable, related parties (in shares)																15,475,235
Ending balance at Sep. 30, 2020	$ 0			$ 466,095			135,521,907			(145,025,761)			(61,199)			$ (9,098,958)
Ending balance (in shares) at Sep. 30, 2020	0			466,094,621
Beginning balance at Mar. 31, 2020	$ 0			$ 297,664			115,951,907			(128,754,104)			(57,408)			(12,561,941)
Beginning balance (in shares) at Mar. 31, 2020	0			297,663,672
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0			$ 0			0			(3,633,020)			0			(3,633,020)
Proceeds from PIPE	$ 0			$ 1,071			148,929			0			0			150,000
Proceeds from PIPE (in shares)	0			1,071,428
Proceeds from stock option exercise	$ 0			$ 225			44,025			0			0			44,250
Proceeds from stock option exercise (in shares)	0			225,000
Beneficial conversion feature on convertible debt	$ 0			$ 0			560,682			0			0			560,682
Shares issued for services	$ 0			$ 2,200			515,300			0			0			517,500
Shares issued for services (in shares)	0			2,200,000
Conversion of short term notes and settlements	$ 0			$ 759			89,986			0			0			90,745
Conversion of short term notes and settlements (in shares)	0			759,328
Conversion of advances from related parties	$ 0			$ 200			15,800			0			0			16,000
Conversion of advances from related parties to equity (in shares)	0			200,000
Foreign currency translation adjustment	$ 0			$ 0			0			0			(6,749)			(6,749)
Ending balance at Jun. 30, 2020	$ 0			$ 302,119			117,326,629			(132,387,124)			(64,157)			(14,822,533)
Ending balance (in shares) at Jun. 30, 2020	0			302,119,428
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0			$ 0			0			(12,638,637)			0			(12,638,637)
Proceeds from PIPE	$ 0			$ 123,550			12,408,966			0			0			12,532,516
Proceeds from PIPE (in shares)	0			123,550,000
LGH Warrants Liability							(249,049)									(249,049)
Preferred Conversion		$ 0	$ 0		$ 16,072	$ 1,429		$ 2,233,928	$ 198,571		$ 0	$ 0		$ 0	$ 0		$ 2,250,000	$ 200,000
Preferred Conversion (in shares)		0	0		16,071,390	1,428,568
Shares issued for services	$ 0			$ 5,000			1,075,000			0			0			1,080,000
Shares issued for services (in shares)	0			5,000,000
Inducement shares issued				$ 200			44,540									44,740
Inducement shares issued (in shares)				200,000
Conversion of short term notes and settlements	$ 0			$ 2,250			207,750			0			0			210,000
Conversion of short term notes and settlements (in shares)	0			2,250,000
Conversion of notes payable, related parties to equity	$ 0			$ 15,475			2,275,572			0			0			2,291,047
Conversion of notes payable, related parties (in shares)	0			15,475,235
Foreign currency translation adjustment	$ 0			$ 0			0			0			2,958			2,958
Ending balance at Sep. 30, 2020	$ 0			$ 466,095			$ 135,521,907			$ (145,025,761)			$ (61,199)			$ (9,098,958)
Ending balance (in shares) at Sep. 30, 2020	0			466,094,621

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (19,272,805)	$ (7,679,766)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of intangibles	244,626	0
Depreciation	200,282	40,150
Bad debt expense	(39,818)	(18,835)
Share-based payment	21,900	256,158
Shares issued for services	1,797,500	0
Shares issued for inducement shares	44,740	0
Loss on extinguishment of debt	503,234	0
Warrants issued for consulting services	0	36,067
Gain or (Loss) on warrant liability	5,590,806	(227,669)
Amortization of debt issuance costs	214,431	0
Accrued interest	191,031	1,139,904
Interest payable, related parties	696,208	508,193
Amortization of operating leases	(3,396)	(14,634)
Waived proceeds from warrant exercise	0	36,000
Changes in operating assets and liabilities
Accounts receivable - trade	(1,280,454)	197,301
Inventory	(136,555)	66,884
Prepaid expenses	(502,346)	(83,007)
Due from related parties	0	1,228
Other assets	10,921	(13,567)
Operating leases	0	9,513
Financing leases	1,980	0
Accounts payable	882,779	118,908
Accrued expenses	492,434	127,586
Accrued employee compensation	1,091,858	863,400
Contract liabilities	(529,245)	(48,425)
NET CASH USED BY OPERATING ACTIVITIES	(9,779,889)	(4,684,611)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of UltraMIST (Note 4)	(20,000,000)	0
Purchases of property and equipment	(39,142)	(28,990)
NET CASH USED BY INVESTING ACTIVITIES	(20,039,142)	(28,990)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of convertible preferred stock	2,450,000	0
Proceeds from convertible promissory note	1,100,000	0
Proceeds from SBA loan	614,335	0
Proceeds from PIPE offering	21,456,468	0
Proceeds from senior promissory notes	13,346,547	0
Proceeds from stock option exercise	44,250	90,000
Proceeds from short term note	0	1,215,000
Proceeds from warrant exercise	10,000	1,378,142
Advances from related parties	0	2,055,414
Payments of debt	(5,457,663)	0
Payments of principal on finance leases	(114,806)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	33,449,131	4,738,556
EFFECT OF EXCHANGE RATES ON CASH	1,036	13,152
NET INCREASE IN CASH AND CASH EQUIVALENTS	3,631,136	38,107
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,760,455	364,549
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,391,591	402,656
NONCASH INVESTING AND FINANCING ACTIVITIES
Acquisition of UltraMIST partially financed with convertible promissory note	4,000,000	0
Conversion of short term notes payable to equity	564,729	2,860,769
Other warrant exercise	0	924,649
Conversion of line of credit, related parties to equity	0	680,000
Conversion of advances from related party to equity	18,098	0
Additions to right of use assets from new finance lease liabilities	127,611	0
Beneficial conversion feature on convertible debt	560,682	0
Reclassification of warrant liability to equity	0	1,542,000
Accounts payable and Accrued employee compensation converted to equity	0	36,500
Conversion of convertible promissory notes to equity	$ 0	$ 1,918,254

XML

Nature of the Business

9 Months Ended

Sep. 30, 2020

Nature of the Business [Abstract]

Nature of the Business

1. Nature of the Business

SANUWAVE Health, Inc. and Subsidiaries (the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Through its recent acquisition of Celularity’s UltraMIST® assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market.

The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. Food and Drug Administration (FDA) granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo process. As a result of this decision, the Company was able to immediately market the product for the treatment of Diabetic Foot Ulcers (DFU) as described in the De Novo request, subject to the general control provisions of the FD&C Act and the special controls identified in this order.

On August 6, 2020 the Company entered into an Asset Purchase Agreement with Celularity Inc. (“Celularity”) pursuant to which the Company acquired Celularity’s UltraMIST assets, as more fully described in Note 4. The UltraMIST® System is a proprietary technology cleared by the FDA for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.

In connection with the Asset Purchase Agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl® (the “License Agreement”). The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the “Field” and “Territory” (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term.

The Company’s portfolio of regenerative medicine products and product candidates activate tissue regeneration biological signaling and angiogenic responses, producing new vascularization and microcirculatory improvement combined with tissue growth which helps restore the body’s normal healing processes. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions. The Company is marketing its dermaPACE System for treatment usage in the United States and is able to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities.

In March 2020, the World Health Organization characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. Since then, the COVID-19 pandemic has rapidly spread across the globe and has already resulted in significant volatility, uncertainty and economic disruption. The primary impact of the COVID-19 pandemic has been seen in our dermaPACE System placements in the United States as our treatment is not widely recognized as an “essential” service. In addition, stay-at-home policies deployed to combat the spread of COVID-19 has greatly constrained visits to wound care centers, doctor’s offices and hospitals since late March 2020 and continuing as of this filing and have therefore delayed placements of new devices that were included in our revenue forecast. The future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. It is difficult at this time to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in future periods due to numerous uncertainties. The Company is closely monitoring the impact of the pandemic on all aspects of its business and operations including its recent acquired assets.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The financial information as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2020.

The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2020 (the “2019 Annual Report”).

XML

Going Concern

9 Months Ended

Sep. 30, 2020

Going Concern [Abstract]

Going Concern

2. Going Concern

The Company does not currently generate significant recurring revenue and may require additional capital during 2020. As of September 30, 2020, the Company had cash and cash equivalents of $5,391,591. For the nine months ended September 30, 2020, the net cash used by operating activities was $9,779,889. The Company incurred a restated net loss of $19,272,805 for the nine months ended September 30, 2020. Such factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this report.

The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

The significant accounting policies followed by the Company are summarized below and should be read in conjunction with the 2019 Annual Report:

Principles of consolidation - The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Estimates – These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of condensed consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These condensed consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimate of the net realizable value of inventory, the determination of the valuation allowances for deferred taxes the estimated fair value of stock-based compensation, debt discounts and warrants, and valuation of acquired assets related to the acquisition of UltraMIST (Note 4).

Fair value of financial instruments - The carrying values of accounts payable, and other short-term obligations approximate their fair values, principally because of the short-term maturities of these instruments.

The Company has adopted ASC 820-10, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value and requires disclosures about fair value measurements. The framework that is set forth in this standard is applicable to the fair value measurements where it is permitted or required under other accounting pronouncements.

The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions.

The Company recognizes all derivatives on the balance sheet at fair value. The fair value of the warrant liability is determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate, and therefore is classified within level 3 of the fair value hierarchy. (See Note 14).

The Company’s notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace.

Inventory - Inventory consists of finished medical equipment and parts and is stated at the lower of cost, which is valued using the first in, first out (“FIFO”) method, or net realizable value less allowance for selling and distribution expenses. The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete. As of September 30, 2020, inventory consists of goods of $2,273,436 and parts of $266,039 for a total inventory of $2,539,475. As of December 31, 2019, inventory consisted of goods of $357,264 and parts of $185,691 for a total inventory of $542,955.

Preferred stock – The Company evaluates Preferred Stock issuances for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and determines appropriate equity or liability accounting treatment. Additionally, the Company determines, if classified as equity, whether it would be recorded as permanent or temporary equity.

Sequencing policy – The Company has granted certain options and warrants which, upon settlement, may exceed the limit on the authorized number of shares of common stock. The Company follows a sequencing policy for which in the event partial reclassifications of contracts subject to ASC 815-40-25 is necessary, due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of earliest issuance date of potentially dilutive instruments with the earliest grants receiving first allocation of shares. On August 6, 2020, the Company issued shares of common stock, convertible debt and warrants exercisable into shares of common stock in connection with a private placement funding and Senior Notes. In the event that all outstanding convertible securities were converted into shares of common stock of the Company, the Company would exceed the total number of shares authorized for issuance in the Company’s Articles of Incorporation. The Company has applied its sequencing policy to and determined that all convertible securities are convertible into shares of common stock other than warrants to purchase 64,119,742 shares of common stock issued on August 6, 2020.  These warrants were valued at $8,656,165 at August 6, 2020 and recorded as a liability in the condensed consolidated balance sheet.

Convertible instruments and liabilities related to warrants issued –  The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with FASB ASC 815 “Derivatives and Hedging” (“ASC 815”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the consolidated statements of operations over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.  A binomial model was used to estimate the fair value of the ECOs of warrants that are classified as derivative liabilities on the consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments.

Recent Accounting Pronouncements

In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

XML

Asset Purchase Agreement

9 Months Ended

Sep. 30, 2020

Asset Purchase Agreement [Abstract]

Asset Purchase Agreement

4. Asset Purchase Agreement

On August 6, 2020, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Celularity pursuant to which the Company acquired (the “Transaction”) Celularity’s UltraMIST assets (“UltraMIST”, or the “Assets”). The acquisition provides the Company with a robust product offering in the advanced wound care market and gives the Company an end-to-end advanced wound care product portfolio that addresses the entire care pathway. The aggregate consideration paid for the Assets was $24,000,000, which consisted of (i) a cash payment of $18,890,000, (ii) the issuance of a convertible promissory note to Celularity in the principal amount of $4,000,000 (the “Seller Note”), and (iii) a credit of $1,110,000 for the previous payment made by the Company to Celularity pursuant to that certain letter of intent between the Company and Celularity dated June 7, 2020.

In connection with the Asset Purchase Agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl® (the “License Agreement”). The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the “Field” and “Territory” (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term.

The Company evaluated whether the Transaction should be accounted for as an asset acquisition or a business combination and determined that the Transaction met the definition of a business per Accounting Standard Update (ASU) 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The Company has treated the transaction as a business combination and applied the related accounting guidance as required, using the acquisition method and a fair value model.

The tables below present the fair value of the consideration exchanged and the preliminary estimates of the fair value of assets acquired of UltraMIST.  Due to the limited amount of time since the UltraMIST acquisition, the valuation of the acquired assets is preliminary and subject to change.  The Company is still evaluating the income tax effects of the transaction.

Purchase consideration
	August 6, 2020
Cash paid at closing	$	18,890,000
Seller convertible note		4,000,000
Previous cash deposit pursuant to letter of intent		1,110,000
Total	$	24,000,000

Net assets acquired	Fair Value at August 6, 2020
Inventory	$	1,859,965
Property, plant and equipment		436,815
Intangible assets (a)		14,443,425
Goodwill (b)		7,259,795
Total	$	24,000,000

^(a) Intangible assets, as provided in the table below, are recorded at estimated fair value.  The estimated fair value of the acquired customer relationships is based on a variation of the income valuation approach and is determined using the multi-period excess earnings method. The estimated fair value of the acquired patent and trade names is based on a variation of the income valuation approach known as the relief from royalty method. The estimated useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows.

	Estimated Fair Value		Estimated Weighted Average Life (Years)
Customer relationships - UltraMIST	$	3,820,000		7
Customer relationships - Biologics		7,618,100		7
Patent		2,311,825		19
Trade names		693,500		19
Total intangible assets	$	14,443,425

^(b) Goodwill represents the excess of the total purchase consideration over fair value of the assets recognized and represents the future economic benefits that we believe will result from combining the operations of Sanuwave and UltraMIST, including expected future synergies and operating efficiencies. Goodwill resulting from the Transaction has been assigned to the Company’s lone operating segment. None of the goodwill recognized is expected to be deductible for income tax purposes.

Acquisition and related costs

During the three and nine months ended September 30, 2020, acquisition costs of $995,353 and $1,084,994, respectively, were expensed as incurred and included in general and administrative expenses in the Condensed Consolidated Statement of Comprehensive Loss. Such costs include professional fees of advisors and integration and synergy costs related to the combination of UltraMIST and Sanuwave. Additionally, $1,653,453 of debt issuance costs related to the NWPSA Senior Debt described in Note 7 were capitalized as a reduction in the principal amount of a promissory note on the Condensed Consolidated Balance Sheet. These debt issuance costs are amortized to interest expense over the life of the NWPSA Senior Debt.

Unaudited actual and pro forma information

The following unaudited pro forma information has been prepared by combining the historical results of Sanuwave and historical results of UltraMIST. The unaudited pro forma combined financial data for all periods presented were adjusted to give effect to pro forma events that are directly attributable to the aforementioned transaction and are factually supportable. The adjustments are based on information available to the Company at this time. Accordingly, the adjustments are subject to change and the impact of such changes may be material. The unaudited pro forma results do not include any incremental cost savings that may result from the integration.

The unaudited combined pro forma information is for informational purposes only and is not necessarily indicative of what the combined company's results actually would have been had the acquisition been completed as of the beginning of the periods as indicated. In addition, the unaudited pro forma information does not purport to project the future results of the combined company.

The acquired Assets were consolidated into our financial statements starting on the acquisition date. The total revenues and net loss of UltraMIST consolidated into our financial statements since the date of acquisition through September 30, 2020 were $1,206,847 and $1,509,943, respectively. The following financial information presents our results as if the Transaction had occurred on January 1, 2019:

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
	(restated)						(restated)
Total revenue	$	2,770,646		$	2,325,640		$	5,973,538		$	6,810,404
Net loss	$	(12,549,181	)	$	(4,863,590	)	$	(23,869,495	)	$	(14,855,293	)

Significant adjustments to the pro forma information above include recognition of non-recurring direct incremental acquisition costs in the nine months ended September 30, 2019 and exclusion of those costs from all other periods presented; recognition of the Biovance® license fee pursuant to the License Agreement; increase in interest expense related to the NWPSA Senior Debt Notes described in Note 7, the Seller Note described in Note 8, the HealthTronics Note described in Note 8, and the Stolarski Note described in Note 10; increase in depreciation expense related to the fair value adjustment of acquired property and equipment; and amortization associated with an estimate of the acquired intangible assets.

XML

Accrued expenses

9 Months Ended

Sep. 30, 2020

Accrued expenses [Abstract]

Accrued expenses

5. Accrued expenses

Accrued expenses consist of the following:

	September 30, 2020		December 31, 2019
Accrued outside services	$	615,547	$	108,033
Accrued legal and professional fees		370,985		134,970
Accrued board of director’s fees		260,000		400,000
Accrued executive severance		167,500		154,000
Accrued travel		120,000		120,000
Accrued inventory		50,275		167,050
Accrued clinical study expenses		13,650		13,650
Accrued other		5,586		13,406
	$	1,603,543	$	1,111,109

XML

Contract liabilities

9 Months Ended

Sep. 30, 2020

Contract liabilities [Abstract]

Contract liabilities

6. Contract liabilities

As of September 30, 2020, the Company has contract assets and liabilities from contracts with customers (see Note 16).

Contract liabilities consist of the following:

	September 30, 2020			December 31, 2019
Service agreement	$	77,538		$	133,510
License fees		-			500,000
Devices		22,500			-
Other		10,518			6,291
Total Contract liabilities		110,556			639,801
Non-Current		(45,519	)		(573,224	)
Total Current	$	65,037		$	66,577

The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate contract liability balances as of September 30, 2020, the Company expects to satisfy its remaining performance obligations associated with $65,037 and $45,519 of contract liability balances within the next twelve months and following thirty-two months, respectively. Of the aggregate contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 and $573,224 of contract liability balances within the next twelve months and following thirty-eight months, respectively.

XML

Senior promissory notes

9 Months Ended

Sep. 30, 2020

Senior promissory notes [Abstract]

Senior promissory notes

7. Senior promissory notes

On August 6, 2020, the Company entered into a Note and Warrant Purchase and Security Agreement (the “NWPSA”), with the noteholder party thereto and NH Expansion Credit Fund Holdings LP, as agent. As a result, the Company issued a $15,000,000 Secured Promissory Note (the “Senior Notes”) and Warrant exercisable into shares of the Company’s common stock (the “Warrant”) in exchange for cash to support operations, repay outstanding debt and close on the acquisition of the UltraMIST assets from Celularity, among other transactions. The Company received net proceeds from issuing the Notes and NH Warrant of $13,346,547. The NWPSA provides for (i) the sale and purchase of secured notes in an aggregate original principal amount of $15 million and (ii) the issuance of 13,091,160 warrants equal to 2.0% of the fully-diluted common stock of the Company as of the issue date. The warrant has an exercise price of $0.01 per share and a 10 year term (Note 11). The warrant agreement contains a put option. Upon payment in full of the Note, the holder has the ability to require the Company to purchase the warrants from the holder for cash. Accordingly, the warrant has been classified as a derivative liability. The holder has the option to exercise the put any time between the payment of the Note and the expiration of the warrants. The Note has a maturity date of September 30, 2025 and accrues interest at a rate that is the sum of: (a) the greater of the quarter end prime rate or 3% plus (b) 9%, due in quarterly arrears.  The Senior Notes are secured by substantially all assets of the Company including in the event of default placing bank accounts under a control agreement, copyrights, trademarks, patents, applications, registered and unregistered, licenses, designs, held or acquired after August 6, 2020 by the Company. The NWPSA contains several default conditions, including non-monetary default events including misrepresentations and material adverse changes. In the case of default, the agent has the right to declare the Senior Notes immediately due, not extend further credit, take actions to protect security (title changes), demand and take possession of the books, and is appointed an Attorney in Fact in certain conditions. Covenants include restrictions on dispositions, mergers or acquisitions, incurring indebtedness and minimum liquidity provisions. As of September 30, 2020, the Company was in compliance with all financial covenants under the NWPSA.

The Company recorded a current warrant liability of $3,050,240 for the fair value of the warrant. The outstanding balance of the Note at September 30, 2020 was $10,448,039 and accrued interest of $280,729. Further, as of September 30, 2020, the Company had unamortized debt issuance costs of $1,600,115.

XML

Convertible promissory notes (Restated)

9 Months Ended

Sep. 30, 2020

Convertible promissory notes (Restated) [Abstract]

Convertible promissory notes (Restated)

8. Convertible promissory notes (Restated)

On August 6, 2020, the Company entered into an asset purchase agreement with Celularity Inc., described in Note 4 pursuant to which the Company acquired Celularity’s UltraMIST assets. A portion of the aggregate consideration of $24,000,000 paid for the assets included the issuance of a promissory note to Celularity in the principal amount of $4,000,000. The Seller Note has a maturity date of August 6, 2021 and accrues interest at a rate equal to 12.0% per annum. In the event that the Seller Note has not been repaid prior to January 1, 2021, Celularity may elect to convert the outstanding principal amount plus any accrued but unpaid interest thereon into shares of the Company’s common stock, at a conversion price of $0.10 per share. As this conversion option is contingent on a future event, the conversion option has not been bifurcated from the host instrument as of September 30, 2020. The Seller Note is expressly subordinate to the NWPSA “Senior Debt” described in Note 7. The Company may prepay the outstanding principal balance, together with any accrued but unpaid interest without premium or penalty. As of September 30, 2020, $4,000,000 remained outstanding and had accrued interest of $73,333.

On June 5, 2020, the Company entered into a Securities Purchase Agreement with investor LGH Investments LLC (the “Investor”) for (i) a Promissory Note (the “Convertible Promissory Note”) in the original principal amount of $1,210,000, convertible into shares of common stock, (ii) warrants entitling the Investor to acquire 1,075,000 shares of common stock (the “Warrants”) and (iii) 200,000 restricted common shares in the Company as an inducement grant (the “Inducement Shares”). Such note contained certain default provisions, as defined, resulting in net proceeds of $1,100,000. As part of the Securities Purchase Agreement, the Company established a reserve of shares of its authorized but unissued and unreserved common stock in the amount of 11,000,000 shares for purposes of exercise of the Warrant or conversion of the Convertible Promissory Note. The Convertible Promissory Note matures on February 5, 2021 and includes a one-time interest charge of 8% to be applied on the issuance date to the original principal amount. The Investor can convert the Convertible Promissory Note and interest at any time prior to maturity to the number of shares of common stock, equal to the amount obtained by dividing (i) the amount of the unpaid principal and interest on the note by (ii) $0.25. The Warrants have an exercise price of $0.35 per share and have a term of five years and recorded as a derivative liability (see Footnote 12). With respect to the Inducement Shares, in the event the Company’s share price has declined on the date on which the Investor seeks to have the restricted legend removed on such shares, the Company agrees to issue the Investor additional shares such that the aggregate value of the Inducement Shares equals the aggregate value of the Inducement Shares as of June 5, 2020. The Inducement Shares were issued on September 11, 2020 and included in common stock and additional paid in capital.

On August 6, 2020, the Company repaid all amounts owing to LGH Investments, LLC in the original principal amount of $1,210,000. As a result, all obligations of the Company under the convertible promissory note have been terminated. The Company recorded a loss on extinguishment of debt of approximately $503,234 during the three and nine months ended September 30, 2020. The Warrants issued to LGH Investments, as more fully described in Note 11, contain certain ratchet provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrants. As a result of certain dilutive issuances of securities by the Company during the third quarter of 2020, the exercise price of the Warrants decreased to $0.01 per share and the number of shares subject to the Warrants increased to 35,000,000 shares as of September 30, 2020.  A Derivative Liability – Warrant was recorded for this decrease in exercise price with the offset to  loss on warrant liability.

XML

SBA Loans

9 Months Ended

Sep. 30, 2020

SBA Loans [Abstract]

SBA Loans

9. SBA Loans

On May 28, 2020, the Company received proceeds from a loan in the approximate amount of $460,000 (the “PPP Loan”) from Truist Bank, as lender, pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (15 U.S.C. 636(a)(36)) (the “CARES Act”). The PPP Loan matures on May 28, 2022 and bears interest at a rate of 1% per annum. Commencing December 12, 2020, the Company is required to pay the lender equal monthly payments of principal and interest. The PPP Loan is evidenced by a promissory note dated May 28, 2020 (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties and covenants. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

All or a portion of the PPP Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application by the Company beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements.The ultimate forgiveness of the PPP Loan is also predicated upon regulatory authorities concurring with management’s good faith assessment that the current economic uncertainty made the loan request necessary to support ongoing operations. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for the PPP Loan, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive the PPP Loan, the Company may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. Under the terms of the PPP Loan, the Company may be eligible for full or partial loan forgiveness in the third quarter of 2020. The Company plans to complete the application for loan forgiveness in the fourth quarter of 2020, however, no assurance is provided that the Company will apply for, or obtain forgiveness for, any portion of the PPP Loan. As of September 30, 2020, $321,821 is classified as current and $142,514 is classified as non-current.

On June 10, 2020, the Company secured a loan offered by the U.S. Small Business Administration (SBA) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of COVID-19 pandemic on the Company’s business. The principal amount of this loan was $150,000 and interest accrued at the rate of 3.75% per annum. This loan was paid off in full on August 5, 2020 with proceeds from the NWPSA Senior Notes as part of the conditions of that agreement.

XML

Convertible notes payable, related parties and Notes payable, related parties

9 Months Ended

Sep. 30, 2020

Convertible notes payable, related parties and Notes payable, related parties [Abstract]

Convertible notes payable, related parties and Notes payable, related parties

10. Convertible notes payable, related parties and Notes payable, related parties

The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal was due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because it is a shareholder in the Company and has a security agreement with the Company to provide a first security interest in the assets of the Company. An Event of Default under the notes payable, related parties occurred on December 31, 2016 (“Default”). As a result of the Default, the notes payable, related parties accrued interest at the rate of 10% per annum since January 2, 2017 through August 5, 2020.

On August 6, 2020, the Company entered into a letter agreement (the “HealthTronics Agreement”) with HealthTronics, Inc. (“HealthTronics”), pursuant to which the Company paid off all outstanding debt due and owed to HealthTronics. Pursuant to the HealthTronics Agreement, as consideration for the extinguishment of the debt due and owed to HealthTronics, (i) the Company paid to HealthTronics an amount in cash equal to $4,000,000, (ii) HealthTronics exercised all of its outstanding Class K Warrants to purchase 7,200,000 shares of common stock, (iii) the Company issued to HealthTronics a convertible promissory note in the principal amount of $1,372,743, and (iv) the Company and HealthTronics entered into a Securities Purchase Agreement dated August 6, 2020 pursuant to which the Company issued to HealthTronics an aggregate of 8,275,235 shares of common stock and an accompanying Class E warrant to purchase up to an additional 8,275,235 shares of common stock. The warrant has an exercise price of $0.25 per share and a three year term.

The convertible promissory note, with principal amount of $1,372,743, matures on August 6, 2021 and accrues interest at a rate equal to 12.0% per annum.  In the event that the Seller Note has not been repaid prior to January 1, 2021, Healthronics may elect to convert the outstanding principal amount plus any accrued but unpaid interest thereon into shares of the Company’s common stock, at a conversion price of $0.10 per share. As this conversion option is contingent, the conversion option has not been bifurcated from the host instrument as of September 30, 2020. The convertible promissory note is expressly subordinate to the NWPSA “Senior Notes” described in Note 8. The Company may prepay the outstanding principal balance, together with any accrued but unpaid interest without premium or penalty. As of September 30, 2020, $1,372,743 remained outstanding and had accrued interest of $24,822.

The notes payable, related parties were fully paid off as of September 30, 2020 due to the letter agreement described above and had an aggregate outstanding principal balance of $5,372,743 at December 31, 2019. The related accrued interest, related parties currently payable totaled $1,859,977 at December 31, 2019. Interest expense on notes payable, related parties totaled $61,334 and $175,522 for the three months ended September 30, 2020 and 2019, respectively and $431,070 and $508,193 for the nine months ended September 30, 2020 and 2019, respectively.

On August 6, 2020, the Company terminated that certain line of credit agreement with A. Michael Stolarski, a member of the Company’s board of directors, dated December 29, 2017 and as amended November 12, 2018, in the amount of $1,000,000 (the “Stolarski Line of Credit”). As consideration for the termination of the Stolarski Line of Credit, the Company issued to A. Michael Stolarski a convertible promissory note in the principal amount of $223,511 (the “Stolarski Note”). The Stolarski Note has a maturity date of August 6, 2021 and accrues interest at a rate equal to 12.0% per annum. In the event that the Stolarski Note has not been repaid prior to January 1, 2021, the holder may elect to convert the outstanding principal amount plus any accrued by unpaid interest thereon into shares of common stock at a conversion price of $0.10 per share.

XML

Warrant Liabilities (Restated)

9 Months Ended

Sep. 30, 2020

Warrant Liabilities (Restated) [Abstract]

Warrant Liabilities (Restated)

11. Warrant Liabilities (Restated)

On August 6, 2020, the Company, issued 132,816,250 warrants to investors and the placement agent in connection with a private placement offering (Note 14). Additionally, on that date, the Company issued 13,091,160 warrants to the holder of the Senior Notes (Note 7) and 8,275,235 warrants to settle certain outstanding debt (Note 10).

At the time of issuance of the warrants, if all outstanding convertible securities were converted into shares of common stock, the Company would have exceeded its available authorized shares of common stock of 600,000,000 shares. If all outstanding convertible securities were converted into shares of common stock, the Company would have 713,439,897 shares issued and outstanding.  As a result of the limits on the Company’s authorized shares, a portion of the Company’s obligations under the warrants have been determined to be a liability.

The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480 “Distinguishing Liabilities from Equity”. In accordance with the accounting guidance, 111,210,902 of the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations.

The fair value of the warrant liabilities was measured using the binomial model. Significant inputs into the model at the inception and reporting period measurement dates are as follows:

Private Placement Warrants

Binomial Assumptions	Issuance date (1) August 6, 2020			Period ended September 30, 2020
Exercise Price(1)	$	0.25		$	0.25
Warrant Expiration Date (1)	August 6, 2023			August 6, 2023
Stock Price (2)	$	0.24		$	0.22
Interest Rate (annual) (3)		0.13	%		0.16	%
Volatility (annual) (4)		91.49	%		88.96	%
Time to Maturity (Years)		3			3
Calculated fair value per share	$	0.135		$	0.119

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company. dated August 6, 2020.}

_{(2) Based on the trading value of common stock of the Company. as of August 6, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of  the Company as of August 6, 2020 and each presented period ending date.}

NH Expansion Warrants:

Binomial Assumptions	Issuance date (1) August 6, 2020			Period ended September 30, 2020
Exercise Price(1)	$	0.01		$	0.01
Warrant Expiration Date (1)	August 6, 2030			August 6, 2030
Stock Price (2)	$	0.24		$	0.22
Interest Rate (annual) (3)		0.21	%		0.69	%
Volatility (annual) (4)		102.09	%		184.77	%
Time to Maturity (Years)		10			10
Calculated fair value per share	$	0.233		$	0.22

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.}

_{(2) Based on the trading value of common stock of the Company as of August 6, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of the Company as of August 6, 2020 and each presented period ending date.}

On August 6, 2020, the Company consummated a series of transactions, involving the issuance of common stock and various equity-linked instruments, each of which constitutes a dilutive issuance in the LGH Warrant Agreement (see Note 8) which triggered the ratchet provision, with the effect of decreasing the warrant’s exercise price to $0.01. With the reduction of the warrant exercise price from the initial $0.35 to $0.01 per share, in order to maintain the $350,000 aggregate exercise amount in effect prior to the adjustment (1,000,000 warrant shares with an exercise price of $0.35), as required by the ratchet provision, the Company was required to increase the number of warrant shares to 35,000,000, thereby entitling LGH to purchase 35,000,000 shares of the Company’s common stock at $0.01 per share.

The Company determined that these warrants meet the definition of a derivative liability.  Pursuant to this conclusion, the warrant was recorded as derivative liability at inception, initially measured at its fair value, and subsequently remeasured at fair value at each reporting date, with changes in the fair value reported in earnings.

The derivative liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility as inputs.  The fair value of the derivative warrant liability was measured using the Black Scholes Merton (“BSM") option pricing model.  Given the plain vanilla nature of the Warrant terms, including the absence of any exercise contingencies, the BSM sufficiently captures the terms of the Warrant as inputs to the valuation and produces a value that is not materially different from a binomial/lattice model using the following assumptions:

LGH
Binomial Assumptions	Issuance date (1) 5-Jun-20			Period ended 30-Jun-20			Ratchet Date (5) 6-Aug-20			Period ended 30-Sep-20
Exercise Price(1)	$	0.35		$	0.35		$	0.01		$	0.01
Warrant Expiration Date (1)	5-Jun-25			5-Jun-25			5-Jun-25			5-Jun-25
Stock Price (2)	$	0.27		$	0.2625		$	0.2437		$	0.22
Interest Rate (annual) (3)		0.29	%		0.29	%		0.20	%		0.26	%
Volatility (annual) (4)		107	%		107	%		103	%		101	%
Time to Maturity (Years)		5			4.93			4.83			4.68
Calculated fair value per share	$	0.25		$	0.25		$	0.24		$	0.21

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated June 5, 2020.}

_{(2) Based on the trading value of common stock of the Company as of June 5, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of June 5, 2020, and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of the Company as of June 6, 2020, and each presented period ending date.}

_{(5) Based on the terms provided in the warrant agreement to purchase common stock at date of the ratchet trigger August 6, 2020.}

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

Warrant Liability	Warrants Outstanding		Fair Value per Share		Fair Value
Fair Value at remeasurement date of June 30, 2020		1,000,000		0.249	$	249,049
Additional Warrants classified as Liabilities August 6, 2020		111,210,902		0.206		22,888,017
Fair Value at date of August 6, 2020		112,210,902		0.206	$	23,137,066
Gain or (Loss) on warrant liability						(5,590,806	)
Fair Value as of period ended September 30, 2020		112,210,902		0.156		17,546,260

During the three and nine months ending September 30, 2020, the Company recorded a loss on changes in fair value of warrant liability of $5,590,806, respectively. During the three and nine months ending September 30, 2019, there were no warrant liabilities or corresponding changes in valuation.

XML

Preferred Stock

9 Months Ended

Sep. 30, 2020

Preferred Stock [Abstract]

Preferred Stock

12. Preferred Stock

On February 6, 2020, the Company entered into a Series C Preferred Stock Purchase Agreement (the “Series C Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of 90 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series C Preferred Stock”), for an aggregate total purchase price of $2,250,000.

On January 31, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series C Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate 90 shares of our preferred stock as Series C Convertible Preferred Stock. On May 14, 2020, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of eight shares of the Company’s Series D Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series D Preferred Stock”), for an aggregate total purchase price of $200,000. On May 14, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series D Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate eight shares of our preferred stock as Series D Convertible Preferred Stock.

Subject to the terms of the Certificates of Designation, each share of Series C Preferred Stock and Series D Preferred Stock is convertible into shares of common stock of the Company at a rate equal to the stated value of such share of Series C Preferred Stock and Series D Preferred Stock of $25,000, divided by the conversion price of $0.14 per share (subject to adjustment from time to time upon the occurrence of certain events as described in the Certificate of Designation). The Certificates of Designation became effective upon filing with the Secretary of State of the State of Nevada. If all outstanding shares of Series C Preferred Stock and Series D Preferred Stock were converted into common stock at the original conversion rate, such shares would convert into an aggregate of 17,500,000 shares of common stock.

On July 23, 2020, in connection with the Company’s 2020 Annual Meeting of Stockholders, the Company’s stockholders approved, among other matters, an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 355,000,000 to 600,000,000.  On September 20, 2020, Series C and D holders converted their preferred shares into 17,499,958 shares of common stock.

XML

Equity transactions

9 Months Ended

Sep. 30, 2020

Equity transactions [Abstract]

Equity transactions

13. Equity transactions

Approval of reverse split of common stock

On July 23, 2020, in connection with the Company’s 2020 Annual Meeting of Stockholders, the Company’s stockholders approved the Company to amend the Company’s Articles of Incorporation to effect a reverse split of the Company’s outstanding common stock at a ratio of between 1-for-10 and 1-for-50, with the exact ratio to be determined by the board of directors of the Company in its sole discretion. As of the filing of this 10-Q report, the Company has not effected a reverse split of its stock.

Warrant Exercises

During the nine months ended September 30, 2020, the Company issued 1,000,000 shares of common stock upon the exercise of 1,000,000 Class P Warrants to purchase shares of stock and an exercise price of $0.01 per share under the terms of the respective warrant agreement.

During the nine months ended September 30, 2020, the Company issued 7,200,000 shares of common stock to a related party upon the exercise of Class K Warrants upon the conversion of accrued interest related to a note payable, related party totaling $636,000, as described in Note 10.

Conversion of liabilities

During the nine months ended September 30, 2020, the Company issued 2,579,789 shares of common stock upon the conversion of short term notes payable in the principal and accrued interest amount of $354,729 with the receipt of notices of Class L warrant exercises, all pursuant to the terms of the short term notes payable.

During the nine months ended September 30, 2020, the Company issued 2,250,000 shares of common stock upon the conversion of short term notes payable in the principal and accrued interest amount of $210,000 pursuant to the terms of the short term notes payable.

During the nine months ended September 30, 2020, the Company issued 15,475,235 shares of common stock to a related party upon the conversion of accrued interest related to a note payable, related party totaling $2,291,047, as described in Note 10.

Conversion of advances from related parties

During the nine months ended September 30, 2020, the Company issued 262,811 shares of common stock upon the conversion of advances from related parties in the amount of $18,098 with the receipt of notice of Series A Warrant exercise to purchase shares of stock under the terms of the respective warrant agreement.

Consulting Agreement

In January 2020, the Company entered into a nine month consulting agreement for which the fee for the services was to be paid with common stock. The number of shares to be paid with common stock was 1,000,000 earned upon signing and an additional 1,000,000 upon agreement by both consultant and the Company no later than May 1, 2020. The Company issued 1,000,000 shares in March 2020 and 1,000,000 shares in April 2020. The fair value of the shares of $380,000 was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

The consulting agreement was extended to November 30, 2020 with an additional 2,000,000 common stock shares issued for services in August and September 2020. The fair value of the shares of $450,000 was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

The Company entered into a separate agreement for investor relations services for which the fee was paid with common stock. The Company issued 3,000,000 common stock shares with a fair value of $630,000 which was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

PIPE Offering (Restated)

On December 11, 2019, the Company entered into a common stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stock at a purchase price of $0.14 per share. During the nine months ended September 30, 2020, the Company issued 1,071,428 shares of common stock in conjunction with this offering and received $150,000 in cash proceeds.

On August 6, 2020, the Company entered into a Securities Purchase Agreement in connection with the acquisition of UltraMIST, as discussed in Note 4, and issued 123,550,000 shares of common stock and accompanying Class E Warrants to purchase up to an additional 123,550,000 shares of common stock to certain investors for an aggregate purchase price of $0.20 per share of common stock and accompanying Warrant. It also issued Class E Warrants to a third-party placement agent to purchase up to 9,266,250 shares of common stock on the same terms as the Warrants. The Warrants have an exercise price of $0.25 per share and a three year term.  The private placement generated net proceeds of $21,456,468. The shares of common stock issued in the private placement have a par value of $0.001, resulting in an increase to common stock of $123,550. Since at the date of issuance the Company did not have a sufficient number of authorized shares to satisfy the Warrants in the event that they were exercised (and all other outstanding convertible securities were converted into shares of common stock) which could cause the net cash settlement of the Warrants, the Company recorded a liability of $8,656,165 for the fair value of the Warrants that were in excess of the available authorized shares. The Company recorded the residual amount of $12,408,966 from the net proceeds to stockholders’ equity.

Inducement Shares

During the nine months ended September 30, 2020, the Company issued 200,000 shares of common stock related to the June 5, 2020, Securities Purchase Agreement with LGH Investments, LLC, as described in Note 10.

Stock Option Exercise

During the nine months ended September 30, 2020, the Company issued 225,000 shares of common stock upon the exercise of stock options resulting in net proceeds of $44,250.

Litigation Settlement

During the nine months ended September 30, 2020, the Company issued 200,000 shares of restricted common stock upon the settlement of outstanding litigation. The fair value of the shares of $50,000 was recorded as a non-cash general and administrative expense during the nine months ended September 30, 2020.

XML

Warrants (Restated)

9 Months Ended

Sep. 30, 2020

Warrants (Restated) [Abstract]

Warrants (Restated)

14. Warrants (Restated)

A summary of the warrant activity during the nine months ended September 30, 2020 is presented as follows:

Warrant class	Outstanding as of December 31, 2019		Issued		Exercised			Expired			Outstanding as of September 30, 2020
Class E Warrants		-		141,091,485		-			-			141,091,485
Class K Warrants		7,200,000		-		(7,200,000	)		-			-
Class O Warrants		909,091		-		-			-			909,091
Class P Warrants		1,365,000		-		(1,000,000	)		(100,000	)		265,000
LGH Warrant		-		35,000,000		-			-			35,000,000
NH Warrant		-		13,091,160		-			-			13,091,160
		9,474,091		189,182,645		(8,200,000	)		(100,000	)		190,356,736

A summary of the warrant exercise price per share and expiration date is presented as follows:

	Exercise price/share		Expiration date
Class E Warrants	$	0.25	August 2023
Class K Warrants	$	0.08	June 2025
Class K Warrants	$	0.11	August 2027
Class O Warrants	$	0.11	January 2022
Class P Warrants	$	0.20	June 2024
LGH Warrant	$	0.01	June 2025
NH Warrant	$	0.01	August 2030

The fair value of the common stock purchase warrants is estimated on the date of grant using the Black-Scholes option pricing model which approximates the binomial model using the following weighted average assumptions for the three and nine months ended September 30, 2020:

Weighted average contractual terms in years	1.3
Weighted average risk free interest rate	0.15	%
Weighted average volatility	92.76	%

XML

Commitments and contingencies

9 Months Ended

Sep. 30, 2020

Commitments and contingencies [Abstract]

Commitments and contingencies

15. Commitments and contingencies

Operating Leases

The Company is a party to certain operating leases. The Company has entered into a lease agreement, as amended, for office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis.

For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as separate lease components. Non-leasing components are not included in the ROU asset.

Right of use assets and Lease liability – right of use consist of the following:

	September 30, 2020
Right of use assets	$	442,197

	September 30, 2020
Lease liability - right of use
Current portion	$	251,372
Long term portion		222,815
	$	474,187

As of September 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following:

Year ending December 31,	Amount
2020 (remainder)	$	71,918
2021		290,552
2022		96,195
2023		68,017
2024		8,028
2025		3,345
Total lease payments		538,055
Less: Present value adjustment		(63,868	)
Lease liability - right of use	$	474,187

As of September 30, 2020, the Company’s operating lease had a weighted average remaining lease term of 2.5 years and a weighted average discount rate of 12%.

Rent expense for the three months ended September 30, 2020 and 2019 was $84,115 and $49,217, respectively, and for the nine months ended September 30, 2020 and 2019 was $201,991 and $148,172, respectively.

Financing Lease

For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease is included in Property and equipment, net on our Condensed Consolidated Balance Sheets. Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense.

Right of use assets and Lease liability – right of use consist of the following:

	September 30, 2020
Right of use assets	$	462,405

	September 30, 2020
Lease liability - right of use
Current portion	$	187,416
Long term portion		284,588
	$	472,004

As of September 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following:

Year ending December 31,	Amount
2020 (remainder)	$	58,648
2021		234,593
2022		199,793
2023		18,388
Total	$	511,422

As of September 30, 2020, the Company’s financing leases had a weighted average remaining lease term of 2.7 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 12.6%.

As of September 30, 2020, the Company did not have additional operating or financing leases that have yet commenced.

Litigation

From time to time, the Company is subject to various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The Company believes that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

XML

Revenue

9 Months Ended

Sep. 30, 2020

Revenue [Abstract]

Revenue

16. Revenue

The Company accounts for revenue in accordance with ASC 606.

Disaggregation of Revenue

The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and nine months ended September 30, 2020 and 2019:

	Three Months Ended September 30, 2020						Three Months Ended September 30, 2019
	United States		International		Total		United States		International		Total
Product	$	1,301,942	$	19,306	$	1,321,248	$	9,832	$	149,023	$	158,855
License fees		-		29,447		29,447		6,250		10,000		16,250
Other Revenue		7,811		608,390		616,201		25		22,510		22,535
	$	1,309,753	$	657,143	$	1,966,896	$	16,107	$	181,533	$	197,640

	Nine Months Ended September 30, 2020						Nine Months Ended September 30, 2019
	United States		International		Total		United States		International		Total
Product	$	1,398,672	$	66,475	$	1,465,147	$	147,999	$	296,088	$	444,087
License fees		-		39,447		39,447		18,750		170,557		189,307
Other Revenue		7,486		686,708		694,194		25		59,160		59,185
	$	1,406,158	$	792,630	$	2,198,788	$	166,774	$	525,805	$	692,579

The Company’s partner in the joint venture agreement in Brazil, the IDIC Group, will have the right to receive prioritized dividends until the full reimbursement of the $600,000 partnership fee and expenses incurred in the formation of the joint venture company.

Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited.

XML

Related party transactions

9 Months Ended

Sep. 30, 2020

Related party transactions [Abstract]

Related party transactions

17. Related party transactions

During the three and nine months ended September 30, 2020 and 2019, the Company recorded $10,105 and $10,682, respectively, and $36,315 and $148,849 respectively, in revenue from an entity owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. Contract liabilities includes a balance at September 30, 2020 and 2019 of $80,838 from this related party.

XML

Stock-based compensation

9 Months Ended

Sep. 30, 2020

Stock-based compensation [Abstract]

Stock-based compensation

18. Stock-based compensation

During the nine months ended September 30, 2020, 60,000 stock options to purchase the Company’s common stock were forfeited due to termination and 1,500,000 stock options to purchase the Company’s common stock expired without exercise.

The range of exercise prices for options was $0.04 to $2.00 for options outstanding at September 30, 2020 and December 31, 2019, respectively. The aggregate intrinsic value for all vested and exercisable options was $1,994,741 and $2,085,866 at September 30, 2020 and December 31, 2019, respectively.

The weighted average remaining contractual term for outstanding exercisable stock options was 6.14 and 6.6 years as of September 30, 2020 and December 31, 2019, respectively.

XML

Earnings (loss) per share

9 Months Ended

Sep. 30, 2020

Earnings (loss) per share [Abstract]

Earnings (loss) per share

19. Earnings (loss) per share

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following:

	September 30, 2020		September 30, 2019
Stock options		32,618,385		33,683,385
Warrants		190,356,736		12,854,091
Convertible promissory notes		56,988,540		9,204,160
Shares issuable		-		14,617,225
Anti-dilutive equity securities		279,963,661		70,358,861

XML

Restatement of financial statements

9 Months Ended

Sep. 30, 2020

Restatement of financial statements [Abstract]

Restatement of financial statements

20. Restatement of financial statements

On February 12, 2021, the Company determined an error in the accounting for certain of the Company’s warrants previously issued. Such warrants should have been reflected as liabilities on the condensed consolidated balance sheets included in the Original 10-Q, rather than as a component of equity.

Specifically, the Company’s financial statements as of and for the three and nine months ended September 30, 2020, contained the following errors: (i) understatement of derivative warrant liability of $8,225,956 (ii) understatement of weighted average shares outstanding of 82,383,022 for the three months ended September 30, 2020 and 2,674,538 for the nine months ended September 30, 2020 and (iii) understatement of the Net Loss on the Statement of Operations of $6,626,907.

The effects of the adjustments on the Company’s previously issued financial statements as of and for the three and nine months ended September 30, 2020 are summarized as follows:

As of September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
LIABILITIES
CURRENT LIABILITIES
Warrant Liability		6,440,249			11,106,011			17,546,260
TOTAL CURRENT LIABILITIES		19,715,578			11,106,011			30,821,589
NON - CURRENT LIABILITIES
Warrant Liability		2,880,055			(2,880,055	)		-
TOTAL NON-CURRENT LIABILITIES		14,023,530			(2,880,055	)		11,143,475
TOTAL LIABILITIES		33,739,108			8,225,956			41,965,064
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
ADDITIONAL PAID-IN CAPITAL		137,120,956			(1,599,049	)		135,521,907
ACCUMULATED DEFICIT		(138,398,688	)		(6,626,907	)		(145,025,761	)
TOTAL STOCKHOLDERS' DEFICIT		(873,002	)		(8,225,956	)		(9,098,958	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	32,866,106		$	(0	)	$	32,866,106

Three Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
OTHER INCOME (EXPENSES)
Gain or (Loss) on warrant derivative liability		1,036,101			(6,626,907	)		(5,590,806	)
TOTAL OTHER INCOME (EXPENSES)		(242,962	)		(6,626,907	)		(6,869,869	)
NET LOSS		(6,011,730	)		(6,626,907	)		(12,638,637	)
TOTAL COMPREHENSIVE LOSS	$	(6,008,938	)	$	(6,626,907	)	$	(12,635,845	)
LOSS PER SHARE
Net loss - basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.03	)
Weighed average shares outstanding - basic and diluted		302,119,428			82,383,022			384,502,450

Nine Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
OTHER INCOME (EXPENSES)
Loss on warrant liability		1,036,101			(6,626,907	)		(5,590,806	)
TOTAL OTHER INCOME (EXPENSES)		(808,637	)		(6,626,907	)		(7,435,544	)
NET LOSS		(12,645,898	)		(6,626,907	)		(19,272,805	)
TOTAL COMPREHENSIVE LOSS	$	(12,645,029	)	$	(6,626,907	)	$	(19,271,936	)
LOSS PER SHARE
Net loss - basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.06	)
Weighed average shares outstanding - basic and diluted		323,730,859			2,674,538			326,405,397

Nine Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(12,645,898	)		(6,626,907	)		(19,272,805	)
Gain or (Loss) on warrant liability		(1,036,101	)		6,626,907			5,590,806
NET CASH USED BY OPERATING ACTVITIES		(9,779,889	)		-			(9,779,889	)

XML

Subsequent events

9 Months Ended

Sep. 30, 2020

Subsequent events [Abstract]

Subsequent events

21. Subsequent events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.

Option Exercise

Subsequent to September 30, 2020, the Company issued 100,000 shares of common stock upon the exercise of 100,000 stock options to purchase shares of stock under the terms of the respective option agreement.

Shares issued for services

Subsequent to September 30, 2020, the Company issued 1,000,000 shares of common stock for consulting services previously rendered.

XML

Supplier Dispute

9 Months Ended

Sep. 30, 2020

Supplier Dispute [Abstract]

Supplier Dispute

22. Supplier Dispute

In May 2021, the Company received notification that it is not in compliance with the License Agreement discussed in Note 6.  The Company is in the process of reviewing the notification and preparing a response.  It is too early to determine the outcome of this matter.  Any potential impact to the Company cannot be fully determined at this time.

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Summary of Significant Accounting Policies [Abstract]

Principles of Consolidation

Principles of consolidation - The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Estimates

Estimates – These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of condensed consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These condensed consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimate of the net realizable value of inventory, the determination of the valuation allowances for deferred taxes the estimated fair value of stock-based compensation, debt discounts and warrants, and valuation of acquired assets related to the acquisition of UltraMIST (Note 4).

Fair value of Financial Instruments

Fair value of financial instruments - The carrying values of accounts payable, and other short-term obligations approximate their fair values, principally because of the short-term maturities of these instruments.

The Company has adopted ASC 820-10, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value and requires disclosures about fair value measurements. The framework that is set forth in this standard is applicable to the fair value measurements where it is permitted or required under other accounting pronouncements.

The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions.

The Company recognizes all derivatives on the balance sheet at fair value. The fair value of the warrant liability is determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate, and therefore is classified within level 3 of the fair value hierarchy. (See Note 14).

The Company’s notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace.

Inventory

Inventory - Inventory consists of finished medical equipment and parts and is stated at the lower of cost, which is valued using the first in, first out (“FIFO”) method, or net realizable value less allowance for selling and distribution expenses. The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete. As of September 30, 2020, inventory consists of goods of $2,273,436 and parts of $266,039 for a total inventory of $2,539,475. As of December 31, 2019, inventory consisted of goods of $357,264 and parts of $185,691 for a total inventory of $542,955.

Preferred Stock

Preferred stock – The Company evaluates Preferred Stock issuances for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and determines appropriate equity or liability accounting treatment. Additionally, the Company determines, if classified as equity, whether it would be recorded as permanent or temporary equity.

Sequencing Policy

Sequencing policy – The Company has granted certain options and warrants which, upon settlement, may exceed the limit on the authorized number of shares of common stock. The Company follows a sequencing policy for which in the event partial reclassifications of contracts subject to ASC 815-40-25 is necessary, due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of earliest issuance date of potentially dilutive instruments with the earliest grants receiving first allocation of shares. On August 6, 2020, the Company issued shares of common stock, convertible debt and warrants exercisable into shares of common stock in connection with a private placement funding and Senior Notes. In the event that all outstanding convertible securities were converted into shares of common stock of the Company, the Company would exceed the total number of shares authorized for issuance in the Company’s Articles of Incorporation. The Company has applied its sequencing policy to and determined that all convertible securities are convertible into shares of common stock other than warrants to purchase 64,119,742 shares of common stock issued on August 6, 2020.  These warrants were valued at $8,656,165 at August 6, 2020 and recorded as a liability in the condensed consolidated balance sheet.

Convertible Instruments and Liabilities Related to Warrants Issued

Convertible instruments and liabilities related to warrants issued –  The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with FASB ASC 815 “Derivatives and Hedging” (“ASC 815”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the consolidated statements of operations over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.  A binomial model was used to estimate the fair value of the ECOs of warrants that are classified as derivative liabilities on the consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

XML

Asset Purchase Agreement (Tables)

9 Months Ended

Sep. 30, 2020

Asset Purchase Agreement [Abstract]

Fair Value of Consideration Exchanged

The tables below present the fair value of the consideration exchanged and the preliminary estimates of the fair value of assets acquired of UltraMIST.  Due to the limited amount of time since the UltraMIST acquisition, the valuation of the acquired assets is preliminary and subject to change.  The Company is still evaluating the income tax effects of the transaction.

Purchase consideration
	August 6, 2020
Cash paid at closing	$	18,890,000
Seller convertible note		4,000,000
Previous cash deposit pursuant to letter of intent		1,110,000
Total	$	24,000,000

Net assets acquired	Fair Value at August 6, 2020
Inventory	$	1,859,965
Property, plant and equipment		436,815
Intangible assets (a)		14,443,425
Goodwill (b)		7,259,795
Total	$	24,000,000

^(a) Intangible assets, as provided in the table below, are recorded at estimated fair value.  The estimated fair value of the acquired customer relationships is based on a variation of the income valuation approach and is determined using the multi-period excess earnings method. The estimated fair value of the acquired patent and trade names is based on a variation of the income valuation approach known as the relief from royalty method. The estimated useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows.

^(b) Goodwill represents the excess of the total purchase consideration over fair value of the assets recognized and represents the future economic benefits that we believe will result from combining the operations of Sanuwave and UltraMIST, including expected future synergies and operating efficiencies. Goodwill resulting from the Transaction has been assigned to the Company’s lone operating segment. None of the goodwill recognized is expected to be deductible for income tax purposes.

Estimates of Fair Value of Assets Acquired

	Estimated Fair Value		Estimated Weighted Average Life (Years)
Customer relationships - UltraMIST	$	3,820,000		7
Customer relationships - Biologics		7,618,100		7
Patent		2,311,825		19
Trade names		693,500		19
Total intangible assets	$	14,443,425

Pro forma Information

The following financial information presents our results as if the Transaction had occurred on January 1, 2019:

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
	(restated)						(restated)
Total revenue	$	2,770,646		$	2,325,640		$	5,973,538		$	6,810,404
Net loss	$	(12,549,181	)	$	(4,863,590	)	$	(23,869,495	)	$	(14,855,293	)

XML

Accrued expenses (Tables)

9 Months Ended

Sep. 30, 2020

Accrued expenses [Abstract]

Components of Accrued Expenses

Accrued expenses consist of the following:

	September 30, 2020		December 31, 2019
Accrued outside services	$	615,547	$	108,033
Accrued legal and professional fees		370,985		134,970
Accrued board of director’s fees		260,000		400,000
Accrued executive severance		167,500		154,000
Accrued travel		120,000		120,000
Accrued inventory		50,275		167,050
Accrued clinical study expenses		13,650		13,650
Accrued other		5,586		13,406
	$	1,603,543	$	1,111,109

XML

Contract liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Contract liabilities [Abstract]

Contract Liabilities

Contract liabilities consist of the following:

	September 30, 2020			December 31, 2019
Service agreement	$	77,538		$	133,510
License fees		-			500,000
Devices		22,500			-
Other		10,518			6,291
Total Contract liabilities		110,556			639,801
Non-Current		(45,519	)		(573,224	)
Total Current	$	65,037		$	66,577

XML

Warrant Liabilities (Restated) (Tables)

9 Months Ended

Sep. 30, 2020

Warrant Liabilities (Restated) [Abstract]

Fair Value of Warrant Liabilities

The fair value of the warrant liabilities was measured using the binomial model. Significant inputs into the model at the inception and reporting period measurement dates are as follows:

Private Placement Warrants

Binomial Assumptions	Issuance date (1) August 6, 2020			Period ended September 30, 2020
Exercise Price(1)	$	0.25		$	0.25
Warrant Expiration Date (1)	August 6, 2023			August 6, 2023
Stock Price (2)	$	0.24		$	0.22
Interest Rate (annual) (3)		0.13	%		0.16	%
Volatility (annual) (4)		91.49	%		88.96	%
Time to Maturity (Years)		3			3
Calculated fair value per share	$	0.135		$	0.119

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company. dated August 6, 2020.}

_{(2) Based on the trading value of common stock of the Company. as of August 6, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of  the Company as of August 6, 2020 and each presented period ending date.}

NH Expansion Warrants:

Binomial Assumptions	Issuance date (1) August 6, 2020			Period ended September 30, 2020
Exercise Price(1)	$	0.01		$	0.01
Warrant Expiration Date (1)	August 6, 2030			August 6, 2030
Stock Price (2)	$	0.24		$	0.22
Interest Rate (annual) (3)		0.21	%		0.69	%
Volatility (annual) (4)		102.09	%		184.77	%
Time to Maturity (Years)		10			10
Calculated fair value per share	$	0.233		$	0.22

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.}

_{(2) Based on the trading value of common stock of the Company as of August 6, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of the Company as of August 6, 2020 and each presented period ending date.}

LGH
Binomial Assumptions	Issuance date (1) 5-Jun-20			Period ended 30-Jun-20			Ratchet Date (5) 6-Aug-20			Period ended 30-Sep-20
Exercise Price(1)	$	0.35		$	0.35		$	0.01		$	0.01
Warrant Expiration Date (1)	5-Jun-25			5-Jun-25			5-Jun-25			5-Jun-25
Stock Price (2)	$	0.27		$	0.2625		$	0.2437		$	0.22
Interest Rate (annual) (3)		0.29	%		0.29	%		0.20	%		0.26	%
Volatility (annual) (4)		107	%		107	%		103	%		101	%
Time to Maturity (Years)		5			4.93			4.83			4.68
Calculated fair value per share	$	0.25		$	0.25		$	0.24		$	0.21

_{(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated June 5, 2020.}

_{(2) Based on the trading value of common stock of the Company as of June 5, 2020 and each presented period ending date.}

_{(3) Interest rate for U.S. Treasury Bonds, as of June 5, 2020, and each presented period ending date, as published by the U.S. Federal Reserve.}

_{(4) Based on the historical daily volatility of the Company as of June 6, 2020, and each presented period ending date.}

_{(5) Based on the terms provided in the warrant agreement to purchase common stock at date of the ratchet trigger August 6, 2020.}

Warrants Outstanding and Fair Values

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

Warrant Liability	Warrants Outstanding		Fair Value per Share		Fair Value
Fair Value at remeasurement date of June 30, 2020		1,000,000		0.249	$	249,049
Additional Warrants classified as Liabilities August 6, 2020		111,210,902		0.206		22,888,017
Fair Value at date of August 6, 2020		112,210,902		0.206	$	23,137,066
Gain or (Loss) on warrant liability						(5,590,806	)
Fair Value as of period ended September 30, 2020		112,210,902		0.156		17,546,260

XML

Warrants (Restated) (Tables)

9 Months Ended

Sep. 30, 2020

Warrants (Restated) [Abstract]

Warrant Activity

A summary of the warrant activity during the nine months ended September 30, 2020 is presented as follows:

Warrant class	Outstanding as of December 31, 2019		Issued		Exercised			Expired			Outstanding as of September 30, 2020
Class E Warrants		-		141,091,485		-			-			141,091,485
Class K Warrants		7,200,000		-		(7,200,000	)		-			-
Class O Warrants		909,091		-		-			-			909,091
Class P Warrants		1,365,000		-		(1,000,000	)		(100,000	)		265,000
LGH Warrant		-		35,000,000		-			-			35,000,000
NH Warrant		-		13,091,160		-			-			13,091,160
		9,474,091		189,182,645		(8,200,000	)		(100,000	)		190,356,736

Warrant Exercise Price Per Share and Expiration Date

A summary of the warrant exercise price per share and expiration date is presented as follows:

	Exercise price/share		Expiration date
Class E Warrants	$	0.25	August 2023
Class K Warrants	$	0.08	June 2025
Class K Warrants	$	0.11	August 2027
Class O Warrants	$	0.11	January 2022
Class P Warrants	$	0.20	June 2024
LGH Warrant	$	0.01	June 2025
NH Warrant	$	0.01	August 2030

Fair Value of Common Stock Purchase Warrants

The fair value of the common stock purchase warrants is estimated on the date of grant using the Black-Scholes option pricing model which approximates the binomial model using the following weighted average assumptions for the three and nine months ended September 30, 2020:

Weighted average contractual terms in years	1.3
Weighted average risk free interest rate	0.15	%
Weighted average volatility	92.76	%

XML

Commitments and contingencies (Tables)

9 Months Ended

Sep. 30, 2020

Commitments and contingencies [Abstract]

Operating Leases, Right of Use Assets and Lease Liability

Right of use assets and Lease liability – right of use consist of the following:

	September 30, 2020
Right of use assets	$	442,197

	September 30, 2020
Lease liability - right of use
Current portion	$	251,372
Long term portion		222,815
	$	474,187

Operating Leases, Maturities

As of September 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following:

Year ending December 31,	Amount
2020 (remainder)	$	71,918
2021		290,552
2022		96,195
2023		68,017
2024		8,028
2025		3,345
Total lease payments		538,055
Less: Present value adjustment		(63,868	)
Lease liability - right of use	$	474,187

Finance Lease, Right of Use Assets and Lease Liability

Right of use assets and Lease liability – right of use consist of the following:

	September 30, 2020
Right of use assets	$	462,405

	September 30, 2020
Lease liability - right of use
Current portion	$	187,416
Long term portion		284,588
	$	472,004

Finance Lease, Maturities

As of September 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following:

Year ending December 31,	Amount
2020 (remainder)	$	58,648
2021		234,593
2022		199,793
2023		18,388
Total	$	511,422

XML

Revenue (Tables)

9 Months Ended

Sep. 30, 2020

Revenue [Abstract]

Disaggregation of Revenue

The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and nine months ended September 30, 2020 and 2019:

	Three Months Ended September 30, 2020						Three Months Ended September 30, 2019
	United States		International		Total		United States		International		Total
Product	$	1,301,942	$	19,306	$	1,321,248	$	9,832	$	149,023	$	158,855
License fees		-		29,447		29,447		6,250		10,000		16,250
Other Revenue		7,811		608,390		616,201		25		22,510		22,535
	$	1,309,753	$	657,143	$	1,966,896	$	16,107	$	181,533	$	197,640

	Nine Months Ended September 30, 2020						Nine Months Ended September 30, 2019
	United States		International		Total		United States		International		Total
Product	$	1,398,672	$	66,475	$	1,465,147	$	147,999	$	296,088	$	444,087
License fees		-		39,447		39,447		18,750		170,557		189,307
Other Revenue		7,486		686,708		694,194		25		59,160		59,185
	$	1,406,158	$	792,630	$	2,198,788	$	166,774	$	525,805	$	692,579

XML

Earnings (loss) per share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings (loss) per share [Abstract]

Anti-dilutive Equity Securities

Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following:

	September 30, 2020		September 30, 2019
Stock options		32,618,385		33,683,385
Warrants		190,356,736		12,854,091
Convertible promissory notes		56,988,540		9,204,160
Shares issuable		-		14,617,225
Anti-dilutive equity securities		279,963,661		70,358,861

XML

Restatement of financial statements (Tables)

9 Months Ended

Sep. 30, 2020

Restatement of financial statements [Abstract]

Error Corrections and Prior Period Adjustments

The effects of the adjustments on the Company’s previously issued financial statements as of and for the three and nine months ended September 30, 2020 are summarized as follows:

As of September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
LIABILITIES
CURRENT LIABILITIES
Warrant Liability		6,440,249			11,106,011			17,546,260
TOTAL CURRENT LIABILITIES		19,715,578			11,106,011			30,821,589
NON - CURRENT LIABILITIES
Warrant Liability		2,880,055			(2,880,055	)		-
TOTAL NON-CURRENT LIABILITIES		14,023,530			(2,880,055	)		11,143,475
TOTAL LIABILITIES		33,739,108			8,225,956			41,965,064
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
ADDITIONAL PAID-IN CAPITAL		137,120,956			(1,599,049	)		135,521,907
ACCUMULATED DEFICIT		(138,398,688	)		(6,626,907	)		(145,025,761	)
TOTAL STOCKHOLDERS' DEFICIT		(873,002	)		(8,225,956	)		(9,098,958	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	32,866,106		$	(0	)	$	32,866,106

Three Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
OTHER INCOME (EXPENSES)
Gain or (Loss) on warrant derivative liability		1,036,101			(6,626,907	)		(5,590,806	)
TOTAL OTHER INCOME (EXPENSES)		(242,962	)		(6,626,907	)		(6,869,869	)
NET LOSS		(6,011,730	)		(6,626,907	)		(12,638,637	)
TOTAL COMPREHENSIVE LOSS	$	(6,008,938	)	$	(6,626,907	)	$	(12,635,845	)
LOSS PER SHARE
Net loss - basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.03	)
Weighed average shares outstanding - basic and diluted		302,119,428			82,383,022			384,502,450

Nine Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
OTHER INCOME (EXPENSES)
Loss on warrant liability		1,036,101			(6,626,907	)		(5,590,806	)
TOTAL OTHER INCOME (EXPENSES)		(808,637	)		(6,626,907	)		(7,435,544	)
NET LOSS		(12,645,898	)		(6,626,907	)		(19,272,805	)
TOTAL COMPREHENSIVE LOSS	$	(12,645,029	)	$	(6,626,907	)	$	(19,271,936	)
LOSS PER SHARE
Net loss - basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.06	)
Weighed average shares outstanding - basic and diluted		323,730,859			2,674,538			326,405,397

Nine Months Ended September 30, 2020	Originally Reported			Restatement Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(12,645,898	)		(6,626,907	)		(19,272,805	)
Gain or (Loss) on warrant liability		(1,036,101	)		6,626,907			5,590,806
NET CASH USED BY OPERATING ACTVITIES		(9,779,889	)		-			(9,779,889	)

XML

Nature of the Business (Details)	Aug. 06, 2020
Nature of the Business [Abstract]
License agreement initial term	5 years
License renewal period	1 year

XML

Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Going Concern [Abstract]
Cash and cash equivalents	$ 5,391,591		$ 5,391,591		$ 1,760,455
Net cash used in operating activities			(9,779,889)	$ (4,684,611)
Net loss	$ (12,638,637)	$ (2,748,018)	$ (19,272,805)	$ (7,679,766)

XML

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2020	Aug. 06, 2020	Dec. 31, 2019
Inventory [Abstract]
Inventory, goods	$ 2,273,436		$ 357,264
Inventory, parts	266,039		185,691
Inventory, net	$ 2,539,475		$ 542,955
Sequencing Policy [Abstract]
Warrants to purchase shares (in shares)		64,119,742
Warrants issued value		$ 8,656,165

XML

Asset Purchase Agreement (Details)	Aug. 06, 2020 USD ($)
Business Acquisition Information [Abstract]
Written notice required prior to expiration of current term	180 days
Celularity's UltraMIST Assets [Member]
Business Acquisition Information [Abstract]
Initial term of license agreement	5 years
License agreement automatic renewal term	1 year
Purchase consideration [Abstract]
Cash paid at closing	$ 18,890,000
Seller convertible note	4,000,000
Previous cash deposit pursuant to letter of intent	1,110,000
Total	$ 24,000,000

XML

Asset Purchase Agreement, Estimates of Fair Value of Assets Acquired (Details) - USD ($)		Sep. 30, 2020	Aug. 06, 2020	Dec. 31, 2019
Net Assets Acquired [Abstract]
Goodwill		$ 14,198,799		$ 0
Amount of goodwill recognized expected to be deductible for income tax			$ 0
Celularity's UltraMIST Assets [Member]
Net Assets Acquired [Abstract]
Inventory			1,859,965
Property, plant and equipment			436,815
Intangible assets	[1]		14,443,425
Goodwill	[2]		7,259,795
Total			$ 24,000,000

[1] Intangible assets, as provided in the table below, are recorded at estimated fair value. The estimated fair value of the acquired customer relationships is based on a variation of the income valuation approach and is determined using the multi-period excess earnings method. The estimated fair value of the acquired patent and trade names is based on a variation of the income valuation approach known as the relief from royalty method. The estimated useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows.

[2] Goodwill represents the excess of the total purchase consideration over fair value of the assets recognized and represents the future economic benefits that we believe will result from combining the operations of Sanuwave and UltraMIST, including expected future synergies and operating efficiencies. Goodwill resulting from the Transaction has been assigned to Sanuwave's lone operating segment. None of the goodwill recognized is expected to be deductible for income tax purposes.

XML

Asset Purchase Agreement, Estimated Useful Lives for Intangible Assets (Details)	Aug. 06, 2020 USD ($)
Celularity's UltraMIST Assets [Member]
Estimated Useful Lives for Intangible Assets [Abstract]
Estimated fair value	$ 14,443,425	[1]
Celularity's UltraMIST Assets [Member] | Customer Relationships [Member]
Estimated Useful Lives for Intangible Assets [Abstract]
Estimated fair value	$ 3,820,000
Estimated weighted average life	7 years
Celularity's UltraMIST Assets [Member] | Patent [Member]
Estimated Useful Lives for Intangible Assets [Abstract]
Estimated fair value	$ 2,311,825
Estimated weighted average life	19 years
Celularity's UltraMIST Assets [Member] | Tradenames [Member]
Estimated Useful Lives for Intangible Assets [Abstract]
Estimated fair value	$ 693,500
Estimated weighted average life	19 years
Biologics [Member] | Customer Relationships [Member]
Estimated Useful Lives for Intangible Assets [Abstract]
Estimated fair value	$ 7,618,100
Estimated weighted average life	7 years

[1] Intangible assets, as provided in the table below, are recorded at estimated fair value. The estimated fair value of the acquired customer relationships is based on a variation of the income valuation approach and is determined using the multi-period excess earnings method. The estimated fair value of the acquired patent and trade names is based on a variation of the income valuation approach known as the relief from royalty method. The estimated useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows.

XML

Asset Purchase Agreement, Acquisition and Related Costs (Details) - Celularity's UltraMIST Assets [Member] - Acquisition and Related Costs [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)
Acquisition and Related Costs [Abstract]
Acquisition costs	$ 995,353	$ 1,084,994
NWPSA Senior Debt [Member]
Acquisition and Related Costs [Abstract]
Debt issuance costs	$ 1,653,453	$ 1,653,453

XML

Asset Purchase Agreement, Unaudited Actual and Pro forma Information (Details) - USD ($)	2 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Unaudited Actual and Pro forma Information [Abstract]
Total revenues		$ 1,966,896	$ 197,640	$ 2,198,788	$ 692,579
Net loss		(12,638,637)	(2,748,018)	(19,272,805)	(7,679,766)
Pro Forma Information [Abstract]
Total revenues		2,770,646	2,325,640	5,973,538	6,810,404
Net loss		$ (12,549,181)	$ (4,863,590)	$ (23,869,495)	$ (14,855,293)
Celularity's UltraMIST Assets [Member]
Unaudited Actual and Pro forma Information [Abstract]
Total revenues	$ 1,206,847
Net loss	$ (1,509,943)

XML

Accrued expenses (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accrued expense [Abstract]
Accrued outside services	$ 615,547	$ 108,033
Accrued legal and professional fees	370,985	134,970
Accrued board of directors' fees	260,000	400,000
Accrued executive severance	167,500	154,000
Accrued travel	120,000	120,000
Accrued inventory	50,275	167,050
Accrued clinical study expenses	13,650	13,650
Accrued other	5,586	13,406
Total accrued expenses	$ 1,603,543	$ 1,111,109

XML

Contract liabilities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Contract liabilities [Abstract]
Total Contract liabilities	$ 110,556	$ 639,801
Non-Current	(45,519)	(573,224)
Total Current	$ 65,037	$ 66,577
Maximum [Member]
Contract liabilities [Abstract]
Remaining performance obligations satisfaction period	32 months	38 months
Minimum [Member]
Contract liabilities [Abstract]
Remaining performance obligations satisfaction period	12 months	12 months
Service Agreement [Member]
Contract liabilities [Abstract]
Total Contract liabilities	$ 77,538	$ 133,510
License Fees [Member]
Contract liabilities [Abstract]
Total Contract liabilities	0	500,000
Devices [Member]
Contract liabilities [Abstract]
Total Contract liabilities	22,500	0
Other [Member]
Contract liabilities [Abstract]
Total Contract liabilities	$ 10,518	$ 6,291

XML

Senior promissory notes (Details) - USD ($)		9 Months Ended
	Aug. 06, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Short Term Notes Payable Conversion [Abstract]
Proceeds from senior promissory notes		$ 13,346,547	$ 0
Issued (in shares)		189,182,645
Accrued interest		$ 354,062		$ 0
Senior Notes and Warrants [Member] | NH Expansion Credit Fund Holdings LP [Member]
Short Term Notes Payable Conversion [Abstract]
Principal amount	$ 15,000,000
Proceeds from senior promissory notes	$ 13,346,547
Percentage of diluted common stock	2.00%
Warrant exercise price (in dollars per share)	$ 0.01
Warrants expiration term	10 years
Accrued interest rate prime rate basis	3.00%
Interest rate due in quarterly arrears	9.00%
Current warrant liability		$ 3,050,240
Senior Notes [Member]
Short Term Notes Payable Conversion [Abstract]
Issued (in shares)	13,091,160
Debt maturity date		Sep. 30, 2025
Senior Notes [Member] | NH Expansion Credit Fund Holdings LP [Member]
Short Term Notes Payable Conversion [Abstract]
Issued (in shares)		13,091,160
Senior notes outstanding		$ 10,448,039
Accrued interest		280,729
Unamortized debt issuance costs		$ 1,600,115

XML

Convertible promissory notes (Restated) (Details) - USD ($)			3 Months Ended		9 Months Ended
	Aug. 06, 2020	Jun. 05, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instruments [Abstract]
Accrued interest			$ 354,062		$ 354,062		$ 0
Common stock warrants issued upon conversion of notes (in shares)	8,275,235
Loss on extinguishment of debt			$ (503,234)	$ 0	$ (503,234)	$ 0
Warrants exercised (in shares)	64,119,742
Convertible Promissory Note [Member] | LGH Investments LLC [Member]
Debt Instruments [Abstract]
Maturity date					Feb. 05, 2021
Interest rate percentage		8.00%
Common stock conversion price (in dollars per share)		$ 0.25
Conversion price on unpaid principal balance before maturity (in dollars per share)		0.25
Warrant exercise price (in dollars per share)		$ 0.35	$ 0.01		$ 0.01
Debt instrument term					5 years
Loss on extinguishment of debt			$ 503,234		$ 503,234
Repayments of convertible promissory note	$ 1,210,000
Warrants exercised (in shares)			35,000,000		35,000,000
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | LGH Investments LLC [Member]
Debt Instruments [Abstract]
Original principal amount converted into common stock shares		$ 1,210,000
Common stock warrants issued upon conversion of notes (in shares)		1,075,000
Net proceeds		$ 1,100,000
Reserve of shares for purposes of exercise of warrant or conversion of convertible promissory note (in shares)		11,000,000
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | LGH Investments LLC [Member] | Inducement Shares [Member]
Debt Instruments [Abstract]
Restricted common stock, shares issued upon conversion of notes (in shares)		200,000
Celularity's UltraMIST Assets [Member]
Debt Instruments [Abstract]
Paid for assets	24,000,000
Celularity's UltraMIST Assets [Member] | Seller Note [Member]
Debt Instruments [Abstract]
Paid for assets	24,000,000
Issuance of promissory notes	$ 4,000,000
Maturity date	Aug. 06, 2021
Interest rate percentage	12.00%
Common stock conversion price (in dollars per share)	$ 0.10
Accrued interest			$ 73,333		$ 73,333
Conversion price on unpaid principal balance before maturity (in dollars per share)	$ 0.10
Celularity's UltraMIST Assets [Member] | Seller Note [Member] | LGH Investments LLC [Member]
Debt Instruments [Abstract]
Outstanding convertible promissory notes			$ 4,000,000		$ 4,000,000

XML

SBA Loans (Details) - COVID-19 [Member] - USD ($)	9 Months Ended
	Sep. 30, 2020	Jun. 10, 2020	May 28, 2020
PPP Loan [Member]
SBA Loans [Abstract]
Proceeds from PPP loan			$ 460,000
Debt maturity date	May 28, 2022
Interest rate			1.00%
PPP loan classified as current	$ 321,821
PPP loan classified as non-current	$ 142,514
Economic Injury Disaster Loan [Member]
SBA Loans [Abstract]
Principal amount		$ 150,000
Accrued interest rate		3.75%

XML

Convertible notes payable, related parties and Notes payable, related parties (Details) - USD ($)		3 Months Ended		9 Months Ended
	Aug. 06, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Notes Payable Related Parties [Abstract]
Notes payable, interest rate				8.00%
Notes payable, due date				Dec. 31, 2018
Notes payable, accrued interest rate in event of default				10.00%
Repayment of debt				$ 5,457,663	$ 0
Warrants to purchase shares (in shares)	64,119,742
Notes payable principal		$ 0		0		$ 5,372,743
Accrued interest		354,062		354,062		0
Accrued interest, related parties		28,864		28,864		$ 1,859,977
Interest expense, related party		$ 61,334	$ 175,522	$ 431,070	$ 508,193
Class K Warrants [Member]
Notes Payable Related Parties [Abstract]
Warrant exercise price (in dollars per share)		$ 0.08		$ 0.08
Class E Warrants [Member]
Notes Payable Related Parties [Abstract]
Warrant exercise price (in dollars per share)		$ 0.25		$ 0.25
Class E Warrants [Member] | Maximum [Member]
Notes Payable Related Parties [Abstract]
Warrants to purchase shares (in shares)	123,550,000
HealthTronics [Member]
Notes Payable Related Parties [Abstract]
Repayment of debt	$ 4,000,000
Principal amount	$ 1,372,743
Common stock, shares issued (in shares)	8,275,235
Warrant exercise price (in dollars per share)	$ 0.25
Warrants expiration period	3 years
Maturity date				Aug. 06, 2021
Interest rate percentage	12.00%
Common stock conversion price (in dollars per share)	$ 0.10
Notes payable principal		$ 1,372,743		$ 1,372,743
Accrued interest		$ 24,822		$ 24,822
HealthTronics [Member] | Class K Warrants [Member]
Notes Payable Related Parties [Abstract]
Common stock, shares issued (in shares)	7,200,000
HealthTronics [Member] | Class E Warrants [Member]
Notes Payable Related Parties [Abstract]
Warrants to purchase shares (in shares)	8,275,235
A. Michael Stolarsk [Member]
Notes Payable Related Parties [Abstract]
Notes payable, interest rate	12.00%
Principal amount	$ 223,511
Maturity date				Aug. 06, 2021
Common stock conversion price (in dollars per share)	$ 0.10
Line of credit	$ 1,000,000

XML

Warrant Liabilities (Restated) (Details)						2 Months Ended	3 Months Ended		9 Months Ended
		Aug. 06, 2020 USD ($) $ / shares shares		Jun. 05, 2020 $ / shares shares		Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Jul. 23, 2020 shares	Jun. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2019 shares
Warrant Liabilities [Abstract]
Warrants issued to investors and underwriter (in shares) | shares		132,816,250
Warrants issued (in shares) | shares									189,182,645
Warrants issued to settle outstanding debt (in shares) | shares		8,275,235
Common stock, shares authorized (in shares) | shares						600,000,000	600,000,000		600,000,000		600,000,000	355,000,000	600,000,000
Aggregate exercise amount of warrants prior to adjustment (in shares) | $		$ 350,000
Warrants exercised (in shares) | shares		35,000,000		1,000,000					8,200,000
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) | shares		112,210,902				112,210,902	112,210,902		112,210,902			1,000,000
Fair value per share (in dollars per share) | $ / shares		$ 0.206				$ 0.156	$ 0.156		$ 0.156			$ 0.249
Gain or (Loss) on warrant liability | $						$ (5,590,806)	$ (5,590,806)	$ 0	$ (5,590,806)	$ 0
Warrant Liability, Fair Value | $		$ 23,137,066				$ 17,546,260	$ 17,546,260		$ 17,546,260			$ 249,049
Senior Notes [Member]
Warrant Liabilities [Abstract]
Warrants issued (in shares) | shares		13,091,160
Warrants [Member]
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) | shares		111,210,902
Fair value per share (in dollars per share) | $ / shares		$ 0.206
Warrant Liability, Fair Value | $		$ 22,888,017
Warrants [Member] | Minimum [Member]
Warrant Liabilities [Abstract]
Common stock, shares authorized (in shares) | shares		600,000,000
Number of shares issued and outstanding (in shares) | shares		713,439,897
Private Placement Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share) | $ / shares	[1]	$ 0.25				$ 0.25	$ 0.25		$ 0.25
Private Placement Warrants [Member] | Measurement Input, Warrant Expiration Date [Member]
Warrant Binomial Assumptions [Abstract]
Warrant Expiration Date	[1]	Aug. 06, 2023				Aug. 06, 2023	Aug. 06, 2023		Aug. 06, 2023
Private Placement Warrants [Member] | Measurement Input, Stock Price [Member]
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares	[2]	$ 0.24				$ 0.22	$ 0.22		$ 0.22
Private Placement Warrants [Member] | Measurement Input, Interest Rate (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants measurement input	[3]	0.0013				0.0016	0.0016		0.0016
Private Placement Warrants [Member] | Measurement Input, Volatility (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants measurement input	[4]	0.9149				0.8896	0.8896		0.8896
Private Placement Warrants [Member] | Measurement Input, Time to Maturity [Member]
Warrant Binomial Assumptions [Abstract]
Time to Maturity (Years)		3 years				3 years	3 years		3 years
Private Placement Warrants [Member] | Measurement Input, Calculated fair value per share [Member]
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares		$ 0.135				$ 0.119	$ 0.119		$ 0.119
NH Expansion Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share) | $ / shares	[1]	$ 0.01				$ 0.01	$ 0.01		$ 0.01
NH Expansion Warrants [Member] | Measurement Input, Warrant Expiration Date [Member]
Warrant Binomial Assumptions [Abstract]
Warrant Expiration Date	[1]	Aug. 06, 2030				Aug. 06, 2030	Aug. 06, 2030		Aug. 06, 2030
NH Expansion Warrants [Member] | Measurement Input, Stock Price [Member]
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares	[2]	$ 0.24				$ 0.22	$ 0.22		$ 0.22
NH Expansion Warrants [Member] | Measurement Input, Interest Rate (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants measurement input	[3]	0.0021				0.0069	0.0069		0.0069
NH Expansion Warrants [Member] | Measurement Input, Volatility (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants measurement input	[4]	1.0209				1.8477	1.8477		1.8477
NH Expansion Warrants [Member] | Measurement Input, Time to Maturity [Member]
Warrant Binomial Assumptions [Abstract]
Time to Maturity (Years)		10 years				10 years	10 years		10 years
NH Expansion Warrants [Member] | Measurement Input, Calculated fair value per share [Member]
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares		$ 0.233				$ 0.22	$ 0.22		$ 0.22
LGH Investments LLC [Member]
Warrant Liabilities [Abstract]
Common stock issued upon exercise of warrants (in shares) | shares		35,000,000
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares		$ 0.01
LGH Warrant [Member]
Warrant Liabilities [Abstract]
Warrants issued (in shares) | shares									35,000,000
Warrants exercised (in shares) | shares									0
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share) | $ / shares		0.01		$ 0.35		$ 0.01	$ 0.01		$ 0.01
Warrant Expiration Date						Jun. 01, 2025	Jun. 01, 2025		Jun. 01, 2025
LGH Warrant [Member] | Measurement Input, Exercise Price [Member]
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share) | $ / shares	[6]	$ 0.01	[5]	$ 0.35		$ 0.01	$ 0.01		$ 0.01			$ 0.35
LGH Warrant [Member] | Measurement Input, Warrant Expiration Date [Member]
Warrant Binomial Assumptions [Abstract]
Warrant Expiration Date	[6]	Jun. 05, 2025	[5]	Jun. 05, 2025		Jun. 05, 2025	Jun. 05, 2025		Jun. 05, 2025			Jun. 05, 2025
LGH Warrant [Member] | Measurement Input, Stock Price [Member]
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares	[7]	$ 0.2437	[5]	$ 0.27	[6]	$ 0.22	$ 0.22		$ 0.22			$ 0.2625
LGH Warrant [Member] | Measurement Input, Interest Rate (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants measurement input	[8]	0.0020	[5]	0.0029	[6]	0.0026	0.0026		0.0026			0.0029
LGH Warrant [Member] | Measurement Input, Volatility (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants measurement input	[9]	1.03	[5]	1.07	[6]	1.01	1.01		1.01			1.07
LGH Warrant [Member] | Measurement Input, Time to Maturity [Member]
Warrant Binomial Assumptions [Abstract]
Time to Maturity (Years)		4 years 9 months 29 days	[5]	5 years	[6]	4 years 8 months 5 days	4 years 8 months 5 days		4 years 8 months 5 days			4 years 11 months 5 days
LGH Warrant [Member] | Measurement Input, Calculated fair value per share [Member]
Warrant Binomial Assumptions [Abstract]
Stock price (in dollars per share) | $ / shares		$ 0.24	[5]	$ 0.25	[6]	$ 0.21	$ 0.21		$ 0.21			$ 0.25

[1] Based on the terms provided in the warrant agreement to purchase common stock of the Company. dated August 6, 2020.

[2] Based on the trading value of common stock of the Company. as of August 6, 2020 and each presented period ending date.

[3] Interest rate for U.S. Treasury Bonds, as of August 6, 2020 and each presented period ending date, as published by the U.S. Federal Reserve.

[4] Based on the historical daily volatility of the Company as of August 6, 2020 and each presented period ending date

[5] Based on the terms provided in the warrant agreement to purchase common stock at date of the ratchet trigger August 6, 2020.

[6] Based on the terms provided in the warrant agreement to purchase common stock of the Company dated June 5, 2020.

[7] Based on the trading value of common stock of the Company as of June 5, 2020 and each presented period ending date.

[8] Interest rate for U.S. Treasury Bonds, as of June 5, 2020, and each presented period ending date, as published by the U.S. Federal Reserve.

[9] Based on the historical daily volatility of the Company as of June 6, 2020, and each presented period ending date.

XML

Preferred Stock (Details) - USD ($)				9 Months Ended
	Sep. 20, 2020	May 14, 2020	Feb. 06, 2020	Sep. 30, 2020	Sep. 30, 2019	Jul. 23, 2020	Jun. 30, 2020	Dec. 31, 2019
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)				5,000,000				5,000,000
Preferred stock, par value (in dollars per share)				$ 0.001				$ 0.001
Aggregate total purchase price				$ 0				$ 0
Anti-dilutive securities (in shares)				279,963,661	70,358,861
Common stock, shares authorized (in shares)				600,000,000		600,000,000	355,000,000	600,000,000
Preferred Stock Conversion [Member]
Preferred Stock [Abstract]
Anti-dilutive securities (in shares)				17,500,000
Series C Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)			90
Shares conversion price (in dollars per share)			$ 0.14
Series C Preferred Stock [Member] | Private Placement [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)				90
Preferred stock, par value (in dollars per share)			0.001
Preferred stock issued, stated value (in dollars per share)			$ 25,000
Aggregate total purchase price			$ 2,250,000
Series D Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)		8
Shares conversion price (in dollars per share)		$ 0.14
Series D Preferred Stock [Member] | Private Placement [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)				8
Preferred stock, par value (in dollars per share)		0.001
Preferred stock issued, stated value (in dollars per share)		$ 25,000
Aggregate total purchase price		$ 200,000
Series C and D Preferred Stock [Member]
Preferred Stock [Abstract]
Convertible preferred stock converted to common stock (in shares)	17,499,958

XML

Equity transactions (Details) - USD ($)					1 Months Ended			3 Months Ended						9 Months Ended
	Aug. 06, 2020	Jul. 23, 2020	Jun. 05, 2020	Dec. 11, 2019	Apr. 30, 2020	Mar. 31, 2020	Jan. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Warrants exercised (in shares)	35,000,000		1,000,000											8,200,000
Conversion of short term notes and convertible notes payable											$ 500,000	$ 180,000	$ 266,667
Conversion of short term notes and settlements (in shares)														2,250,000
Conversion of short term notes and settlements								$ 210,000	$ 90,745	$ 263,984
Conversion of notes payable, related parties (in shares)														15,475,235
Conversion of notes payable, related parties to equity								2,291,047						$ 2,291,047
Fair value of shares issued for services								$ 1,080,000	$ 517,500	$ 200,000
Warrants to purchase shares (in shares)	64,119,742
Common stock, par value (in dollars per share)								$ 0.001						$ 0.001		$ 0.001
Stock option exercised (in shares)														225,000
Proceeds from stock option exercise														$ 44,250	$ 90,000
Liability recorded								$ 8,656,165						8,656,165
Residual amount														$ 12,408,966
Minimum [Member]
Stockholders' Equity Note [Abstract]
Reverse stock splits (in shares)		10
Maximum [Member]
Stockholders' Equity Note [Abstract]
Reverse stock splits (in shares)		50
Litigation Settlement [Member]
Stockholders' Equity Note [Abstract]
Restricted common stock issued, shares (in shares)														200,000
Fair value of restricted common stock issued														$ 50,000
Private Placement [Member]
Stockholders' Equity Note [Abstract]
Common stock, shares issued (in shares)	123,550,000			21,071,143
Proceeds from private placement	$ 21,456,468
Common stock, par value (in dollars per share)	$ 0.001			$ 0.14
Increase in common stock due to proceeds from PIPE stock and warrants	$ 123,550
Common stock issued in conjunction with offering, shares (in shares)														1,071,428
Cash proceeds from common stock issued in conjunction with offering														$ 150,000
Third Party Placement Agent [Member]
Stockholders' Equity Note [Abstract]
Warrant exercise price (in dollars per share)	$ 0.25
Warrants expiration period	3 years
Consulting Agreement [Member]
Stockholders' Equity Note [Abstract]
Term of consulting agreement														9 months
Shares to be issued for services, shares (in shares)							1,000,000
Additional shares to be issued for services, shares (in shares)							1,000,000
Shares issued for services (in shares)					1,000,000	1,000,000
Fair value of shares issued for services														$ 380,000
Consulting Agreement Extended [Member]
Stockholders' Equity Note [Abstract]
Additional shares to be issued for services, shares (in shares)														2,000,000
Fair value of shares issued for services														$ 450,000
Investor Relation Services Agreement [Member]
Stockholders' Equity Note [Abstract]
Additional shares to be issued for services, shares (in shares)														3,000,000
Fair value of shares issued for services														$ 630,000
LGH Investment LLC [Member]
Stockholders' Equity Note [Abstract]
Common stock, shares issued (in shares)														200,000
Class P Warrants [Member]
Stockholders' Equity Note [Abstract]
Common stock issued upon exercise of warrants (in shares)														1,000,000
Warrants exercised (in shares)														1,000,000
Purchase price per share (in dollars per share)								$ 0.01						$ 0.01
Warrant exercise price (in dollars per share)								0.20						$ 0.20
Class L Warrants [Member]
Stockholders' Equity Note [Abstract]
Conversion of short term notes and convertible notes payable (in shares)														2,579,789
Conversion of short term notes and convertible notes payable														$ 354,729
Series A Warrants [Member]
Stockholders' Equity Note [Abstract]
Common stock issued upon conversion of advances from related parties, shares (in shares)														262,811
Common stock issued upon conversion of advances from related parties, amount														$ 18,098
Class E Warrants [Member]
Stockholders' Equity Note [Abstract]
Warrants exercised (in shares)														0
Purchase price per share (in dollars per share)	$ 0.20
Warrant exercise price (in dollars per share)								0.25						$ 0.25
Class E Warrants [Member] | Maximum [Member]
Stockholders' Equity Note [Abstract]
Warrants to purchase shares (in shares)	123,550,000
Class E Warrants [Member] | Third Party Placement Agent [Member] | Maximum [Member]
Stockholders' Equity Note [Abstract]
Warrants to purchase shares (in shares)	9,266,250
Class K Warrants [Member]
Stockholders' Equity Note [Abstract]
Common stock issued upon exercise of warrants (in shares)														7,200,000
Warrants exercised (in shares)														7,200,000
Warrant exercise price (in dollars per share)								$ 0.08						$ 0.08
Conversion of notes payable, related parties to equity														$ 636,000

XML

Warrants (Restated), Summary of Warrant Activity (Details) - shares			9 Months Ended
	Aug. 06, 2020	Jun. 05, 2020	Sep. 30, 2020
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			9,474,091
Issued (in shares)			189,182,645
Exercised (in shares)	(35,000,000)	(1,000,000)	(8,200,000)
Expired (in shares)			(100,000)
Outstanding, ending (in shares)			190,356,736
Class E Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			0
Issued (in shares)			141,091,485
Exercised (in shares)			0
Expired (in shares)			0
Outstanding, ending (in shares)			141,091,485
Class K Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			7,200,000
Issued (in shares)			0
Exercised (in shares)			(7,200,000)
Expired (in shares)			0
Outstanding, ending (in shares)			0
Class O Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			909,091
Issued (in shares)			0
Exercised (in shares)			0
Expired (in shares)			0
Outstanding, ending (in shares)			909,091
Class P Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			1,365,000
Issued (in shares)			0
Exercised (in shares)			(1,000,000)
Expired (in shares)			(100,000)
Outstanding, ending (in shares)			265,000
LGH Warrant [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			0
Issued (in shares)			35,000,000
Exercised (in shares)			0
Expired (in shares)			0
Outstanding, ending (in shares)			35,000,000
NH Warrant [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			0
Issued (in shares)			13,091,160
Exercised (in shares)			0
Expired (in shares)			0
Outstanding, ending (in shares)			13,091,160

XML

Warrants (Restated), Exercise Price Per Share and Expiration Date (Details) - $ / shares	Sep. 30, 2020	Aug. 06, 2020	Jun. 05, 2020
Class E Warrants [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.25
Expiration date	Aug. 01, 2023
Class K Warrants [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.08
Expiration date	Jun. 01, 2025
Class K Warrants [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.11
Expiration date	Aug. 01, 2027
Class O Warrants [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.11
Expiration date	Jan. 01, 2022
Class P Warrants [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.20
Expiration date	Jun. 01, 2024
LGH Warrant [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.01	$ 0.01	$ 0.35
Expiration date	Jun. 01, 2025
NH Warrant [Member]
Warrant Exercise Price per Share and Expiration Date [Abstract]
Exercise price/share (in dollars per share)	$ 0.01
Expiration date	Aug. 01, 2030

XML

Warrants (Restated), Weighted Average Assumptions (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Warrants (Restated) [Abstract]
Weighted average contractual term in years	1 year 3 months 18 days	1 year 3 months 18 days
Weighted average risk free interest rate	0.15%	0.15%
Weighted average volatility	92.76%	92.76%

XML

Commitments and contingencies, Operating Leases, Right of Use Assets and Lease Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Commitments and contingencies [Abstract]
Monthly rent payable	$ 14,651
Percentage of rent adjustment on annual basis	3.00%
Right of use assets and Lease liability [Abstract]
Right of use assets	$ 442,197	$ 323,661
Lease liability - right of use [Abstract]
Current portion	251,372	173,270
Long term portion	222,815	$ 185,777
Lease liability - right of use	$ 474,187

XML

Commitments and contingencies, Operating Leases, Remaining Lease Terms (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Maturities of Lease Liability - right of use [Abstract]
2020 (remainder)	$ 71,918		$ 71,918
2021	290,552		290,552
2022	96,195		96,195
2023	68,017		68,017
2024	8,028		8,028
2025	3,345		3,345
Total lease payments	538,055		538,055
Less: Present value adjustment	(63,868)		(63,868)
Lease liability - right of use	$ 474,187		$ 474,187
Weighted average remaining lease term, operating lease	2 years 6 months		2 years 6 months
Weighted average discount rate, operating lease	12.00%		12.00%
Rent expense	$ 84,115	$ 49,217	$ 201,991	$ 148,172

XML

Commitments and contingencies, Financing Lease, Right of Use Assets and Lease Liability (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Financing Lease [Abstract]
Right of use assets	$ 462,405
Lease liability - right of use [Abstract]
Current portion	187,416	$ 121,634
Long term portion	284,588	$ 271,240
Lease liability - right of use	$ 472,004

XML

Commitments and contingencies, Financing Lease, Remaining Lease Terms (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Maturities of Lease Liability - Right of Use [Abstract]
2020 (remainder)		$ 58,648
2021		234,593
2022		199,793
2023		18,388
Total		$ 511,422
Weighted average remaining lease term, finance lease	2 years 8 months 12 days
Weighted average discount rate, finance lease	12.60%

XML

Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue [Abstract]
Partnership fees and expenses			$ 600,000
Disaggregation of Revenue [Abstract]
Revenues	$ 1,966,896	$ 197,640	2,198,788	$ 692,579
Product [Member]
Disaggregation of Revenue [Abstract]
Revenues	1,321,248	158,855	1,465,147	444,087
License Fees [Member]
Disaggregation of Revenue [Abstract]
Revenues	29,447	16,250	39,447	189,307
Other Revenue [Member]
Disaggregation of Revenue [Abstract]
Revenues	616,201	22,535	694,194	59,185
United States [Member]
Disaggregation of Revenue [Abstract]
Revenues	1,309,753	16,107	1,406,158	166,774
United States [Member] | Product [Member]
Disaggregation of Revenue [Abstract]
Revenues	1,301,942	9,832	1,398,672	147,999
United States [Member] | License Fees [Member]
Disaggregation of Revenue [Abstract]
Revenues	0	6,250	0	18,750
United States [Member] | Other Revenue [Member]
Disaggregation of Revenue [Abstract]
Revenues	7,811	25	7,486	25
International [Member]
Disaggregation of Revenue [Abstract]
Revenues	657,143	181,533	792,630	525,805
International [Member] | Product [Member]
Disaggregation of Revenue [Abstract]
Revenues	19,306	149,023	66,475	296,088
International [Member] | License Fees [Member]
Disaggregation of Revenue [Abstract]
Revenues	29,447	10,000	39,447	170,557
International [Member] | Other Revenue [Member]
Disaggregation of Revenue [Abstract]
Revenues	$ 608,390	$ 22,510	$ 686,708	$ 59,160

XML

Related party transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction Disclosures [Abstract]
Contract liabilities	$ 110,556		$ 110,556		$ 639,801
A. Michael Stolarski [Member]
Related Party Transaction Disclosures [Abstract]
Revenues from related party	10,105	$ 10,682	36,315	$ 148,849
Contract liabilities	$ 80,838	$ 80,838	$ 80,838	$ 80,838

XML

Stock-based compensation (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation [Abstract]
Stock options forfeited (in shares)	60,000
Stock option expired (in shares)	1,500,000
Exercise prices for options, lower range limit (in dollars per share)	$ 0.04	$ 0.04
Exercise prices for options, upper range limit (in dollars per share)	$ 2.00	$ 2.00
Aggregate intrinsic value for vested and exercisable options	$ 1,994,741	$ 2,085,866
Weighted average remaining contractual term for outstanding exercisable stock options	6 years 1 month 20 days	6 years 7 months 6 days

XML

Earnings (loss) per share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	279,963,661	70,358,861
Stock Options [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	32,618,385	33,683,385
Warrants [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	190,356,736	12,854,091
Convertible Promissory Notes [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	56,988,540	9,204,160
Shares Issuable [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	0	14,617,225

XML

Restatement of financial statements, Balance Sheets (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
CURRENT LIABILITIES [Abstract]
Warrant Liability	$ 17,546,260			$ 0
TOTAL CURRENT LIABILITIES	30,821,589			12,415,352
NON-CURRENT LIABILITIES [Abstract]
Warrant Liability	0
TOTAL NON-CURRENT LIABILITIES	11,143,475			1,030,241
TOTAL LIABILITIES	41,965,064			13,445,593
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT [Abstract]
ADDITIONAL PAID-IN CAPITAL	135,521,907			115,457,808
ACCUMULATED DEFICIT	(145,025,761)			(125,752,956)
TOTAL STOCKHOLDERS' DEFICIT	(9,098,958)	$ (14,822,533)	$ (12,561,941)	(10,063,601)	$ (13,318,174)	$ (16,355,506)	$ (15,693,947)	$ (15,356,099)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	32,866,106			$ 3,381,992
Originally Reported [Member]
CURRENT LIABILITIES [Abstract]
Warrant Liability	6,440,249
TOTAL CURRENT LIABILITIES	19,715,578
NON-CURRENT LIABILITIES [Abstract]
Warrant Liability	2,880,055
TOTAL NON-CURRENT LIABILITIES	14,023,530
TOTAL LIABILITIES	33,739,108
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT [Abstract]
ADDITIONAL PAID-IN CAPITAL	137,120,956
ACCUMULATED DEFICIT	(138,398,688)
TOTAL STOCKHOLDERS' DEFICIT	(873,002)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	32,866,106
Accounting Error Related to Warrant Derivative Liability [Member] | Restatement Adjustment [Member]
CURRENT LIABILITIES [Abstract]
Warrant Liability	11,106,011
TOTAL CURRENT LIABILITIES	11,106,011
NON-CURRENT LIABILITIES [Abstract]
Warrant Liability	(2,880,055)
TOTAL NON-CURRENT LIABILITIES	(2,880,055)
TOTAL LIABILITIES	8,225,956
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT [Abstract]
ADDITIONAL PAID-IN CAPITAL	(1,599,049)
ACCUMULATED DEFICIT	(6,626,907)
TOTAL STOCKHOLDERS' DEFICIT	(8,225,956)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 0

XML

Restatement of financial statements, Income Statement (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
OTHER INCOME (EXPENSES) [Abstract]
Gain or (Loss) on warrant derivative liability	$ (5,590,806)	$ 0	$ (5,590,806)	$ 227,669
TOTAL OTHER INCOME (EXPENSE), NET	(6,869,869)	(362,363)	(7,435,544)	(1,414,163)
NET LOSS	(12,638,637)	(2,748,018)	(19,272,805)	(7,679,766)
TOTAL COMPREHENSIVE LOSS	$ (12,635,845)	$ (2,762,079)	$ (19,271,936)	$ (7,666,614)
LOSS PER SHARE: [Abstract]
Net loss - basic and diluted (in dollars per share)	$ (0.03)	$ (0.01)	$ (0.06)	$ (0.04)
Weighted average shares outstanding - basic and diluted (in shares)	384,502,450	211,423,362	326,405,397	181,088,995
Originally Reported [Member]
OTHER INCOME (EXPENSES) [Abstract]
Gain or (Loss) on warrant derivative liability	$ 1,036,101		$ 1,036,101
TOTAL OTHER INCOME (EXPENSE), NET	(242,962)		(808,637)
NET LOSS	(6,011,730)		(12,645,898)
TOTAL COMPREHENSIVE LOSS	$ (6,008,938)		$ (12,645,029)
LOSS PER SHARE: [Abstract]
Net loss - basic and diluted (in dollars per share)	$ (0.02)		$ (0.04)
Weighted average shares outstanding - basic and diluted (in shares)	302,119,428		323,730,859
Accounting Error Related to Warrant Derivative Liability [Member]
LOSS PER SHARE: [Abstract]
Weighted average shares outstanding - basic and diluted (in shares)	103,834,635		173,171,615
Accounting Error Related to Warrant Derivative Liability [Member] | Restatement Adjustment [Member]
OTHER INCOME (EXPENSES) [Abstract]
Gain or (Loss) on warrant derivative liability	$ (6,626,907)		$ (6,626,907)
TOTAL OTHER INCOME (EXPENSE), NET	(6,626,907)		(6,626,907)
NET LOSS	(6,626,907)		(6,626,907)
TOTAL COMPREHENSIVE LOSS	$ (6,626,907)		$ (6,626,907)
LOSS PER SHARE: [Abstract]
Net loss - basic and diluted (in dollars per share)	$ (0.01)		$ (0.02)
Weighted average shares outstanding - basic and diluted (in shares)	82,383,022		2,674,538

XML

Restatement of financial statements, Cash Flows (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES [Abstract]
Net loss	$ (12,638,637)	$ (3,633,020)	$ (3,001,148)	$ (2,748,018)	$ (2,734,431)	$ (2,197,317)	$ (19,272,805)	$ (7,679,766)
Gain or (Loss) on warrant liability	5,590,806			$ 0			5,590,806	(227,669)
NET CASH USED BY OPERATING ACTIVITIES							(9,779,889)	$ (4,684,611)
Originally Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES [Abstract]
Net loss							(12,645,898)
Gain or (Loss) on warrant liability	(1,036,101)						(1,036,101)
NET CASH USED BY OPERATING ACTIVITIES							(9,779,889)
Accounting Error Related to Warrant Derivative Liability [Member]
CASH FLOWS FROM OPERATING ACTIVITIES [Abstract]
Net loss							(6,946,907)
Accounting Error Related to Warrant Derivative Liability [Member] | Restatement Adjustment [Member]
CASH FLOWS FROM OPERATING ACTIVITIES [Abstract]
Net loss							(6,626,907)
Gain or (Loss) on warrant liability	$ 6,626,907						6,626,907
NET CASH USED BY OPERATING ACTIVITIES							$ 0

XML

Subsequent events (Details) - shares	2 Months Ended	9 Months Ended
	Nov. 23, 2020	Sep. 30, 2020
Subsequent Event [Abstract]
Common stock, shares exercised (in shares)		225,000
Subsequent Event [Member]
Subsequent Event [Abstract]
Common stock, shares issued (in shares)	100,000
Common stock, shares exercised (in shares)	100,000
Common stock, shares issued for services (in shares)	1,000,000